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Abstract
The thesis has two broad aims. The first aim is to evaluate the effectiveness and 
“cost-effectiveness” of routine childhood varicella vaccination in the UK. To do so, a 
deterministic realistic age-structured model was built which incorporated herd- 
immunity effects and the indirect impact of varicella vaccination on zoster. The model 
predicts that although the overall morbidity due to varicella is likely to decrease 
following infant vaccination, these benefits will be offset by a significantly increase in 
zoster cases. These modelling results were used to explore the possible economic 
desirability of mass varicella vaccination. To do so, we perform the three major types 
of economic evaluation. The economic analysis predicts that using cost-utility and 
cost-effectiveness analysis, routine infant varicella vaccination is unlikely to be ’’cost- 
effective” and may produce an overall increase in morbidity. On the other hand, 
varicella is highly cost-beneficial when using £ as the outcome measure. Finally, we 
show that results are less sensitive to parameter estimates than model and 
methodological assumptions
The second aim of the thesis is to address the major methodological issues related to 
the economic evaluation of vaccination programs using varicella vaccination as an 
example. Firstly, we compare results from a dynamic model with those of a static 
model to illustrate the impact of including herd-immunity and to help provide 
guidance on which model should be used when assessing the impact of vaccination. 
Secondly, we assess the average willingness to pay for varicella vaccination and the 
QALY lost due to chickenpox using various elicitation techniques. We then identify 
important attributes of vaccination and what elicitation techniques can capture these 
components. Results are compared to investigate what valuation techniques should be 
used in the economic evaluation of vaccine programmes. Thirdly, we assess the 
sensitivity of economic analysis to the choice of model, methodological assumptions 
and parameter estimates. Finally, we propose guidelines for the economic evaluation 
of vaccination programmes based on the various findings of the thesis.
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Introduction
Few health programmes have been as successful as immunisation both in terms of 
public health impact and cost-effectiveness. Policy decisions about the 
implementation of early vaccines such as polio, pertussis and measles were relatively 
easily made due to the high mortality and morbidity attached to these diseases. 
However, policy decisions about the use of new vaccines, such as varicella, are more 
difficult due to the lower public health impact of these vaccines and capped health 
budgets. Economic evaluation is useful under such conditions. It provides an analytical 
framework in which to assess the desirability of vaccination compared with other uses 
of the same scarce resources.
To ensure the quality/comparability of methods/results, it has been suggested that 
specific guidelines are needed for the economic evaluation of vaccination programmes 
(Edmunds et al., 1999; Beutels et al., 2002). The main reasoning behind this stems 
from the unique characteristic of vaccination against infectious disease:
Mass vaccination not only reduces the incidence of disease in those 
immunised, but also indirectly protects non-vaccinated susceptibles 
against infection.
The concept of indirect protection of susceptibles (e.g. non vaccinees), termed herd- 
immunity, is the textbook example of externality in the consumption of healthcare. 
Predicting herd-immunity effects requires the use of dynamic mathematical models, 
which are rarely used as part of economic evaluation of vaccination and there are no 
guidelines as to how and when they should be applied.
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The thesis has two objectives. The first aim is to evaluate the effectiveness and “cost- 
effectiveness" of routine childhood varicella vaccination in the UK. The second aim is 
to address the major methodological issues related to the economic evaluation of 
immunisation programmes, using varicella vaccination in the United-Kingdom as an 
example.
Chapter 1 gives brief background information necessary to understand the rationale 
behind the thesis. Further background is given at the beginning of subsequent 
chapters. Chapter 2 examines the epidemiology and natural history of varicella zoster 
virus.
In Chapter 3, we use a dynamic mathematical model to estimate the overall 
effectiveness of varicella vaccination taking into account herd-immunity externalities. 
In doing so, we examine the different dynamical effects of vaccination and present 
which parameters are most influential on model results. Finally, we illustrate how 
herd-immunity externalities influence the benefit of vaccination.
In Chapter 4, we estimate the value of varicella vaccination programmes from both 
the individual and population perspectives. We estimate the average willingness to pay 
for varicella vaccination and the QALY lost due to chickenpox (individual perspective). 
We then attempt to identify what attributes of vaccination are important to vaccinees 
and what elicitation technique can capture these components. Finally, we explore 
different methods of aggregating individual revealed preferences to the population 
level taking into account herd-immunity as well as the non-health attributes of 
vaccination.
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In Chapter 5, we estimate the cost-effectiveness, cost-utility and cost-benefit of 
varicella vaccination and investigate using univariate and multivariate sensitivity 
analysis, the impact of model and methodological assumptions on results of economic 
evaluation. This, to better understand how the results of economic evaluation of 
vaccination programs are influenced by the methods used.
Finally, Chapter 6 is divided into three sections. First, we summarise the main findings 
of the thesis. Secondly, we present guidelines for the evaluation of immunisation 
programmes. Finally, we discuss future work.
16
Chapter 1
Background and Rationale
1.0 GENERAL INTRODUCTION
The aims of the thesis are two-fold. 1) to assess the public health and health 
economic impact of introducing routine varicella vaccination in the United- 
Kingdom, 2) to investigate the methodological challenges related to the unique 
characteristics of vaccination in the context of economic evaluation. In this first 
chapter we give brief background information necessary to understand the 
rationale behind the second aim of this thesis. Further, detailed, background is 
given at the beginning of each chapter.
1.1 EP IDEM IO LO GY OF INFECTIOUS D ISEASE
The focus of this thesis is to address the challenges related to the economic 
evaluation of vaccination programmes. These challenges stem from the unique 
characteristics of infectious disease: transmission and herd-immunity. In this first 
section we describe the basic principals of infectious disease epidemiology and 
how these concepts can be applied using models to predict and understand the 
impact of control programmes on infectious diseases.
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This section is largely based on publications by Beutels (2002), Anderson and May 
(1991), Halloran (1998) and Begg and Gay (1996). Unless stated otherwise, the 
material presented in this section can be found in these sources.
1.1.1 INFECTION AND NATURAL HISTORY OF DISEASE
There are many stages of infection and disease (see Figure 1.1). Both infection 
and disease begins with exposure/infection of the susceptible individual. Not all 
exposure results in infection and not all infection results in symptomatic disease. 
The first stage of infection is the latent period, which can be defined as the time 
from infection to infectiousness (when the individual is infectious to others). The 
next stage is the period of infectiousness. The final stage is the one where the 
host becomes non-infectious. Non-infectious individuals can be dead, immune, 
return to be susceptible or return to the latent class.
A. Stages of infection 
Exposed - infected
Susceptible r Latent ,
r
Infectious
Non -Infectious
■ Dead
■ Removed
, ■ Recovered
B. Stages of dis 
Exposed -
1
ease
infected
r Incubation r Symptomatic,
Time
Non -Diseased
■ Dead
■ Recovered
■ Immune
■ Carrier
:------------------------------------ ►
Time
Figure 1.1. Time Line for a) infection and b) disease (adapted from Halloran 
(1998)).
The different stages of disease also commence at the time of infection. During the 
latent and beginning of the period of infectiousness the host typically does not 
have symptoms. This first stage of disease, between exposure and symptomatic 
disease, is called incubation period. The second stage of disease is the 
symptomatic period. The host can leave the symptomatic stage through death, by 
recovering from symptoms, becoming immune or a carrier. It should be noted that 
not all infection results in symptoms or disease.
It is important to note that, although it is the effectiveness at reducing the burden 
of disease which is used to substantiate intervention, it is the characteristics of 
infection that determine the pattern of infectious disease before and after 
intervention as well as the approach that should be used. Hence,
it is the natural history of infection that is modelled when studying the 
effectiveness of intervention programmes against infectious disease.
The key parameters of transmission are duration of the latent infection and 
infectious periods, the probability of exposure and transmission and whether or 
not individuals develop immunity following infection. The Basic Reproduction 
number Ro, which we describe in the next section, encompasses the impact of 
many of the above parameters. It is also a key parameter to understand the basic 
concepts of infectious disease theory.
1.1.2 BASIC AND EFFECTIVE REPRODUCTION NUMBER 
Basic reproduction number. The basic reproduction number, Ro (reproductive 
rate is also used in the literature), is defined as the number of secondary 
infections that would be produced in a completely susceptible large population by
19
a typical infectious individual (Anderson and May, 1991). Ro can be formally 
written as (adapted from Anderson and May, 1991):
Ro = cpd (1)
where, c is the average number of new contacts (exposure with infection) made 
by an individual per unit of time; p is the probability of transmission per contact 
and; d is the duration of infectiousness. Hence, Ro is composed of both infectious 
disease (p, d) and socio-demographic (c) characteristics and therefore its value 
not only varies between infectious agents, but also between different populations 
(e.g. rural vs. urban). This is important as the effectiveness of an intervention 
may vary from one population to another or within a population.
Effective reproduction number. Ro assumes that all individuals in the population 
are susceptible which is, most often, clearly not the case. In most situations (the 
recent SARS outbreak being a notable exception) not all individuals are susceptible 
to infection, as some are immune through previous infection or vaccination. In 
such populations the expected number of new cases produced by an infectious 
individual is less than Ro, since contact with an immune individual does not result 
in infection. The effective reproduction number, R(t), is defined as the number of 
secondary cases an infectious individual causes on average in a population at time 
t (adapted from Anderson and May, 1991). R(t) can formally be written as:
R(t)= RoS(t) (2)
where, S(t) is the time-dependent proportion of contacts (population) that are 
susceptible to infection. It should be stated that this formal representation of R(t) 
represents a simplified case where the population mixes homogeneously without 
immigration or emigration.
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R(t), the state of infection in a population and impact of vaccination. Ro and
R(t) provide us with a simplified conceptual framework to understand the 
important issues of infection in a population as well as the effects of intervention 
against infectious disease. The value of R(t) indicates whether the number of new 
infections are increasing (R(t)>1), at equilibrium (R(t)=1) or decreasing (R(t)<1) in 
a population. For an infection to establish itself in a population Romust be greater 
than 1. If the infection becomes endemic and is at equilibrium (average incidence 
does not change) then R(t)=1 (each infectious case produces on average one new 
infection). Given equations (1) and (2) the proportion of susceptibles (S(t)) at 
equilibrium will be:
R = R0S(t) = 1
S(t) = 1/R0 (3)
R(t) must be lower than 1 for transmission to be reduced in the population 
(R(t)<1). Since, Rodoes not change within a population unless its characteristics or 
the infection changes, it is by reducing the fraction (S(t)) of susceptibles that R(t) 
can be kept lower than 1. If the proportion of the population that is susceptible 
(S(t)) is maintained (by preventing new susceptible of entering) so that R(t) 
remains lower than 1, the number of new cases in each successive generation of 
cases will be insufficient to sustain infection in the population and would 
eventually lead to elimination.
The necessary fraction of susceptibles for elimination can be maintained by 
vaccinating a proportion of the birth cohort. The necessary coverage (proportion 
immunised), p, can formally be written as:
R = Rox =R0(1-p) < 1 
p ¿  1-1/R0
21
(4)
This means that a higher Ro requires higher vaccine coverage for elimination. A 
higher Ro can correspond to a mix of higher contacts (exposure), transmission 
probability per exposure or increased duration of infectiousness.
It should be noted that if infection is controlled but not eliminated by vaccination 
(coverage and therefore threshold of susceptible is not attained), in the long run 
the infection will reach a new lower equilibrium of infection (R*=1).
1.1.3 HERD-IMMUNITY
As seen in the previous section, it is possible to eliminate an infectious disease in 
a population without vaccinating everyone. This is the classic example of the 
indirect effect produced by herd-immunity. There are many definitions for Herd- 
immunity. In this thesis we use the definition proposed by Fox et al. (1971), which 
is as follows:
*’Herd-immunity is the resistance of a group to the attack by a disease to 
which a large proportion of the members are immune, thus lessening the 
likelihood of a patient with a disease coming into contact with a 
susceptible individual.”
We use this definition as it includes both total and partial protection. Total 
protection produced by herd-immunity, also known as the threshold concept of 
herd-immunity, is when a typical primary infection produces less than one 
secondary case (i.e. R(t)<1)). That is, when the number of susceptibles in the 
population is below the epidemic threshold. Partial protection is when the 
presence of immune individuals lessens the risk of infection in susceptibles. In 
Chapter 3 we illustrate and describe in detail the effects of herd-immunity on the 
dynamics of infection using routine varicella vaccination as an example.
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1.1.4 FORCE OF INFECTION
The force of infection is defined as the instantaneous incidence rate of infection 
amongst susceptibles. Formally, in a homogeneously mixed population it can be 
defined as:
A(t) = pd(t)
where c is the average number of new contacts made by an individual per unit of 
time, p is the probability of transmission per contact and l(t) is the number of 
individuals at time t that are infected. The force of infection at any time depends 
on the number of infectious individuals in the population at that time. Vaccination 
can significantly reduce the number of infective individuals in a population 
reducing the force of infection and therefore the risk of new infection amongst 
susceptibles. As described in the previous section, this mechanism can be defined 
as Herd-immunity (partial protection).
Please refer to Grenfell and Anderson (1985) and Farrington et al. (1990) for more 
details on the different methods that can be used to measure the force of 
infection. In Chapter 2, we formally present the method developed by Farrington 
et al. (1990) using varicella as an example.
1.1.5 IMPACT OF VACCINATION
The overall impact of vaccination is dependent on the type of strategy that is 
adopted to control the infectious disease. There are three main strategies: 1) 
Routine Targeted Vaccination, 2) Routine Mass Vaccination, 3) Vaccination 
Campaigns (or Catch-up). These programmes are designed to achieve one or all of 
the three main goals of vaccination: 1) reduction of morbidity (through control of 
infection), 2) elimination and 3) eradication (Allwright, 1988). Herd-immunity can
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play an important factor in reaching these goals. However, its impact depends on 
the vaccination strategy.
Routine Targeted Vaccination. The goal of routine targeted (or selective) 
vaccination is to reduce infection/transmission and/or morbidity in a specific sub­
group of a population that is either more at risk of infection, transmission or 
disease. Vaccination can be targeted at core transmitters of the virus (core 
groups). Such a policy has an aim of substantially reducing overall morbidity in the 
population by immunising a limited sub-group of the population. In these cases 
herd-immunity is the basis of the vaccination strategy. An example of this is 
vaccination of highly sexually active individuals (e.g. prostitutes) to reduce 
sexually transmitted disease in the overall population.
Vaccination can also be targeted at sub-groups, which are at greater risk of 
infection or disease but are not core transmitters. Example of this can be targeted 
vaccination of health care workers, travellers or the elderly against influenza, 
pneumococcal disease or zoster. Vaccination in such instances does not have a 
significant impact on transmission in the population (does not significantly reduce 
the force of infection) and therefore herd-immunity is not a factor of influence. In 
Chapter 3, we investigate the impact of targeted vaccination of susceptible pre­
adolescents against varicella and illustrate how herd-immunity has little impact on 
overall reduction of infection and disease.
Routine Mass Vaccination. Routine Mass (Universal) vaccination has historically 
been the most common vaccination strategy (although this is changing due to 
scarcity of resources and the smaller impact of new vaccines). Universal 
vaccination consists of vaccinating most individuals in a population when they
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reach a target age. The age at vaccination is chosen to minimise the time 
individuals in a population are susceptible. Usually, such a strategy is given to very 
young children. However, with vaccines that are being developed to prevent 
sexually transmitted infection/disease (i.e. Human Papillomavirus and HIV) 
routine mass vaccination could be targeted at adolescents before the start of 
sexual activity. Routine mass vaccination usually requires the maintenance of an 
infrastructure to ensure high coverage to increase the effectiveness of the 
programme and to limit the chances of adverse effects.
There are three levels of control that can result from routine mass vaccination. 
The most common is control of infection (infection remains endemic but at a 
lower level than before vaccination). If vaccine coverage is sufficient and it 
protects against infection it will affect the transmission and thus produce herd- 
immunity effects (externalities). The main herd-immunity externalities are: 1) 
reduction of infection in susceptibles (e.g. non vaccinees), and 2) shift in the age 
at infection and possible increase in overall morbidity (usually from children to 
adults). In Chapter 3, we describe in detail and illustrate these herd-immunity 
effects using varicella vaccination as an example.
The second level of control through universal vaccination is elimination. 
Elimination of an infectious disease occurs when there is no longer endemic 
transmission within a population (De Serres et al., 2000). Only when cases are 
imported do isolated outbreaks occur. As described in section 1.1.2, this occurs 
when the herd-immunity threshold is surpassed. An example of this is measles in 
developed countries such as Canada and the USA (De Serres et al., 2000).
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Finally, the highest level of control from routine vaccination is eradication. This 
occurs when the virus, bacteria or other pathogen that causes infection is 
eradicated from the planet. Eradication can also allow cessation of routine 
immunisation and thus can produce infinite savings and benefits (although in 
practice discounting negates this effect). Smallpox is the only disease that has 
been eradicated. However, a programme is underway to eradicate poliomyelitis.
Vaccination Campaigns (Catch-up). Vaccination campaigns consist of vaccinating 
a target age range within a short period of time. It is usually used in addition to 
routine mass vaccination to accelerate the effectiveness of such programmes. We 
show, in Chapter 3, the effect of Catch-up campaigns using varicella vaccination 
as an example.
In the thesis, we have chosen to investigate the public health and health economic 
impact of introducing routine targeted and mass varicella vaccination in the 
United-Kingdom (with or without catch-up), rather than targeted vaccination of at 
risk populations such as healthcare workers. This is due to three main reasons. 
First, previous evidence has shown that a vaccination strategy for healthcare 
workers has the potential to be a cost-effective use of health care resources (Gray 
et al., 1997; Nettleman 6t Schmid, 1997). Secondly, the main policy question 
regarding varicella vaccine in Australia, Canada, the United Kingdom, and many 
countries in Europe currently is whether mass vaccination is desirable (Canada, 
1999; England and Wales, 2002). Although the United-States introduced routine 
varicella vaccination in 1994 (Committee on Infectious Diseases, 1995), some 
important concerns have prevented the introduction and implementation of 
routine vaccination in many developed countries such as Australia, the United- 
Kingdom and most countries in Europe. Finally, the second main aim of the thesis
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is to investigate the methodological challenges related to the unique 
characteristics of vaccination (e.g. herd-immunity externalities) which are mainly 
present in the evaluation of mass vaccination.
1.2 M O DELL ING  TH E EFFECT IVENESS OF VACC INATION
PROGRAM M ES
There are many types of epidemiological models that are used to assess the 
impact of vaccination. The choice of an adequate model should depend on the 
type of population, infectious disease and vaccination programme being 
evaluated. There are two main classes of model that are used in the evaluation of 
vaccination programmes: 1) static and 2) dynamic models. Both classes can model 
the natural history of infection (Figure 1.1). The main difference between these 
two models is the way in which the force of infection (per-susceptible rate of 
infection) is calculated. Using the dynamic approach the force of infection is 
dependant on the number of infectious individuals in the population (Edmunds et 
al., 1999; Anderson and May, 1991; Nokes and Anderson, 1988), whereas static 
models treat this rate as a fixed parameter (Edmunds et al., 1999). Since mass 
vaccination results in fewer infectious individuals in the population, under the 
dynamic framework the force of infection will decline over time producing herd- 
immunity externalities. On the other hand, under the static framework the force 
of infection remains unaltered and therefore herd-immunity is not included. 
Presently, the majority of economic analysis of vaccination programmes use static 
models. Although these models do not take into account the effects produced by 
herd-immunity, authors occasionally claim to be taking account this externality.
An in-depth description of the different types of infectious disease transmission 
models is beyond the scope of this thesis. For a comprehensive textbook on the
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subject please refer to Anderson and May (1991) or Bailey (1975). For more 
information on the difference between static and dynamic models please refer to 
Edmunds et al. (1999). In Chapter 3, we quantify and illustrate the difference 
between static and dynamic deterministic models, using varicella vaccination as 
an example.
1.3 M EASURING  TH E BENEF IT  OF VACC INATION
1.3.1 FRAMEWORK FOR JUDGING VALUATION TECHNIQUES
In health economics, there are, at least, two competing views of what should be 
measured when estimating the benefit of health interventions: 1) Welfarism and
2) Extra-Welfarism (Tsuchiya and Williams, 2001; Brouwer and Koopmanschap, 
2000). Welfarists believe that the output of health intervention should be judged 
according to the extent to which it contributes to overall welfare, as determined 
by individual preferences over health relative to arguments in the utility function 
(Dolan 2001) and that monetary valuation of benefits should be used. Extra- 
Welfarists believe that other types of measure can be used, and would be more 
pertinent, than individual preferences in the context of resource allocation 
(Culyer, 1990; Wagstaff, 1991; Brouwer and Koopmanschap, 2000) and that the 
benefits of health interventions should be based on quantifiable and comparable 
health outcome measures such as Life-years and QALYs gained (McGuire, 2001). 
The aim of this thesis is not to examine which theoretical foundation is most 
justified. Rather, we examine from an empirical perspective, what are the 
advantages and disadvantages of the different valuation methods in the context of 
vaccination.
Vaccination is different from most health interventions found in the literature 
because it:
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1) is a preventative intervention (in contrast to curative or palliative),
2) protects against infectious disease,
3) often prevents diseases that are short-lived and/or self-limiting (and can 
be mild),
4) is usually given to young children from whom it is very difficult to elicit 
health/program preferences.
Because of this unique combination of characteristics, vaccination may possess its 
own valuation problems. Brazier and Deverill (1999) proposed a checklist for 
judging the merits of measures of interventions, which include: 1) Practicality, 2) 
Reliability, 3) Validity (description, valuation and empirical) (see Table 1.1a). In 
this thesis we modify this and concentrate on Practicality, Validity (Content and 
Empirical) and Sensitivity (Responsiveness) in the context of vaccination (See 
Table 1.1b for the checklist for judging valuation techniques). Below we define 
these different components in the context of vaccination.
Practicality
An instrument must be acceptable to the responder and to those representing 
him/her, such as ethics committees (Brazier and Deverill, 1999). Measures of 
practicality can be duration of questionnaire, response rate and completion rate 
(refusal rates) and ethical refusal.
Validity
Validity is defined as the degree to which a valuation technique (test) is measuring 
what it is supposed to measure (Empirical validity) (Streiner and Norman, 1989). 
Furthermore, it is concerned with the relationship of the measure and the purpose 
to which it is being used (Content validity) (Streiner and Norman, 1989). That is, 
whether what is valued is relevant to the purpose of the study.
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Content validity. Content validity consists of determining (through value 
judgement) whether the instrument (technique) used takes into account all 
relevant/important domains or attributes (Streiner and Norman, 1989; Brazier and 
Deverill, 1999). Although this validity exercise is dependent on value judgements, 
it is important that the user of the instrument (as well as decision-makers) 
consider whether the assumptions and attributes being measured are appropriate 
for the intervention being evaluated.
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Table 1.1a. Checklist for judging the merits of preference-based measures of 
health (Brazier and Deverill, 1999)._______________________________________
Components
P rac t ica lity ■ H ow  long doe s the  in strum en t take ?
■ W hat is  the  re sponse  rate?
■ W hat is  the  com p le tion  rate
R e lia b ility ■ W h a t is  the  te st-re te st re liab ility ?
■ W ha t a re  the  im p lica tions fo r sam p le  s ize ?
■ W hat is  the  in te r-ra te r re liab ility?
■ W ha t is  the  re liab ility  betw een  p laces o f  adm in istra tion ?
Validity
Description ■ C on ten t Valid ity:
■  D oes the  in strum en t co ve r a ll d im en sion s o f  health  of 
in te re st?
■  Do the  item s seem  sensitive  enough ?
■ Face  Valid ity:
■  A re  the  item s re levan t and  app rop ria te  fo r  the  popu lation ?
• C on stru ct Va lid ity:
■  Can  the  unscored  c la ss if ica tion  o f  the  in strum ent detect 
know n o r expected  d iffe rence s o r chan ge s in hea lth ?
Valuation ■ Do the  a ssum ption s abou t p re fe rence s seem  c red ib le ?
■  W ha t is  the  m ode l o f  p re fe rence s be ing  a ssum ed?
■  W ha t a re  the  m ain  assum ption s o f  th is  m ode l?
■  H ow  w e ll are  the  patien t/gene ra l popu lation/decision - 
m akers like ly  to  con fo rm  to  the se  assum ption s?
■ W as the  techn ique  o f va luation  cho ice -based ?
■ Q ua lity  o f data
■  W ha t w e re  the  background  characte rist ic s  o f  the  re spondents 
to  the  va lua tion  su rvey?
■  W ha t w a s the  degree  o f va ria tion  in the  va lua tion  survey?
■  D id  re sponden ts’ unde rstand  the  va lua tion  task?
■  W ha t w a s the  m ethod  o f e stim ation  (w here  re levant)?
■ W hose  va lu e s  have  been u sed ?
Empirical ■ Is the re  any  e v idence  fo r  the  em p irica l va lid ity  o f  the  in strum ent 
against:
■  Revealed  p re fe rence s?
■  Stated  p re fe rences?
■  H ypothe sised  p re fe rence s?
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Table 1.1b. Framework for judging measures of the benefit of vaccination.
__________________Components_____________________________________
Practicality ■ How long does the instrument take?
■ What is the response rate?
■ What is the completion rate?
Validity 
Content Validity
Empirical Validity
Sensitivity
Does the  in strum ent cove r o r cap tu re  a ll re levant/ im portant 
dom a in s o r a ttr ibu te s?
■  D irect Health  e ffect?
■  C u rren t u se  Non H ealth  e ffects?
1. Caring  (A ltru ist ic  ex te rna lity ) am ong  vacc inées.
2. Secu rity  (In su rance  type  benefit)
■  N on -C u rren t u se  A ttr ibu te
1. A ltru ism  am ong  ind iv idua l w ho  is  not a t  risk  o f  d isease
2. O ption  Va lue
3. U nce rta in ty  o f  the  ou tcom e  o f in tervention
4. H erd -Im m un ity  E x te rna lity  (Se lfish  exte rna lity )
C rite rion  Valid ity:
■  H ow  do resu lts com pare  to  the  “G old  S ta n d a rd " o r  observed  
p re fe rences?
C onve rgen t Valid ity:
■  W ha t is  the  corre la tion  o f  the  in strum en t w ith  o thers w ith in  
s im ila r popu lation s?
C on struct Valid ity:
■  A re  re su lts con sisten t w ith  e xpected  theory ?
Techn ica l q ua lity  o f  the  study
■  Is the  sam p le  size  adequa te ?
■  Is the  m ethod  o f adm in istra tion  o f  the  questionna ire  
app rop ria te  (e.g. ?
W hose  va lu e s  a re  e lic ited ?
Is the  in strum ent sensit ive  to  sm a ll change s in w e ll fa re ?
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It has been demonstrated that health is not the only source of well-being that can 
be derived from public health interventions (Mooney, 1994; Birch et al., 1999; 
Olsen and Smith, 2001)). Individuals may find benefit in the characteristics of an 
intervention which do not affect the health outcome (Mooney, 1994). We classify 
intervention attributes according to three mutually exclusive categories: 1 ) Heath 
related attributes, 2) “Current use” non-health attributes and 3) “Non current 
use” attributes (Olsen and Smith, 2001).
11 Direct effect on health: The principal benefit that can be derived from 
vaccination is that it prevents the vaccinee from acquiring disease and thus losing 
health related quality of life. Health related quality of life being defined as a 
state of physical, mental and social well-being and not merely absence or 
presence of disease (World Health Organisation, 1947). Hence, an individual’s 
health state should comprise not only of main quantitative health outcomes such 
as physical function, social function and mortality but also qualitative outcomes 
such as, health perception and psychological function. Other direct effects on 
health from vaccination could also be the side-effects related to the vaccine 
itself.
21 “Current use” non-health attributes: As mentioned above, individuals may find 
that an intervention can yield benefits beyond improvement in health (Mooney, 
1994). In the literature the most commonly measured non-health attribute is 
“process utility” (Berwick and Weinstein, 1985; Donaldson et al., 1995; Donaldson 
and Shackley, 1997; Donaldson et al., 1997; Ryan, 1996) in which patients gain 
utility from the process by which the intervention is provided (e.g. content or 
delivery of a programme)(Mooney, 1994). There are two potential non-health
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attributes specific to vaccinees: 1) Caring externality (Altruism) and 2) Security 
(Insurance type benefits).
Caring externality (Altruism): Externalities can be classified into two broad 
categories: selfish and altruistic (Labelle 8t Hurley, 1992; Johannesson, 1996). 
Altruism occurs when individual A cares about individual B’s consumption of health 
care and/or health status and this enters A’s utility function. Selfish externalities 
exist when individual A cares about individual B’s consumption of health services 
because B’s consumption of health services affects A’s (expected) health status. 
Vaccinees may derive benefit from the knowledge that by being vaccinated they 
will not infect others. Such a benefit can be called caring (paternalistic or 
altruistic Altruism). It should be noted that this externality should be considered 
different to the herd-immunity externality, which can be considered a selfish 
externality among non-users (i.e. individuals find benefit in that others are 
vaccinated because it indirectly protects them against disease (see below for 
more details)). For non-infectious disease, caring externalities (Altruism) are 
usually “non-current use” attributes, which are derived from individuals (not at 
risk) finding benefit from the knowledge that others in the population have access 
to an effective intervention (O’Brien et al., 1998; Neumann and Johannesson, 
1994)).
Security (Insurance type benefits). Immunisation is a preventative intervention 
against the uncertain future event of catching disease. Thus, being vaccinated can 
be viewed as taking insurance against disease. Because individuals are generally 
risk averse in relation to health, they may find an added benefit in the knowledge 
that they are protected against disease (i.e. a potential for improving welfare by 
reducing or eliminating uncertainty). This type of attribute is similar to the “Non
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current use” attribute referred to as Option value, where individuals find value in 
the presence of a programme because they may need it in the future (O’Brien and 
Gafni, 1996; Birch et al., 1999).
31 “Non-current” use attributes: The types of Non current use attributes most 
addressed in the health economic literature are: 1) caring externality, in which 
individuals find benefit in vaccination although they are not at risk of the disease, 
2) Option value and 3) Uncertainty of the outcome of intervention (Olsen et at., 
2001; O’Brien and Gafni, 1996; O’Brien et at., 1998; Birch et at., 1999). Apart 
from these, vaccination also produces Herd-Immunity Externalities (Selfish 
Externality).
Herd-Immunity Externalities (Selfish Externality): As described above, the herd- 
immunity externality (Weisbrod, 1961), comes from the benefits of being partially 
protected to infectious disease because a proportion of the population is 
vaccinated. However, as will be shown in Chapter 3, herd-immunity can produce 
both positive and negative effects (e.g. protects non-vaccinated susceptibles 
against infection but can increase overall morbidity and mortality by shifting the 
age at infection).
In Chapter 4, we examine whether some of the attributes of vaccination 
mentioned above exist, are measurable and, if so, assess their relative importance 
compared to direct health effects. We now concentrate on Empirical Validity.
Empirical Validity. Empirical validation of valuation techniques in health care 
are very difficult due to the hypothetical nature of many of the questions 
(Drummond, 1997). Ideally, results should be compared to a “gold-standard” or
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criterion (criterion validity). Furthermore, if the aim is to measure individuals’ 
preferences then the goal is to verify if the values elicited reflect practice. 
Because of the difficulty measuring criterion validity (due to the lack of a “gold 
standard”), other validation tests have been suggested. First, if other valuation 
instruments exist, convergent validity can be used, which consists of measuring 
the correlation of the instrument with others within a same sample population. 
The second approach is to measure construct validity. This consists of examining 
whether the instrument produces results that are consistent with expected theory 
(i.e. the value of preventing a disease increases with its severity).
Many economic instruments for measuring the benefit of intervention will use data 
elicited from valuation studies. These studies vary in terms of their respondents, 
the size of the sample, response completion, and the method of administering the 
questionnaires (e.g. interview or self-administered questionnaire, paper vs. 
electronic questionnaire, and use of props), which have important implications on 
the internal and external validity of results. Hence, an important component of 
validity is what is termed technical quality of the study.
The validity of an instrument is also dependant on whose values are elicited 
(Brazier and Deverill, 1999). Valuations can vary by disease experience, state of 
health, age, education and sex. Whose values should be used? Should it be those 
who are at risk or affected by the disease or the general public? De Wit et al. 
(2000) consider this question in detail. Our aim here will not be to argue which 
value should be used but to show the divergence/convergence of responses 
according to responders’ characteristics. As described above, an added problem 
with vaccination is that it is usually given to young children from whom it is very 
difficult to elicit health/program preferences due to measurability (too young to
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answer questionnaires) and comparability issues (ability to comprehend questions 
evolves over time for children) (Petrou S, 2003). The use of proxies is thus 
needed, which adds an additional level of complexity. See Petrou (2003) and Eiser 
and Morse (2001) for more information on the methodological challenges of 
measuring the health status of children using preference based approaches.
Sensitivity to change (Responsiveness)
The goal of a valuation technique, in economic evaluation, is to measure changes 
in well-being (or change in welfare) following intervention. Hence, valuation 
techniques must be sensitive to change. This is of particular importance with 
vaccination, as many of the diseases it prevents are short-lived, self-limiting 
and/or mild.
1.3.2 INTERVENTION OUTCOMES AND VALUATION TECHNIQUES
There are three predominant types of economic analysis (Drummond et aL, 1997):
■ Cost-Benefit: Analysis in which both costs and consequences (benefits) of 
alternatives are measured in dollars.
■ Cost-Effectiveness: Analysis in which costs are compared to a single, common 
effect which may differ in magnitude between the alternative programmes 
(e.g. Cost per life-year gained, Cost per case averted).
■ Cost-Utility: Analysis in which utilities are employed to measure the value of 
an intervention (e.g. Cost per Quality-Ad justed Life-Year).
The feature that distinguishes among techniques of economic evaluation is the 
way in which the benefit of health care programmes are valued.
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In the following section we describe the different valuation 
instruments/techniques and outcomes that can be used to measure the benefit of 
interventions, focussing on the potential advantages and disadvantages of their 
use in the valuation of vaccination programmes (using the checklist proposed in 
Table 1.1b).
1.3.2.1 Monetary Values
The main advantage of using monetary values is that it values benefits in the same 
unit as the costs and therefore allows direct comparison (Olsen and Smith., 2001, 
Birch et al., 1999, Bala et al., 1998; O’Brien and Viramontes, 1994; O’Brien and 
Gafni, 1996; Klose, 1999). Furthermore, it allows intersectoral comparisons (e.g. 
transport and environment) of resource use (O’Brien and Gafni, 1996). On the 
other hand, the main disadvantage is the widespread reluctance of policymakers 
in the healthcare sector to evaluate health changes in monetary terms (Drummond 
et al., 1997; Johannesson, 1996; Brouwer and Koopmanschap, 2000).
Here, we define and discuss the properties of the three general approaches to the 
monetary valuation of the benefit health interventions: 1) Human Capital, 2) 
Revealed preferences, 3) Stated preferences (Contingent valuation) (Drummond et 
al., 1997). See Table 1.2 for details.
Human Capital Approach. The Human Capital approach consists of measuring 
monetary weights on healthy time using market wage rates and the value of the 
programme is assessed in terms of the Present Value of future earnings 
(Drummond et al., 1997). Monetary valuation of the benefit of health 
interventions started with this approach which was popularised in the early 1960s 
by Becker (1964). One of the more cited examples of Human Capital was for the
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evaluation of Rubella vaccination (Schoenbaum et al., 1976). The Human Capital 
approach was widely criticised in the 1970s by economists who argued that the 
approach was not rooted in welfare economics or the economic concept of 
opportunity cost (Shelling, 1968; Mishan, 1971). This combined with its many other 
disadvantages (Table 1.2) lead empirical work on monetary valuation of health 
intervention in two main directions: 1) Revealed preference and 2) Contingent 
valuation (Stated preference).
Revealed preference. The Revealed preference approach measures individual 
observed trade-offs (e.g. conscience choice to buy/not to buy or use/not use a 
good or service) (Viscusi, 1978; Marin and Psacharopoulos, 1982). Its major 
advantage is that it is based on observed consumer choices rather than the stated 
preferences (e.g. Contingent valuation, see below) (Drummond et al., 1997). 
However, it is difficult and often impossible, to find an occupation where the 
relevant outcome is the focus of compensation. This is particularly true when 
evaluating the benefit of vaccination where the disease prevented is infectious, 
often mild and acute. Furthermore, because of the many imperfections in the 
labour market and limitations in how individuals perceive occupational risk, it may 
not reflect the rational choice revealing preferences wanted (Viscusi, 1992). 
Because of theses limitations Revealed preferences are very seldom used in 
economic evaluation. See Viscusi (1992) for an in-depth review of Revealed 
preference.
Contingent Valuation (CV). The use of Monetary values to assess benefit, and 
therefore Cost-Benefit analysis, has had renewed interest among health 
economists due to the increased popularity of CV which, was first developed in 
environmental economics to estimate the value of environmental changes (Olsen
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and Smith, 2001; O’Brien and Gafni, 1996; Klose, 1999; Diener et al., 1998; 
Johannesson, 1993; Johannesson and Weinstein, 1996). CV consists of presenting 
to respondents hypothetical scenarios about programmes and asking them to 
express their maximum Willingness to Pay (WTP) to have the programme in place 
(or some variation of this which we will present later) (Diener et al., 1998; 
O’Brien and Gafni, 1996; Johannesson and Weinstein, 1996; Drummond et al., 
1997). There is enormous diversity on how a CV study in health care can be 
performed. To describe the methodological questions and considerations we 
present in Table 1.3 the framework proposed by O’Brien and Gafni (1996) (for 
more detailed information on CV and WTP please refer to Johannesson (1993), 
O’Brien and Gafni (1996), Johannesson and Weinstein (1996), Drummond et al. 
(1997), Olsen (1997), Dienar et al. (1998), Klose (1999), Bala et al. (1999) and, 
Olsen and Smith (2001)).
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Table 1.2. Monetary values in the context of vaccination
Human Capital Revealed Preference Contingent Valuation
Definition ■  Healthy time measured as the ■  
Present Value of future earnings
Wage-Risk trade-off. ■  Respondents are given hypothetical scenarios about the 
programme or problem under evaluation.
Theoretical
basis
■  Not rooted in welfare economics ■ 
(1,2).
Rooted in welfare economics: Measures 
consumer choice involving heath versus 
money (6).
■  Based on welfare economic theory (7-11 ).
Practicality ■  NA ■ NA ■  Good response and completion rates (8,10), except when 
open-ended questions are used (11,12,13)).
Validity
Content
E m p ir ic a l
Cannot measure non-health 
attributes of an intervention.
Raises problems on how to place 
shadow prices on non-market 
resources (e.g. child health time) 
(3,4,5).
Criterion, Convergent or Construct 
validity not demonstrated.
Cannot measure non-health attributes 
of an intervention.
Difficult or impossible to find an 
occupation where the relevant 
outcome is the focus of compensation.
Does not reflect the rational choice 
revealing preferences wanted due to 
many imperfections in the labour 
market (6).
Estimates vary widely and values are 
very context and job-specific (6).
No restrictions on which dimensions of a programme 
people are allowed to express a value for (7,9-11 ).
Criterion Validity. Hypothetical WTP exceeds observed 
WTP (14).
Construct Validity. Strong Correlation with health gain 
and income. (10,13,15-17)
Convergent Validity. Week correlation with other 
monetary (13) and non-monetary health measures 
(10,13,18,19).
Bias: Evidence of warm-glow effects and strong evidence 
of starting point bias (14,20,21)
Sensitivity ■  Sensitive to small changes in well 
being
Not sensitive to small changes in well 
being
Sensitive to small changes in well being (8,16,22). 
However, may be oversensitive to small changes in well 
being (19,23,24)
Insensitive to size of the programme (14),
1. Shelling 1968; 2. Mishan 1971; 3. Klarman 1967; 4. Weisbrod 1968, 5. Drummond et al., 1997; 6. Viscusi 1992; 7. Olsen et al., 2001; 8. Birch et a t, 1999; 9. Bala et al., 1998; 10. O’Brien and 
Viramontes, 1994; 11. O’Brien and Gafni, 1996; 12. Johannesson and Weinstein, 1996; 13. Klose, 1999; 14. NOM, 1993; 15. O’Connor and Pennie, 1995;16. Kartman et al., 1996; 17. Zillich et 
al., 2002; 18. Stavern, 2002; 19. Clarke, 2002; 20. Boyle et al., 1985; 21. Stalhammar, 1996, 22. Smith, 2001; 23. Seip and Strand, 1992; 24. Duffield and Patterson; 1991.
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Table 1.3. Questions and Considerations for a Contingent Valuation Study
Q u e st io n  C o n s id e ra t io n
What question do we want to answer?
What type of measure is used?
What is asked of whom?
What characteristics of the program 
are important for determining how it is 
valued?
What question formats minimise bias 
and increase precision?
Problem  Definition:
1. Pricing and demand studies
2. Project appraisal for resource allocation 
Current Status of Program:
1. Program  currently exists
2. Program does not currently exist 
(Disutility of program to respondent:
1. Gain in utility from  program
2. Loss of utility from program 
Monetary measure of utility change:
1. Compensating Variation: Use money to adjust consumers’ 
utilities to their pre-programme level.
2. Equivalent Variation: Use money to adjust consumers’ 
utilities to their post-programme level.
‘‘Direction" of measurement:
1. W illingness to pay (WTP)
2. Willingness to accept (WTA)
Externality and option value:
1. Currently Diseased
2. Currently Non-diseased: At future risk
3. Currently Non diseased: Not at future risk 
Framing of program consumption and payment:
1. Ex-post user-based question: Respondent is asked to 
assume he or she is at the point of consuming some unit of 
the programme being evaluated.
2. Ex-ante insurance-based question: Respondent is asked to 
assume they are at risk, in the future, of a disease and 
consuming some unit of the programme being evaluated.
Program outcome description:
1. Certain outcomes
2. Uncertain outcomes
Nature of “market” for valuation scenario:
1. Public good m arket
2. Political market 
Valuation scenario:
1. Holistic versus decomposed
2. Degree of Realism 
Value elicitation method:
1. Open-ended questions: Respondent asked directly for 
maximum WTP (minimum WTA)
2. Bidding Games: A first bid is made to the respondent, who 
accepts or rejects, and then the bid is raised or lowered.
3. Payment Card: Range of WTP (WTA) values from which the 
respondent may choose.
4. Take it or leave it: Respondent is asked if he is WTP (WTA) 
a random chosen value (out of a large number of 
determined prices).
5. Take it or leave it (with follow-up): Take it or leave it 
method with a follow-up bid question given to the 
respondent.
Questionnaire type (Added from O’Brien and Gafni (1996):
1. Face to Face interview:
2. Telephone Interview
3. Mail Questionnaire
4. Interactive Computerised Questionnaire:_______________
Adap ted  from  O ’Brien and  G afn i (1996).
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Table 1.2 shows the strengths and weaknesses of the CV method. The main 
arguments for the superiority of WTP as a measure for health intervention are that 
it: 1) is theoretically correct, because of its base in Welfare economic theory, 2) 
values benefits in the same unit as the costs and therefore allows direct 
comparison and, 3) provides a method of valuation that is familiar to individuals 
(Olsen and Smith, 2001; O’Brien and Gafni, 1996; Klose, 1999; Diener et al., 1998; 
Johannesson, 1993) although the extent to which this is true in health care 
systems that are largely free at the point of service is debatable. Other 
aspects/qualities of CV may make it particularly appropriate for evaluating 
vaccination (Birch et al., 1999). It is sensitive to small changes in well-being at 
the individual level (Birch et al., 1999; Kartman et al., 1996; Smith, 2001) and 
many vaccines that are now available prevent self-limiting, acute and/or mild 
diseases (e.g. varicella and influenza). This may also be a disadvantage if CV is 
oversensitive to small changes in well-being making the results unstable (see 
below). Second, it imposes no restrictions on which dimensions of a vaccine 
programme individuals are allowed to express a value for (Olsen et al., 2001; Birch 
et al., 1999; Bala et al., 1998; O’Brien and Gafni, 1996). WTP should thus be able 
to measure the different “Current use” non-health attributes and “Non current 
use” attributes of vaccination described above (caring externalities, security).
On the other hand, the principal disadvantage of the CV techniques is that the 
hypothetical WTP is usually found to be higher than the actual WTP and may be 
oversensitive to small changes in health or programme benefits (Seip & Strand, 
1992; Duffield and Patterson; 1991; Clarke, 2002). Individuals may be limited by 
their ability to pay. Finally, there is little evidence of empirical validity (Klose et 
al, 1999; National Oceanic and Atmospheric Administration, 1993).
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1.3.2.2 Natural Units
In cost-effectiveness analysis, costs are compared to a single one-dimensional 
natural unit of health, which may differ in magnitude between the alternative 
programmes. Examples of natural units are cases, hospitalisations and deaths 
averted. The most commonly used natural unit is life-years gained (Tsuchiya and 
Williams, 2001).
Table 1.4. Natural Units in the context of vaccination
Natural Units
Definition ■ Single one-dimensional unit of health change.
Theoretical ■ Not based on welfare economic theory or on the concept
basis of choice and opportunity cost.
Practicality ■ Easy to estimate outcomes based on literature review or 
results from clinical trials.
Validity
Content ■ Cannot capture more than one health attribute.
• Cannot measure non-health attributes.
Empirical ■ Dependent on the studies the outcome is based upon. 
Easier to assess than Contingent Valuation or Quality of 
Life Measures. Can measure Criterion Validity.
Sensitivity • Dependent on the outcome that is chosen.
The main advantage of Natural Units are that they are easier to estimate, have 
greater validity and are less subjective than Monetary Values or Quality of Life 
outcomes as they can be found in a review of medical literature or taken directly 
from clinical data on effectiveness (Table 1.4). On the other hand, Natural Units 
are one-dimensional and therefore cannot capture simultaneously the benefit of 
an intervention on all attributes of health and therefore, it is difficult to make 
comparison across a broad range of effects (Table 1.4). This is a major 
disadvantage when estimating the desirability of vaccination under scarcity. For 
example, currently many developed countries are choosing between vaccinating 
children against varicella (which is prevalent but mild) and/or meningogoccal 
disease (which has low prevalence but a high case-fatality) and/or pneumococcal
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disease (which has low prevalence but high morbidity). In this situation, only by 
using measures that incorporate multiple dimensions of Health (Monetary Values 
or Quality of Life measures) can the different vaccination programmes be 
appropriately compared. Alternatively, an array of different Natural outcomes can 
be presented to decision-makers who then must make their own trade-off 
between effects (Drummond et al., 1997).
1.3.2.3 Health-Related Quality-of-Life Outcomes
The main advantage of using Health-Related Quality-of-Life (HR-QOL) values is 
that it allows a broad range of health attributes to be included into a single 
measure, which allows comparisons across a wide variety of health intervention 
programmes (Olsen and Smith., 2001, Birch et al., 1999, Bala et al., 1998; O’Brien 
and Viramontes, 1994; O’Brien and Gafni, 1996; Klose, 1999). On the other hand, 
its major critique is that it is incapable of capturing non-health benefits (Olsen 
and Smith, 2001; Donaldson et al., 1997).
Quality-Adjusted Life-Years (QALYs) are the most used method for measuring 
outcomes (Elixhauser et al., 1998), mainly because of the reluctance of 
policymakers in the healthcare sector to evaluate interventions in monetary terms 
(Drummond et al., 1997; Johannesson, 1996; Brouwer and Koopmanschap, 2000). 
The concept of QALY was developed to capture simultaneously gains from reduced 
morbidity and reduced mortality, and to combine these into a single measure. The 
measure assigns a Quality of life-weight, ranging from 0 to 1, where a weight of 1 
corresponds to optimal health and 0 corresponds to a health state judged 
equivalent to death (some states may be considered worse than death and would 
thus have a negative QALY). This weight is then multiplied by the years of life 
spent in the health state. The QALY gained is the difference, over time, between
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the QALY weight with and without the intervention. Several alternatives to the 
QALY have been suggested: Healthy-Year Equivalents (HYE), Saved-Young-Life 
Equivalents (SAVE), Disability-Adjusted Life-Years (DALY). Discussion of 
alternatives to QALY is beyond the scope of the thesis for more information please 
consult Drummond et al. (1997), Mehrez and Gafni (1989, 1991, 1992), Nord, 
(1992a) and World Bank (1993).
As discussed earlier, in this thesis we do not debate which theoretical foundation 
economic analysis should be based on, or whether QALYs are measures of utility, 
rather, we examine from an empirical perspective the different valuation 
techniques. In this section we describe and discuss the properties of the different 
methods that are used to value health interventions in terms of QALYs. These 
instruments are the 1) Visual Analogue Scale (VAS), 2) Standard Gamble (SG), 3) 
Time-Trade-Off (TTO), and 4) Multi-Attribute Utility Scales (MAUS). See Brazier et 
al. (1999) for an in-depth review of these techniques.
Visual Analogue Scale. VAS is used here interchangeably with the category rating 
scale (CR). The VAS consists of asking the respondent to reveal their preferences 
on a scale with well defined end points, which can be numbers, categories, or 
consist of a line on a page (Green et al., 2000; Drummond et al., 1997). Some 
empirical studies suggest that VAS can be transformed into SG or TTO by using 
power curves (Torrance, 1976; 1996).
The main advantages of the VAS is its practicality (i.e. ease of use and high 
completion rates) and its sensitivity to changes in health (Juniper et al., 2002; 
Salaffi et al., 2002) (Table 1.5). The main disadvantages of the VAS are that: 1) it 
is not a choice-based technique and therefore has no foundation in economic
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theory (Brazier et al., 2000) and, 2) there is evidence of poor to moderate 
correlation with choice-based techniques (SG and TTO) (Froberg et al., 1989; 
Bakker et al., 1994; Clarke et al., 1997; Read et at., 1984; Nord, 1992; Rutten-van 
Molken et al., 1995;). Furthermore, it has shown to produce End-of scale bias in 
which individuals tend to refrain from using the upper and lower end of the scales.
Standard Gamble. SG is the standard technique of measuring preferences under 
uncertainty. It is based on the Expected Utility Theory of decision-making under 
uncertainty, first presented by von Neumann and Morgenstern (1944). Similarly to 
CV it uses the economic concept of opportunity costs under uncertainty. SG asks 
individuals the probability (p) of immediate death (or some other outcome worse 
than the one being valued) they are prepared to accept to avoid the certainty of 
the health-state being valued (HSf - see Figure 1.2).
Figure 1.2. Standard Gamble
For a temporary Health State (HSj) a QALY-weight can be estimated from the SG as 
follows. The standard gamble questionnaire elicits the probability p that makes 
the respondent indifferent between the current condition (HS( * t + 1 * (L - t)) 
and the expected benefit of treatment ((1-p) * L + p * 0) (based on Figure 1.2).
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Where, HSi is the QALY-weight of health state i, QALY-weight for death is 0, QALY- 
weight for Healthy is 1, t is duration of disease, L is the current life expectancy 
and p is the probability of instant painless death following the intervention. From 
these equations we have:
HSi = {(L *(1-p))- (L-t)} /t
If the disease is chronic (t = L), then HS( = 1-p. We do not use discounting, here, 
because it is inconsistent with the QALY utility model (Mehrez and Gafni, 1989; 
Johannesson et al., 1994). Furthermore, these equations assume constant- 
proportional trade-off (Pliskin et al., 1980). Preferences for temporary health 
states can also be measured relative to each other using the SG and Chained 
methods. With the Chained methods, the health state to be evaluated is not 
weighed directly against death as it is in conventional SG measurement, but in a 
multi-step procedure using intermediate anchor health states, which are worse 
than the health state being valued. See Drummond et al., 1997 for more details 
and Jansen et al., 1998 for a published example of the method.
Researchers have suggested that the SG is too complex and not intuitive to most 
respondents (Froberg, 1989). The main reported problems with SG are refusals due 
to conflicts with personal beliefs or straightforward difficulties in understanding 
the tasks or dealing with small probabilities (Green et al., 2000). Completion rates 
have, however, been reported to be acceptable in many studies across different 
populations (Green et al., 2000). The main advantage of SG is that it has a basis in 
economic theory. That is, it is choice-based and is based on the Expected Utility 
Theory of decision-making under uncertainty (Table 1.5). The main disadvantage 
of using SG for vaccine preventable disease is that many are acute and non-life 
threatening. The use of SG (and TTO) to value morbidity for acute diseases has
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well documented measurement and evaluation problems (Bala, and Zardin, 2000; 
Bala et al., 1999; Stalmeier et al., 1996; Gafni, 1994; Dolan and Gudex, 1995; 
Stiggelbolt, 1995; Bleichrodt and Johannesson; 1997). Furthermore, SG has been 
shown to be insensitive to small changes in health status (De Wit et al., 2000). 
Finally, there is limited evidence of empirical validity of SG.
Time Trade-Off. TTO was developed by Torrance et al. (1986) as a simple 
alternative to the SG (i.e. to overcome problems of presenting probabilities of 
death). The TTO consists of asking the respondent to choose between two 
alternatives both with certain outcomes: health state i for time ti followed by 
death or Perfect health (or a better Health State) for time t2<ti. Time t2 is varied 
until the respondent is indifferent between the two alternatives. The preference 
score (HSj) for health state i is: HSf =1 -t2/ti. As with the SG technique, Chained 
methods can be used within the TTO framework to measure preferences for 
temporary health states relative to each other. See Drummond et al., 1997 for 
more details and Jansen et al., 1998 for a published example of the method.
i k
1 Alternative 1
Value
HSi Alternative 2
0 t2 ti "  Time
Figure 1.3. Time Trade-Off.
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TTO has been found to be easier to use and has shown better completion and 
response rates than the SG (Lenert et al., 2001; Dolan et al., 1996). Furthermore, 
although the literature available is sparse, TTO seems to have slightly higher 
empirical validly than SG (Green et al., 2000; Brazier et al., 1999). On the other 
hand, SG has greater foundation in economic theory (Table 1.5).
The main disadvantages of using TTO for vaccine preventable disease are similar 
to SG. That is, similarly to SG, TTO seems to be insensitive to small changes in 
health (Muirhead et al., 1994; Tsevat et aL, 1993; Bala, and Zardin, 2000; Bala et 
al., 1999; Stalmeier et al., 1996; Gafni, 1994; Dolan and Gudex, 1995; Stiggelbolt, 
1995).
Multi-Attribute Utility Scales (MAUS). Pre-scored Multi-attribute health status 
indices or Multi-Attribute Utility Scales (MAUS) are a simple alternative to the 
complex task of measuring preference through the techniques described above. 
These Multi-Attribute Health Status Classification systems can be transformed into 
utilities (QALYs) by adding one additional assumption to the three axioms of utility 
theory. The assumption is that utility independence among the attributes of 
health can be represented by at least first-order utility independence, and 
perhaps stronger utility independence (i.e additive utility independence)(Keeney 
and Raiffa, 1976). Here, we briefly describe three of the main systems available: 
1) EuroQol (EQ-5D), 2) Short-Form 6D (SF-6D) and 3) Health Utilities Index Mark 
ll(HUI2). For further information please refer to Brazier et al. (1999).
EQ.-5D. The EQ-5D was developed by the EuroQol Group (a multidisciplinary, 
European research network) as a generic, single index measure of health status for 
the use in the evaluation of health care interventions (EuroQol Group, 1990). It
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has widely been adopted in clinical studies and is in use in more than 30 countries 
world-wide. The EQ-5D includes five attributes: mobility, self-care, usual activity, 
pain/discomfort, and anxiety/depression. Each attribute has three levels thus 
producing 243 healthy states exclusive of unconscious and dead. The preference 
scores were originally measured using the TTO technique in the UK (Dolan et al., 
1996)
HUI2: The HUI2 was developed as a generic, single index measure of health status 
for the use in the evaluation of health care interventions (Torrance, 1996). 
Preferences for the HUI2 scoring function were measured on a random sample of 
parents of schoolchildren in the City of Hamilton (Canada) and surrounding 
districts using both the SG and a VAS. The HUI2 is comprised of 7 attributes: 
Sensation, Mobility, Emotion, Cognition, Self-care, Pain and Fertility (Fertility can 
be excluded if not required (Torrance, 1996)). The HUI2 is of particular interest 
for valuation of child vaccination as it was developed for chronic childhood 
diseases using parents as proxies.
SF-6D. The SF-6D was developed as a possible alternative to the EQ.-5D (O’Brien et 
al., In press). It is based on 6 of the 8 dimensions of the SF-36: Physical 
functioning, Role limitations, Social functioning, Pain, Mental health, Vitality. The 
General Health dimension was omitted from the SF-36 and Emotional and Physical 
Role limitation were combined into one dimension (Brazier et al., 2002). The 
combination of levels and attributes produce a universe of 18000 health states 
(Brazier et al., 2002). SG was used to elicit preferences among the UK general 
public (Brazier et al., 2002)
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The major advantages of MAUS, described in this section (i.e. HUI, EQ-5D, SF-6D), 
are that: 1) it is easy-to-use and briefly self-completed (compared to SG and TTO) 
(Brazier et al., 1999), 2) it has basis in economic theory (Keeney and Raiffa, 
1976), and 3) it can capture small changes in heath status (De Wit et al., 2000; de 
Vries et al., 1998) (Table 1.5). A further advantage for the HUI2, is that it is 
validated for childhood diseases (Torrance, 1996).
The major disadvantages of MAUS is that it cannot measure the potential non­
health attributes of vaccination and evidence of empirical validity is limited. A 
further concern is the recent empirical evidence, which casts doubt on whether 
QALYs estimated from the EQ-5D, HUI3 and SF-6D are comparable (O’Brien et al. 
(In press), Longworth and Bryan (In press)).
It should be pointed out that although we compare MAUS with VAS, SG and TTO in 
Table 1.5 we are not comparing like with like. This is because MAUS are not a 
method for collecting valuations but rather a method of calculating them. Hence, 
as shown in Table 1.5 MAUS inherit all of the theoretical problems of the valuation 
methods underlying them (SG, TTO or VAS) and incorporate assumptions about an 
underlying valuation model. Moreover, they use valuations from a sample other 
than the people in the study, unlike the other methods. Therefore, it should be 
born in mind that there are more differences between the techniques than are 
included in the Table 1.5. The goal of Table 1.5 is to show the advantages and 
disadvantages of different techniques that are used to estimate QALY values, 
which will be different between VAS, SD, TTO and SG.
Other HR-QoL instruments. Ratio Scaling or Magnitude Scaling (ME), developed in 
pychometrics, consists of asking respondents to provide a ratio of undesirability of 
pairs of health states (Green et al., 2000; Drummond et al., 1997). That is, a
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patients will state that health state A is 10 times worse than health state B. By 
asking a series of questions the disutility can then all be linked together and 
converted into an interval scale of preference. The Person Trade-Off (PTO), for 
example, asks respondents to state how many patients in a certain health state 
should have their lives extended by one year in order to be equivalent to 
extending the lives of 100 healthy patients by one year (Nord et al., 1993). We do 
not discuss these techniques as they are seldom used and their feasibility, 
practicality and theoretical validity are relatively unknown (Green et al., 2000).
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Table 1.5 .  HR-QoL techniques to value QALYs in the context of vaccination (Based on G reen  e t  al., 2000)
VAS Standard Gamble Time Trade-Off
Theoretical
basis
■  Not based on welfare 
economics.
■  Does not involve choice or 
opportunity cost (1,2,3,4).
■  Not based on welfare economics.
■  Based on Utility theory.
• Involves choice and opportunity costs 
under uncertainty (1,5,6).
• Not based on welfare economics or 
utility theory.
■ Involves choice and opportunity costs 
(1).
MAUS (HUI, EQ-5D, SF-6D)
Valued from SG (HUI, SF-6D) and 
TTO (EQ-5).
Practicality
Validity
Content
Empirical
Easy to use and quick.
High completion and response 
rates (6-12).
Complex and non-intuitive (6). 
Acceptable completion and response 
rates (21 -24). Lower than VAS and 
TTO (7,21).
Good completion and response rates 
(21,23, 28-30).
Easy to use and quick.
High completion and response 
rates (32).
Cannot measure non-health 
attributes (13).
Criterion Validity. Absence of a 
reference unit (1).
Construct Validity: Correlation 
with health gain (14,15). 
Convergent Validity: Moderate 
correlation/agreement with SG, 
TTO (6,11,16-19).
Bias: End of Scale Bias (2,9,20).
Cannot measure non-health attributes
(13).
Criterion Validity. Absence of a 
reference unit (1).
Construct Validity. Correlation with 
health gain (21,25).
Convergent Validity.
■  Reasonable (1,5,21,26) and poor 
(25,27) correlation/agreement 
between SG and TTO.
■  SG elicit greater utilities than TTO 
(1,3,25).
Bias: Possibility of starting point bias.
Cannot measure non-health attributes
(13).
Criterion Validity: Absence of a 
reference unit (1).
Construct Validity: Correlation with 
health gain (21,25,29, 31)
Convergent Validity:
■  Reasonable (1,5,21,26) and poor 
(25,27) correlation/agreement 
between SG and TTO.
■  TTO elicit lower utilities than SG 
(1,3,25).
Bias: Possibility of starting point bias.
Cannot measure non-health 
attributes (13).
Restrictive in the health 
dimensions being valued (32). 
Criterion Validity. Absence of a 
reference unit.
Construct Validity. Correlation 
with health gain (32,33). 
Convergent Validity: Reasonable 
correlation between SG and TTO 
(32). Differences in correlation 
between MAUS instruments (34- 
36).
Sensitivity ■  Sensitive to small changes in ■  Not sensitive to small changes in well ■  Not sensitive to small changes in well ■  Sensitive to small changes in well
________________ well being (14,15)._______________ being (15,40-45).______________________being (14,38-45)______________________ being (37).___________________
1. Green et a/., 2000; 2. Nord, 1991; 3. Drummond et at., 1997; 4. Richardson, 1994; 5. Torrance, 1986; 6. Froberg et al., 1989; 7. Lenert eta/., 2001; 8. Torrance, 1987; 9. Kaplan etal., 1993;
10. Busschbach et al., 1994; 11. Bakker et at., 1994; 12. Gudex et al., 1999; 13. Olsen et at., 2001; 14. Salaffi et at., 2002; 15. Juniper et al., 2002; 16. Clarke et al., 1997; 17. Read et at.,
1984; 18. Nord, 1992; 19. Rutten-van Molken et al., 1995; 20. Bleichrodt and Johannesson, 1997; 21. Dolan et al., 1996; 22. Rabin et al., 1993; 23. Patrick et al., 1994; 24. Lenert et al., 1997;
25. deW it, 2000;; 26. Krabbe et al., 1997; 27. Hornberger et al., 1992; 28. Johnson etal., 1996; 29. Ashby etal., 1994; 30. Fryback et al., 1993; 31. Gage etal., 1996; 32. Brazier etal., 1999;
33. Barr et al., 1993; 34. Stavern K, 1999; 35. O’Brien et a/.(in press); 36. Longworth et al. (in press); 37. de Vries et al., 1998; 38. Muirhead et al., 1994; 39. Tsevat et al., 1993. 40. Bala, and 
Zardin, 2000; 41. Bala et al., 1999; 42. Stalmeier et al., 1996; 43. Gafni, 1994; 44. Dolan and Gudex, 1995; 45. Stiggelbolt, 1995.
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1.3.2.4 Discussion
In this section we provide a framework for the evaluation of the different 
valuation techniques used to measure the benefit of vaccination (Table 1.1b). 
A review of the literature suggests that CV is the most appropriate technique 
to evaluate benefits in terms of Monetary values because of its greater 
theoretical basis, practicality, content validity and sensitivity (Table 1.2). For 
HR-QoL, the most appropriate techniques seem to be SG, TTO and MAUS (EQ- 
5D, HUI and SF-6D) because they are choice-based (or based on choice-based 
techniques) (Brazier et al., 1999).
The main empirical advantage of the CV method over the HR-QoL techniques is 
that it imposes no restrictions on which attributes of vaccination people are 
allowed to express a value for (Table 1.2 and 1.5). Furthermore, contrary to 
SG and TTO, CV is sensitive to small changes in well-being (Table 1.2 and 1.5). 
Evidence of empirical validity is scarce for all techniques (CV, SG, TTO and 
MAUS) due to the absence of a “Gold-Standard”. However, there exists more 
evidence against the criterion and convergent validity of CV than SG, TTO and 
MAUS (NOAA, 1993).
The main difference between Cost-Benefit and Cost-Utility analysis is the way 
in which the benefits of health care programmes are valued. Only very few 
studies have directly compared WTP (from CV) and QALY’s (from SG, TTO or 
MAUS) (Bala et al., 1998; O’Brien and Viramontes, 1994; Stavem K, 2002). The 
results raised questions as to whether the use of QALY’s or WTP in economic 
evaluation would lead to similar allocation of health resources.
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In Chapter 4, we compare CV, SG and HUI2 in the context of varicella 
vaccination. In so doing we investigate whether attributes of vaccination, such 
as security and caring, are measurable and, if so, assess their relative 
importance compared to direct health effects. Furthermore, we assess 
whether HR-QoL techniques (SG and HUI2) are truly incapable of measuring 
small changes in well-being individuals and non-health benefits. Finally, we 
investigate the construct and convergent validity of CV and HR-QoL 
instruments. In Chapter 4 we also examine how individual preferences can be 
aggregated to estimate the overall population’s value of the benefit of 
vaccination taking into account herd-immunity externalities and non-health 
effects using mathematical models.
1.4 D ISCUSSION: FRAM EW O RK FOR TH E  ECONOM IC  
EVALUATION OF VACC INAT IO N  PRO GRAM M ES
Many guidelines have been published to ensure the quality of economic 
evaluation and standardisation/comparability of methods/results, (Drummond 
et al., 1996; Commonwealth of Australia, 1995; Torrance et al., 1996; Lovatt, 
1996)). It has been suggested that, due to its unique characteristics, additional 
specific guidelines may be needed for the economic evaluation of vaccination 
programmes (Beutels et al., 2002; Edmunds et al., 1999). In this chapter, we 
give brief background information necessary to understand the different 
methodological issues that are specific to the economic evaluation of 
vaccination programmes. In subsequent chapters, we will use varicella 
vaccination to illustrate and investigate the different methodological issues in 
order to provide evidence from which specific guidelines for economic 
evaluation of vaccination programmes can be built.
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We separate methodological issues into 4 categories: 1) Mathematical Model
(Chapter 3), 2) Intervention outcome and valuation technique (Chapter 4), 3)
Study Design (Chapter 5), and 4) Sensitivity Analysis (Chapter 5).
The specific questions that will be addressed are:
1. Mathematical Model:
■ What model should be used in economic evaluation of vaccine 
programmes?
■ What is the impact of including herd-immunity externalities?
2. intervention outcome and valuation technique:
• What valuation technique and intervention outcome (i.e. type of 
economic analysis) should be used in the economic evaluation of 
vaccine programmes?
■ What are the important attributes of vaccination?
■ How can outcome measures be aggregated from an individual to a 
population level?
3. Study Design:
■ What is the impact of the study design on the results of economic 
analyses?
4. Sensitivity Analysis:
■ What type of sensitivity analysis should be used?
■ What should be varied in the sensitivity analysis? What is the relative 
importance of the choice of model, methodological assumption and 
parameter estimates on results of economic analysis?
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Chapter 2
Epidemiology of Varicella-Zoster 
virus
2.0 INTRODUCTION
The aims of chapter 2 are twofold, to:
1) Provide base-line epidemiological data for the economic evaluation of 
varicella vaccination, and
2) Study the dynamics and natural history of varicella-zoster virus to help in the 
design and parameterisation of a realistic model of VZV transmission, which 
will be used to evaluate the economic and public health impact of varicella 
vaccination.
First, in this chapter, we analyze general practitioner surveillance, hospitalisation 
and mortality data from England and Wales to investigate the following age- 
specific epidemiological characteristics of varicella and zoster: 1) incidence, 2) 
GP consultations, 3) hospitalisation and 4) mortality. These results will provide 
base-line data for our economic analysis.
Secondly, in this chapter, we investigate the relationship between varicella and 
zoster incidence, which will provide insight into the dynamics of the varicella- 
zoster virus. This will allow us to develop a realistic model of VZV transmission,
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which will be used to predict the overall benefit of varicella vaccination 
(including externalities such as herd-immunity and exogenous boosting).
2.1 BACKGRO UND
Varicella zoster virus (VZV) produces two distinct clinical syndromes: varicella 
and zoster (Hope-Simpson, 1965). Varicella or chickenpox is the primary 
manifestation of VZV infection. Following primary infection the virus becomes 
latent in dorsal root ganglia and may reactivate years or decades later to cause 
zoster, also known as shingles, in a significant proportion of the population 
(Hope-Simpson, 1965). The events leading to reactivation are not clearly 
understood although decreased cell-mediated immunity is thought to play a major 
role (Hope-Simpson, 1965). The precise relationship between varicella and zoster 
incidence is still unclear. It has been established that zoster is infectious and can 
transmit varicella (Hope-Simpson, 1965). By doing so zoster appears to stabilise 
the variability in varicella epidemics permitting VZV to persist in small 
populations (Garnett and Grenfell, 1992a; Garnett and Grenfell, 1992b; Ferguson 
et al., 1996). Although zoster is thought to be less infectious than varicella, the 
contribution zoster makes to the overall force of varicella infection remains 
uncertain. The role of varicella on zoster incidence is more ambiguous primarily 
because of the lack of understanding of the mechanism of reactivation. It has 
been suggested that varicella can decrease the risk of zoster by boosting specific 
immunity to VZV (Hope-Simpson, 1965; Palmer et al., 1985; Brisson et al., 2002; 
Thomas et al., 2002; Gershon et al., 1996). Economie analysis relies greatly on 
epidemiology for valid base-line data (such as incidence of disease, 
hospitalisation and mortality) and for insight on the natural history of infection 
and disease, which is essential to build valid mathematical models for prediction 
of the benefits of intervention.
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2.2 DATA SO URCES
General Practitioner Surveillance Data. Information on the age-specific 
consultation rate for varicella and zoster is available through the Royal College of 
General practitioners (RCGP), which instituted a sentinel surveillance program in 
1967 using a representative sample of the practitioners throughout England and 
Wales (Fleming, 1999). The clinical diagnosis, age and sex of each patient with a 
new illness are reported weekly by around 70 GP practices in England and Wales 
(this currently covers a population of about 570,000 although variations in the 
number of practices reporting occur). Additional age-specific consultation rates 
for varicella and zoster are available from the National Survey of Morbidity in 
General Practice (MSGP4) database, which was derived from a survey of English 
and Welsh general practices in 1991-1992 (McCormick et al., 1995). The study 
covered approximately a 1% sample of the population of England and Wales 
(502,493 patients, 468,042 person-years at risk). Details of all consultations were 
recorded during the study year, along with socio-economic and socio-demographic 
information on the patients.
Hospitalisation Data. Hospitalisation data for England is available from 
Hospitalisation Episode Statistics (HES database), which covers every inpatient 
National Health Service admission in England (approximately 49 million person- 
years at risk per year). However, HES does not provide details of the drugs used in 
hospitals, or information concerning out-patients.
HES currently collects 12 million records per year, and each record contains over 
50 items of information. This includes the dates of admission and discharge, 
discharge method and seven discharge diagnosis fields coded by International 
Classification of Disease code (ICD-10, ICD-9 before 1995/96) as well as details
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relating to the patient (for a full description of all data fields in HES see 
http://tap.ccta.gov.uk/doh/hes dd.nsfl. A recent systematic review of studies 
comparing routine discharge hospital episode statistics in the UK with the original 
medical records found that the median coding accuracy was 77% for ICD-9 
(Campbell et at., 2001). Hence, the level of inaccuracy should be born in mind 
when interpreting these statistics and should be taken into account in the 
sensitivity analysis of economic evaluations that use this data.
Mortality Data. The annual number of deaths attributed to varicella and zoster 
in England and Wales is available from the Office for National Statistics (Office 
for National Statistics, 2000). The ONS mortality database includes information on 
the underlying cause of all deaths in England and Wales. Underlying cause of 
death is coded into ICD-9, from death certificates, using an automated 
computerised system (Rooney and Devis, 1996).
2.3 EP IDEM IOLO GY OF VAR ICELLA  AND  ZO STER
2.3.1 METHODS - DATA ANALYSIS
Incidence. The force of infection, X, is the instantaneous incidence rate of 
infection amongst susceptibles. The force of varicella infection was estimated, 
here, from physician consultation data (MSGP4 data). To estimate the force of 
infection from physician consultation data, consultation rates were adjusted 
given that physicians do not see all children with chickenpox (see Brisson et at., 
2001 for age-specific rates). The proportions of varicella cases seeking physician 
consultation were derived from a review of the literature (Lieu et at., 1994; 
Sulivan-Bolyai et at., 1987; Saddier et at., 1998; Law et at., 1999a; Brisson et at., 
2001) and assuming that all individuals contract varicella during their lifetime. 
The estimated percent of individuals with varicella seen by a GP for 0 to 4, 5 to
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14, 15 to 44, 45 to 64, 65 + age groups respectfully were 43, 33, 52, 53, and 86% 
The adjusted MSGP4 rates were validated using 1996 serologic data from England 
and Wales (Figure 2.1).
The force of infection was calculated by using Farrington et al. (1990)’s 
functional form to generate an expected proportion of individuals of age t who 
would have been exposed to the virus:
F(t) = 1- exp{(a/b)te'bt+ (1/b)(a/b - c)(e bt-1 )-ct] (1 )
where a, b and c > 0. The function is fitted to the observed age-specific 
proportion of individuals with history of infection using maximum likelihood 
methods. The model log likelihood, l(t), stratified by age group (t), was obtained 
from the binomial likelihood:
l(t)=(1 -x(t))ln[1 -F(t)]+ x(t)ln[F(t)] (2)
where, x(t) is the observed age-specific proportion of individuals with history of 
infection calculated from MSGP4 adjusted rates and F(t) is the proportion of 
individuals with history of infection as predicted by the model (equation 1).
F i g u r e  2 .1 .  V a r ic e l la  s e r o p r e v a le n c e .
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The age-specific varicella incidence rate was calculated using the force of 
infection estimates and the average age-specific population of England and Wales 
between 1991-2000 (Office for National Statistics, 2000). The estimated 
proportion of positives by age shows good agreement to the age-specific 
serological data (Figure 2.1).
Because of its high severity individuals with zoster are likely to consult a general 
practitioner. Zoster consultation rates were thus assumed to be reasonable 
estimates of incidence rates. The age-dependent proportion of zoster cases which 
result in Post-Herpetic Neuralgia (PHN - defined as pain lasting more than 1 
month after the onset of zoster) was taken from a prospective study of PHN in 
general practice (Hope-Simpson, 1975) and from the MSGP4 database, by 
comparing the reported incidence of PHN (ICD-9 0531) with the total number of 
zoster episodes. The average time to complete cessation of PHN was estimated 
from two population-based studies (Hope-Simpson, 1975; de Morgas and Kierland, 
1975) and from 3 large datasets compiled from controlled randomised clinical 
trials of antiviral therapy for the treatment of acute herpes zoster (Dworkin et 
al., 1998; Wood et al., 1996; Wood et al., 1998). Time to complete cessation of 
pain was measured for each of the six groups: two placebo groups and two 
aciclovir, one famciclovir and one valaciclovir treatment groups (we took an 
average of those receiving valaciclovir within 48 and 72 hours after rash onset). 
Only individuals in pain after one month of onset of herpes zoster were included, 
as this is the definition of PHN used in the study.
Hospitalisation. Hospitalisation statistics for England were extracted from the 
HES database for the 1995/96 financial year. We extracted all records with a 
varicella (ICD-10 B01) or zoster (B02) code in any of the seven diagnostic fields.
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fIn HES, a patient’s period of care under a consultant is called an episode and the 
overall stay in the hospital is termed a spell. If responsibility for a patient is 
transferred from one consultant to another during a spell a new HES record is 
completed with possibility of additional diagnosis. Hence, for a particular spell in 
hospital, there are as many HES records as episodes. To aid in the analysis of 
spells, episodes are given an order number in HES (epiorder). Since we are mostly 
interested in the number and length of hospital admission for varicella and 
zoster, multiple records of the same spell must be de-duplicated. Records were 
de-duplicated by identifying and deleting records, which had identical admission 
and discharge dates and personal identifiers (birth date, postal code and gender). 
In our analysis, we kept the record with the highest episode number.
All hospital separations with a varicella (ICD-10 B01) or zoster (B02) diagnostic 
code in the first position were considered to be admissions due to VZV. 
Furthermore, a person was considered to have an underlying condition (condition 
associated with greater risk of zoster) if there was a discharge diagnosis code for 
at least one of the following conditions: Human immunodeficiency virus (ICD-10 
B20-4), all malignant neoplasms (COO-97), all in situ neoplasms (D00-09), 
neoplasms of uncertain or unknown behaviour (D37-48), agranulocytosis (D70), 
certain disorders involving the immune mechanism (D80-89) and cystic fibrosis 
(E84).
Hospitalisation rates were estimated by dividing the number of hospitalisations in 
1995/1996, as derived from HES, by the estimated mid-1995 population of 
England (Office for National Statistics, 2000).
Mortality. The annual number of deaths for which the underlying cause was
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recorded as varicella and zoster in England and Wales during 1993-2000 were 
extracted from the Office for National Statistics (Office for National Statistics, 
2000). In 1993 computerised cause of death coding was introduced in England and 
Wales to increase the consistency and international comparability (Rooney and 
Devis, 1996). This created discontinuities in time trends between 1992 and 1993 
(Rooney and Devis, 1996). Mortality data before 1993 were therefore excluded 
from the analysis.
The varicella and zoster death rates were calculated using the average number of 
deaths in England and Wales during 1993-2000 as the numerator and the average 
population of England and Wales during this time period as the denominator.
2.3.2 EPIDEMIOLOGY OF VARICELLA
Incidence. The estimated values for the force of infection of varicella in England 
and Wales are shown in Table 2.1. The force of infection was used to estimate 
the age-specific annual number of cases and incidence rate of varicella in England 
and Wales (Table 2.2). The overall incidence of varicella is estimated to be 1,291 
cases per 100,000 person-years, the highest rate occurs in children less than 5 
years of age (10,331 cases per 100,000 person-years). These rates suggest that a 
total of 670,000 cases of varicella occur in England and Wales every year. 
Children under 15 years are estimated to account for 84% of these cases. The bulk 
of remaining cases (14%) are estimated to occur in adults of childbearing age (15- 
44 years).
The age-specific number of varicella cases reported by general practitioners is 
determined by patient consultation patterns, which may be age and time 
dependant. The consultation patterns also depend on the type of primary health
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care available, which can vary by country. Therefore, consultation rates should 
not be interpreted as varicella incidence rates. They are, however, useful to 
examine trends in disease incidence. During the 1990’s, there have been changes 
in the age-specific varicella consultation rates in England and Wales (Figure 2.2). 
Although the consultation rates have remained relatively stable in children under 
5 years, the rate in older children (5-14 years) and adults (15+) have roughly 
halved between 1990 and 2000 (Figure 2.2). Table 2.2 shows the average 
consultation rates for varicella in England and Wales between 1991-2000.
Table 2.1. Maximum likelihood estimates of the varicella force of infection
Age Group England and Wales3
0-1 0.11
2-4 0.18
5-11 0.15
12-18 0.09
19-24 0.09
25-44 0.08
45-64 0.07
65+ 0.07
a. MSGP4 data, 1991-1992.
Deviance = 11.8, degrees of freedom = 15
300
250
200
150
100
50
Figure 2.2. Annual age-specific varicella consultation rate in England and Wales 
from 1991-2000.
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Hospitalisation. The age-specific number of hospitalisations, hospitalisation 
rate, risk of hospitalisation per varicella case and mean length of stay are 
presented in Table 2.2. In 1995/96, the overall hospitalisation rate for varicella 
was 4.5 per 100,000 person-years. Seventy percent of hospitalisations were in 
children under 15 years. However, the risk of hospitalisation per case of varicella 
and the average length of stay increases steeply with age (Table 2.2). The risk of 
hospitalisation and mean length of stay are 8 and 5-times greater in adults over 
65 years than children under 5 years, respectively.
Among all hospitalised patients, 5% had a least one reported underlying condition 
(Table 2.3). The percent of hospitalisations with an underlying condition 
increased with age from 4% in individuals younger than 45 years to 21% in adults 
older than 65 years. The most common condition was malignant neoplasm (70%, 
half of which was leukaemia), followed by cystic fibrosis (9%), agranulocytosis 
(9%), certain disorders involving the immune mechanism (8%) and human 
immunodeficiency virus (4%). The risk of death during hospitalisation was less 
than 0.5% (1 death out of 9 was in an individual with an underlying condition).
Mortality. The average age-specific annual number of deaths, mortality rates 
and case-fatality ratios for varicella in England and Wales is presented in Table 
2.2. An average of 25 people a year died of varicella in England and Wales 
between 1993-20000 (0.05 deaths per 100,000 population-year). Adults accounted 
for 85% of deaths. The case-fatality is highly age dependant; it is low in children 
(less than 1 per 100,000 case) but increases dramatically in adults (from 9 to 689 
deaths per 100,000 case in over 65 year olds - Table 2.2). It should be noted that 
the overall number of deaths due to varicella have been falling over the past 5 
years from 32 in 1996 to 18 in 2000.
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Table 2.2. Age-specific epidemiology of varicella in England and Wales.
Incidence Consultation Hospitalisation Mortality
Na % Rate0 Nc % Rate0 Nd % Rate0 Hospitalisation* 
(per 100 case)
Length of Stay N* % Rate0 Case-Fatality8 
(per 100,000 case)
0to4 344,662 51 10331 148,754 54 4,459 1,240 57 38.7 0.4 2.2 3 10 0.08 1
5to14 224,242 33 3384 73,482 27 1,109 287 13 4.6 0.1 3.0 1 5 0.02 1
15to44 95,730 14 435 49,306 18 224 560 26 2.7 0.6 4.0 9 35 0.04 9
45to64 4,945 1 42 2,642 1 22 64 3 0.6 1.4 5.8 4 14 0.03 73
65+ 1,289 0 16 1,103 0 13 38 2 0.5 3.1 10.6 9 35 0.11 689
Overall 670,868 100 1291 275,286 100 522 2,189 100 4.5 0.3 3.0 25100 0.05 4
a. Estimated average annual number of cases of varicella in England and Wales 1991-2000.
b. Rate per 100,000 person years.
c. Estimated average annual number of varicella cases seeking medical advice in England and Wales 1991 -2000.
d. Observed number of varicella hospitalisations in England, HES 1995/96.
e. Hospitalisation rate divided by the estimated incidence rate.
f. Observed average number of varicella deaths in England and Wales, ONS 1991 -2000.
g. Mortality rate divided by the estimated incidence rate.
Table 2.3. Underlying Conditions and outcome among individuals hospitalised with varicella and zoster, England 1995/96.
Underlying condition/outcome
N
Varicella 
Percent of 
Hospitalisations N
Zoster 
Percent of 
Hospitalisations
Human immunodeficiency virus 5 0.2 11 0.5
All malignant neoplasms 81 3.7 154 7.2
All in situ neoplasms 0 0.0 0 0.0
Neoplasms of uncertain or unknown behaviour 0 0.0 0 0.0
Agranulocytosis 11 0.5 3 0.1
Certain disorders involving the immune mechanism 9 0.4 4 0.2
Cystic Fybrosis 10 0.5 5 0.2
Total 116 177
At least one underlying condition 106 4.8 164 7.6
Death 9 0.4 52 2.4
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2.3.3 EPIDEMIOLOGY OF ZOSTER
Incidence. The average annual incidence of zoster in England and Wales (1991- 
2000) by age group is shown in Table 2.4. The overall rate of zoster is 373 cases 
per 100,000 population year. The incidence increases with age from 200 cases per 
100,000 in children (5-14 years) and young adults (15-44 years) to over 900 cases 
per 100,000 person-years in those aged 65 years or greater. These rates suggest 
that there are approximately 225,000 cases of zoster every year in England and 
Wales. Adults over 45 years account for over 70% of these cases. During the 
1990's, the overall zoster consultation rate has been slowly increasing in England 
and Wales (Brisson et al., 2001) due, in large part, to the ageing of the 
population.
Post Herpatic Neuralgia. The proportion of zoster cases which result in chronic 
pain (PHN) increases from close to zero in the under 30s to greater than 30% in 
those over the age of 80 years (Figure 2.3a). There is reasonably good agreement 
between estimates derived from the MSGP4 survey and Hope-Simpson’s survey in 
general practice (Hope-Simpson, 1975), the somewhat higher rates observed in the 
MSGP4 survey probably being due to the code ICD-9 0531 including other 
neurological complications of zoster, not just PHN (for this reason Hope-Simpson’s 
estimates were used in the economic analysis (Chapter 5)). Figure 2.3b shows the 
proportion of individuals (over the age of 50 years) reporting pain more than one 
month after rash onset. It appears that antiviral therapy during acute shingles 
hastens initial pain resolution in some individuals (Figure 2.3b) but has little 
impact on the rate at which individuals resolve pain if they have had PHN for a 
number of months, as noted previously (Dworkin and Portenoy, 1996). Most of the 
studies presented in Figure 2.3b do not have sufficiently long periods of follow-up 
to accurately estimate the mean duration of PHN. Applying the clearance rate in
70
individuals who have had pain for at least 6 months from Hope-Simpson’s study to 
the others, it is possible to estimate the mean duration of pain from each of the 
groups of patients. This ranges from 0.93 years for patient groups receiving 
aciclovir therapy to 2.14 years for patients in the placebo arm of the famciclovir 
trial. In the economic analysis a base-case value of 1.40 years was taken, derived 
from Hope-Simpson’s study (Hope-Simpson, 1975). This value was chosen as Hope- 
Simpson’s study was the only one of sufficient duration to accurately quantify the 
mean length of PHN, and the rate of resolution of PHN in this study is similar to 
the placebo groups in the aciclovir trials and is intermediate between the other 
studies (Figure 2.3b). Furthermore, it is likely that a significant proportion of 
individuals with herpes zoster will not consult a physician early enough to receive 
antiviral therapy (i.e. within 3 days of rash onset)
Hospitalisation. Zoster hospitalisation statistics are presented in Table 2.4. The 
overall zoster hospitalisation rate was 4.4 per 100,000 person-years in England 
during 1995/96. Sixty-nine percent of hospitalisations were in adults older than 65 
years. The proportion admitted to hospital per case of zoster is low in children 
under 4 years of age (1%) falls to 0.6% in 5 to 64 year olds then increases to more 
than 2% in those over 65 years (Table 2.4). The average number of inpatient days 
per zoster admission also increases with age from approximately 4 days in 0 to 4 
year olds to 14 days in the elderly (over 65 years) (Table 2.4).
Of the 2148 hospitalisations due to zoster in England in 1995/96, 8% had at least 
one underlying condition (Table 2.3). The percent of hospitalisations with an 
underlying condition for 0-14, 15-64 and 65+ groups was 20%, 13% and 5% 
respectively. The most common condition was malignant neoplasm (87%), followed 
by HIV infection (6%). Overall, 2% of all admissions due to zoster resulted in death
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in hospital (Table 2.3), 4% of which were in patients with an underlying condition.
Mortality. An average of 49 deaths a year were recorded with zoster as the 
underlying cause in England and Wales between 1993-2000 (0.09 deaths per 
100,000 population-year-Table 2.4). Zoster is rarely recorded as the underlying 
cause of death in those under the age of 65 (Table 2.4). The estimated mortality 
rate of zoster in this age group is less than 0.014 deaths per 100,000 person-years. 
In the older age group (65+ years), the estimated mortality rate increases to 0.566 
deaths per 100,000 person-years. The case-fatality ratio is also highly age 
dependant increasing from less than 1 death per 100,000 cases in children to more 
than 61 deaths per 100,000 cases in adults older than 65 years. The number of 
deaths due to zoster have been falling, from 64 deaths in 1993-1994 to 40 deaths 
in 1999-2000. The number of deaths attributed to zoster (49 deaths per year - 
Table 2.4) by the ONS is similar to the annual number of deaths in individuals 
hospitalised for zoster (52 deaths per year - Table 2.3).
72
Table 2.4. Age specific epidemiology of zoster in England and Wales.
Incidence Hospitalisation Mortality
Na % Rateb Nc % Rateb Hospitalisation1 
(per case)
Length of Stay Ne % Rateb Case-Fatalityf 
(per 100,000 case)
0to4 3081 1 92 40 2 1.2 1.1 3.5 0 0 0.000 0
5to14 14537 6 219 86 4 1.4 0.7 3.4 0 0 0.002 1
15to44 46760 21 212 222 10 1.1 0.5 4.6 1 2 0.003 2
45to64 83674 37 712 327 15 3.0 0.6 5.2 2 3 0.014 2
65+ 76766 34 932 1473 69 19.1 2.3 13.5 47 95 0.566 61
Overall 224818 100 373 2148 100 4.4 1.2 10.8 49 100 0.094 25
a. Estimated average annual number of zoster cases in England and Wales 1991-2000.
b. Rate per 100,000 person years.
c. Observed number of varicella hospitalisations in England, HES 1995/96.
d. Hospitalisation rate divided by the estimated incidence rate.
e. Observed average number of zoster deaths in England and Wales, ONS 1993-2000.
f. Mortality rate divided by the estimated incidence rate.
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F ig u r e  2 .3 .  P H N :  (a ) the proportion of acute zoster episodes resulting in PHN and 
(b) the proportion of individuals who report being in pain following acute zoster. 
The studies from which the data were taken are given in the legend. Note that 
those patient groups that did not receive antiviral therapy have solid markers, in 
contrast to those who received treatment. [1 ] Hope-Simpson, 1975; [2] de Moragas 
and Kierland, 1975; [3] Wood et al., 1996; [4] Dworkin et al., 1998- [5] Wood et 
al., 1998.
74
2.3.4 DISCUSSION
Many countries are now deciding if they should Integrate varicella vaccine into 
their routine immunization schedule. A good understanding of the epidemiology of 
varicella zoster virus infection is necessary to help inform this decision, design 
immunization programs and to adequately measure the impact of vaccination. 
Moreover, analysis of surveillance data provides base-line estimates of varicella 
and zoster incidence, hospitalisation and mortality for modelling and cost- 
effectiveness studies as well as post-vaccine surveillance studies.
The overall epidemiology of varicella and zoster in England and Wales is consistent 
with studies in other developed countries. Varicella consultations (85% in this study 
vs. 79-92% in other studies) and hospitalisations (70% vs. 53-82%) occur mainly in 
children under 15 with the highest rates in 0 to 4 year olds (Deguen et al., 1998; 
Brisson et al., 2001; Choo et al., 1995; Coplan et al., 2001; Lin et al., 2000; 
Bramley and Jones, 2000; Finger et al. 1994; Guess et al., 1984; Wharton et al., 
1990; Wharton et al., 1996). Most varicella deaths are, however, in adults (Meyer 
et al., 2000; Bramley and Jones, 2000; Rawson et al., 2002). In contrast, most of 
the burden of zoster is suffered by adults. The majority of zoster cases (68% in this 
study vs. 64-82% in other studies) and hospitalisations (84% vs. 84-91%) due to 
zoster are in adults over 45 years (Lin et al., 2000, Brisson et al., 2001, Hope- 
Simpson, 1965; Hope-Simpson, 1975; Paparatti et al., 1999; Ragozzino et al., 
1982; de Moragas and Kierland, 1957). The highest rate of zoster is in 65+ year olds 
(Wharton et al., 1996; Ragozzino et al., 1982; Brisson et al., 2001; Hope-Simpson, 
1965; Hope-Simpson, 1975) and seems to be increasing in the elderly population 
(Brisson et al., 2001). Although the age-specific distribution is similar, the 
consultation and hospitalisation rates presented here are lower than France but 
higher than Canada and the United States (Brisson et al., 2001; Deguen et al., 
1998; Choo et al., 1995; Lin et al., 2000; Coplan et al., 2001, Wharton et al., 1990;
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Wharton et al., 1996; Guess et a l, 1984). These dissimilarities are likely to be 
mainly due to the differences in the structure of the various health systems
The shape of the force of infection estimated England and Wales (increasing in the 
pre-school years, peaking during primary school and declining thereafter) is 
consistent with other countries (Brisson et a l, 2001; Halloran et a l, 1994) and 
with that of other childhood infections such as measles, mumps and rubella 
(Edmunds et a l, 2001). This suggests that preschool and school-age mixing is an 
important determinant of varicella transmission as with other childhood infections 
such as measles and rubella.
The proportion of varicella and zoster hospitalisation with at least one underlying 
cause is different in England than studies in other countries. Lin et a l  (2000) 
report that, in the US, 17% and 31% of hospitalisations due to varicella and zoster 
respectively have an underlying cause compared to 5% and 8% for England. Gil et 
a l  (2001) report that, in Spain, 8% of varicella hospitalisations have underlying 
conditions. The higher prevalence of HIV in the United-States and Spain may 
account for much of these differences. Excluding HIV, the proportion of varicella 
hospitalisation with an underlying condition is 5%, 8% and 5% in England, the United 
States and Spain. However, HIV does not explain discrepancies in the proportion of 
zoster hospitalisations with an underlying condition between the US and England. 
Results suggest that the majority of varicella hospitalisations (95%) and deaths 
(approximately 85%) are among otherwise healthy individuals and thus could be 
prevented by mass vaccination.
The epidemiology of varicella and zoster has been changing in England and Wales 
over the past two decades (Fairley and Miller, 1996; Brisson et a l, 2001; Ross and 
Fleming, 2000). During the 1980's, there was a dramatic increase in varicella
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consultation rates in children less than 5 years and in adults. Because varicella 
mortality and morbidity increases steeply with age, the rise in adult cases was a 
source of concern (Fairley and Miller, 1996). However, during the 1990’s, varicella 
consultations have halved in adults (Figure 2.2). The fall in adult varicella cases is 
broadly reflected in the gradual decrease in varicella deaths in adults during the 
past decade. The epidemiology of zoster is also changing with the steady increase 
in overall incidence and the fall in mortality over the 1990s. Furthermore, 
hospitalisation results are sensitive to the algorithm used to identify admissions 
due to varicella and zoster. If mention of varicella or zoster in any of the 7 
diagnostic positions is used instead of the first position then hospitalisation rates 
are increased by approximately 30% and 100% for varicella and zoster respectively. 
The average length of stay is also increased by approximately 30% for both varicella 
and zoster. The proportion of hospitalisation with an underlying condition increases 
from 5% to 6% for varicella and 8% to 13% for zoster. Therefore, the figures 
presented in Tables 2.2-2.4 should be used with caution as base-line estimates.
Hospital admission and mortality data from England show a steep rise in varicella 
and zoster hospitalisations per case, average number of inpatient days and 
mortality with age. Since, currently, varicella occurs mainly in children the 
increase in severity with age does not lead to a high number of varicella related 
deaths or hospital days. However, mass immunization results in an increase in the 
average age at infection in those who are not immunized. Therefore, there is a 
danger that mass immunization can lead to an increase in hospitalisation and 
death. Such perverse outcomes from mass infant vaccination has been observed for 
rubella in Greece (Panagiotopoulos etal., 1999).
Zoster is considered to be much more severe than varicella (Miller et at., 1993) 
However, the age-specific severity, as measured by the age-specific proportion
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hospitalised per case and inpatient days, are relatively similar between the two 
diseases (Tables 2.2 and 2.4), this statement ignores QALYs, which we measure in 
Chapter 4. However, the overall burden of disease is considerably higher for zoster 
because over 85% of cases occur in adults (less than 15% for varicella). The total 
annual number of inpatient days and deaths were 4 (23,000 vs. 6,500 days) and 2 
(49 vs. 24 deaths) times higher for zoster than varicella respectively. Zoster may 
occur more frequently in adults who have not been boosted by varicella contacts 
(exogenous boosting) (Hope-Simpson, 1965). A reduction of varicella incidence 
after mass immunization could lead to an increase in the incidence of zoster. This 
could have a major impact on the overall effectiveness and cost-effectiveness of 
varicella vaccination. In the next section we investigate whether exposure to VZV 
reduces the rate of reactivation (zoster incidence).
2.4 RELA T IO N SH IP  BETW EEN VA R ICELLA  AND  ZO STER  INC IDEN CE
2.4.1 METHODS
2.4.1.1 Data
Data were taken from the MSGP4 dataset. Details of all consultations were 
recorded during the study year, along with socio-economic information on the 
patients (McCormick et al., 1995). For children under 16 years, all first episodes of 
varicella and zoster were included in the analysis. For adults, first episodes of 
varicella and zoster were included in the analysis if data were available on whether 
the case currently lived with a child <16 years of age or not (82% of cases). To 
estimate the incidence of varicella, consultation rates were adjusted (using 
previously estimated age-specific rates (see earlier)) because not all children with 
varicella consult a general practitioner. All zoster cases are assumed to visit a 
general practitioner.
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2.4.1.2 Statistical Analysis
We analysed data stratified by 1-year age groups, sex, ethnicity, social class and 
presence of a child in the household using a Poisson regression model with an 
adjustment for person-years observed to test whether the incidence of disease was 
different in adults living with children. The model was used to estimate the overall 
incidence ratio and to test whether this was age dependent.
The poisson regression can be described as follows. Let y, represent the number of 
cases of zoster. We assume that y, is represented by the following function:
y=xp + s (3)
where, x is the vector of variables, p is the vector of regression coefficients and s 
is the error term. The model assumes that e - Poisson (A). The model log 
likelihood, la M , stratified by 1-year age groups (a), sex (g), ethnicity (e), social
class (s) and presence of a child in the household (i) was obtained from the 
following function:
la,s,e,s,i=  n a,a,e,s,ilOg(AaigietSti)-A a ,g,e,s,l (4)
where, n is the observed number of cases of zoster and A is the expected incidence 
predicted by the model (equation 3). The analysis was performed in GLIM (Francis 
et al., 1994). The command function was glm where the y-variable was the count 
for a celt ($yvar count) with poisson error ($error p) and log-link (Slink l) with an 
offset based on the logarithm of person-ears at risk (Soffset log(pyears)).
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2.4.1.3 Model Structure
The model represents the natural history of varicella and zoster in a population 
stratified according to age (a) and presence of at least one child in the household 
(i=C (children), N (no children)) (see Figure 2.4 for flow diagram). The population is 
divided into 4 mutually exclusive epidemiological groups: the proportion 
susceptible to varicella, denoted S((a,t); immune to varicella and temporarily 
immune to zoster, R,(a,t); susceptible to zoster, Y,(a,t); and recovered from zoster, 
Z,(a,t). For simplicity repeat cases of zoster were not modelled since recurrence is 
thought to be low and is not well characterized in the literature. The rates, with 
respect to time and age, at which individuals flow between epidemiological states, 
are described by the following set of partial differential equations:
~dt + & = +Pf(a) +M.a))Si(a,t)
= +p> W M - t e  •-MM+ pM + K a))Yi(ait)
+Ka))ZXa,t)
Here, subscripts i and i’ represent opposite classes (i.e. if j=C then i’=N), M(a) is 
the death rate (Office for National Statistics, 2000), p,(a) are the rates at which 
individuals move between living with and without children, Ji,(a,t) is the force of 
infection (per capita rate at which susceptibles to varicella are infected and 
susceptibles to zoster are boosted), a is the rate of loss of immunity to zoster 5(a) 
is the rate of reactivation of VZV in those who are susceptible to zoster.
K5)
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2.4.1.4 Parameter Estimation
We estimated the rate at which individuals flow between living with and without 
children, pja), by modelling the age-specific proportion of adults with at least one 
child in their household. The population can be broadly represented by 6 mutually 
exclusive groups: the proportion who live with “siblings” aged less than 16 years, 
denoted B(a); who have left home and are not living with children, M(a); who are 
living with “their" children, K(a); whose children have left home, L(a); who are 
living with “their" grand-children, C(a) and; who have stopped living with their 
“grand-children", H(a) (Figure 2.5). Hence groups B, K  and G live with children, 
and groups M, L and H do not.
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Figure 2.5. Proportion of adults who live with and without children. The solid 
line (%No Child) represents the observed age-specific proportion of adults not living 
with children. The width of each colour band represents the estimated age-specific 
proportion of adults in the 6 groups described by the model.
The rate of flow from B(a) and M(a) to K(a) was estimated from observed data on 
the age that adults have their first child . Remaining rates
were estimated by fitting the model to the age-specific proportion of adults living 
with children in England and Wales as reported in MSGP4 survey (Figure 2.5). The 
population was split into 2 exposure groups, high exposure C (K+G) and low 
exposure N (B+M+L+H). We included adults who live with siblings (8) into exposure 
group N because their exposure is likely to be to previously infected older children. 
The overall age-specific rates at which individuals flow between the two groups are 
given by:
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(6)
Pc(a) =  
P n (<*) =
(/BK& YMkM  YLG^)
(b + m + l + h )
& klK + yqHG)
{K + G )
Where, yu(a) is the rate of flow from class I to J, pc(a) is the rate of flow to group C 
and, pn(a) is the rate of flow to group N.
Having determined the flows between exposure groups the parameters describing 
rates infection and development of zoster were estimated using maximum 
likelihood. At pre-vaccine endemic equilibrium (t=0), the force of infection in 
children less than 16 years, X,(a<16,0), is assumed to have a Gamma functional 
form:
^(o,O)=0[(a+K)a~1e'a/0/r(a)j3a]. (7)
The force of infection in adults, H a > 16,0), was assumed to depend only on 
whether they live with or without children (i). The age-specific rate of reactivation 
of VZV, 8(a), was assumed to possess the following functional form: coe'^*m\
The model log likelihood, li,d(a), stratified by presence of at least one child in the 
household (i), disease (d=varicella or zoster) and age (a), was obtained from the 
binomial likelihood:
li,d(a)=xi,tj(a){n[mi,d(a)]+(ni(a)-xi'd(a))[{\[l- m,,d(a)]  (8)
where, n,(a) is the number of person-years in the study, xiid(a) is the observed 
number of cases of disease (d) in the MSGP4 database and mKd(a) is the incidence 
predicted by the model (equation 5). The predicted incidence in adults living with
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children includes a contribution from group B as well as the higher exposure groups 
and G. The full-model likelihood is the sum, over a, i and d, of the specific model 
log likelihoods. Estimates for parameters e, k, «and jB (which are parameters of 
the gamma functional form describing A,(a<i6,0) (equation 7)), Ac(a>16,0), 
kv(a>16,0), co, cp, a  and 7 (which describe the functional form of S(a)) and <j, were 
obtained by maximizing the full-model log likelihood. In total these 11 parameters 
were estimated from 364 data points.
2.4.2 ROLE OF ZOSTER ON VARICELLA
The force of varicella infection due to zoster has been estimated to be 1% of the 
total force of varicella infection. This estimate was based on data collected by the 
Immunization Monitoring Program - Active (IMPACT), a Canadian paediatric 
hospital-based surveillance network. Of 1119 children admitted for chickenpox or a 
related complication, a source of infection was identified for 576 and of these only 
5 followed exposure to Herpes Zoster whereas the rest followed exposure to 
chickenpox (unpublished data from Dr. Barbara Law). An additional study by 
Ferguson e i al. (1996) estimated zoster to contribute to 7% of varicella cases.
2.4.3 ROLE OF VARICELLA ON ZOSTER
In Figure 2.6a we present the age-specific annual incidence rate of zoster in 
England and Wales by household exposure to children (Figure 2.6a). Living with 
children was found to be significantly protective against zoster (P < 0.001) with an 
incidence ratio of 0.75 (95% Cl 0.63-0.89). There was no evidence of confounding 
by sex, ethnicity or socio-economic class. Furthermore, the protective effect of 
living with children did not differ significantly by age (P for interaction 0.79). It is 
worth noting that although the protective effect of living with children is highly 
significant it is likely to be underestimated by this incidence ratio, as many adults 
not currently living with children may have done so in the recent past.
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To examine the mechanisms which lead to VZV reactivation, we first examined 
whether adults living with children were significantly more exposed to varicella. 
Young adults living with children have a higher crude varicella incidence rate than 
those who do not (Age Range=20 to 40 years, Incidence Ratio=1.29, 95% Cl 1.08- 
1.55, P < 0.005), but this difference is not evident in older adults (Figure 2.6b). 
This is the pattern expected if all adults who live with children have greater 
exposure to varicella, because, at older ages, the proportion of adults susceptible 
to infection is lower among those who live with children than those who do not, 
due to their history of higher exposure to infection.
To further investigate this relationship we developed an age-structured 
mathematical model of the natural history of VZV that allows exposure to varicella 
to boost against the development of Herpes-zoster (see earlier). The quality of fit 
of the model to the data was good (Figure 2.7). Under the ‘best fit’ model, the 
force of infection (per capita rate at which susceptibles become infected) in adults 
with and without children in the household is 0.15 and 0.07 per year respectively. 
Exposure to varicella is thus estimated to be twice as high in adults living with 
children compared with those who do not. Furthermore, exposure to varicella is 
estimated to boost cell-mediated immunity for an average of 20 years (95% Cl 7-41 
years). The maximum likelihood estimates of the other parameters are: for a<16 
years, Xl(a,0)=6[(a+ ^  V “*//fa)/?7, where *=2.86, 0=2.00, a=6.80, /?=1.38; and; 
S(a)=(oe *a+na'’, where p=0.17, /z=1.06E-05, rj=1.91.
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2.4.4 DISCUSSION
First, in this section we describe previous work, which suggest that zoster 
contributes significantly to the incidence of varicella. This would stabilise the 
dynamics of varicella after vaccination. It would also reduce the shift of the age at 
infection of varicella after vaccination (Ferguson et al., 1996).
Secondly, we present strong epidemiological evidence supporting the hypothesis 
that exposure to varicella inhibits Herpes-zoster. Primarily, our analysis shows that 
exposure to varicella is greater in adults living with children and that this exposure 
is highly protective against zoster. We further estimate that the average period of 
immunity conferred by exposure to varicella is 20 years. A recent study by Thomas 
et al. (2002) produced similar conclusion (Edmunds et al., 2002). The study 
compared 244 cases of recently diagnosed zoster to controls with no history of 
shingles that were matched by age, sex and general practice. Patients and controls 
were interviewed regarding their contacts with varicella cases or children (assumed 
to be a proxy for exposure to VZV) over the last 10 years. The degree of protection 
increased with presumed exposure, so that the risk of developing zoster in the 
most heavily exposed group was less than one fifth that in unexposed group.
Previously, other evidence has supported the hypothesis that re-exposure to VZV 
offers protection against zoster. Increases in immunity levels to VZV have been 
observed in individuals exposed to varicella cases or vaccinated with the live 
attenuated vaccine (Arvin et al., 1983; Sperber et al., 1992; Levin et al., 1998). A 
study conducted in Japan found that the incidence rate of zoster in pediatricians 
and family practitioners was half to 1/8 that of the general population (Terada et 
al., 1995). Further studies have reported a negative correlation, although not 
statistically significant, between varicella and zoster incidence (Hope Simpson, 
1965; Brisson et al. 2001; Ikada et al. 1973). Finally, a small study among
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vaccinated leukemic children showed that both household exposure to varicella 
and receipt of more than 1 dose of vaccine were highly protective against zoster (P 
« 0.01) (Gershon et at., 1996). Currently, a large clinical trial is underway to 
determine whether varicella vaccination can protect against zoster in the elderly 
through boosting cell-mediated immunity to VZV (Oxman, 1995). If vaccination 
does prevent or inhibit zoster in this clinical trial, then it is likely that exposure to 
the wild virus would perform a similar function.
Our findings have major implications for varicella vaccination: by reducing varicella 
cases (and thus the opportunity of exposure to VZV), mass infant immunization 
could increase the incidence of zoster in individuals who have not been vaccinated 
(Gershon et at., 1996, Plotkin, 1994).
2.5 SU M M A RY
In this chapter we provide a comprehensive picture of the pre-vaccine 
epidemiology of VZV, which will provide base-line data for the economic analysis of 
varicella vaccination and aid in the design of a realistic model of VZV transmission. 
Two results are of importance for varicella vaccination:
1. Varicella relatedmorbidity and mortality increases signifirantiy M r .
immunization results in an increase in the average age at infection in those who 
are not immunized. The worry is that enough adults with severe varicella will 
be infected to counterbalance the benefit in reduction in children. Because 
severity of varicella increases steeply with age, this danger is a legitimate one.
2. Exposure_to varicella protects against zoster a  the overall burden of ,c
significantly higher for zoster. We show that exposure to varicella reduces the 
risk of zoster by boosting specific immunity to the virus (exogenous boosting). 
These findings could have major implications for varicella vaccination: by
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reducing varicella cases (and thus the opportunity of exposure to VZV), mass 
immunisation could increase the incidence of zoster. Due to the higher severity 
of zoster, a small increase in zoster incidence could counterbalance the 
reduction in varicella morbidity compromising the effectiveness and cost- 
effectiveness of varicella vaccination.
Both dangers of varicella vaccination are classic examples of externalities, which 
must be taken into account when assessing the overall benefit (detriment) of mass 
varicella vaccination. To adequately measure these externalities mathematical 
modelling is necessary. In Chapter 3 we investigate these concerns.
The research in this chapter has been published in full (or in part) in the 
following peer reviewed articles:
• Brisson M, Edmunds WJ. Epidemiology of Varicella-Zoster virus in England and 
Wales. J Med Virol 2003;70 Suppl 1:S9-14.
• Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to Varicella Boosts 
Immunity to Herpes-zoster: Implications for mass vaccination against 
chickenpox. Vaccine 2002; 20: 2500-2507.
• Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella and zoster in 
Canada and the United-Kingdom. Epidemiol Infect 2001; 127:305-314.
• Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and 
potential cost-effectiveness of vaccination in England and Wales. Vaccine 
2001; 19: 3076-90.
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Chapter 3
Modelling the Impact of Vaccination 
Programmes
3.0 IN TRO DU CTIO N
The aims of Chapter 3 are to:
1) Predict the impact of varicella vaccination from the individual and population 
perspectives,
2) Illustrate the effect of herd-immunity on the dynamics of infectious disease 
using varicella vaccination as an example, and
3) Assess the importance of herd-immunity externalities when estimating the 
overall of benefit vaccination.
First, in this chapter, we model varicella vaccine efficacy. That is, we estimate 
the direct effect of varicella vaccination on the vaccinee, which we call the 
individual perspective. Second, we estimate the overall impact of varicella 
vaccination using a dynamic mathematical model taking into account herd- 
immunity externalities, which we call the population perspective. We investigate 
the dangers of varicella vaccination: 1) upward shift the age at infection and 2) 
increase in zoster incidence. In doing so, we illustrate the different dynamical 
effects of vaccination and present which parameters are most influential on model 
results. Thirdly, we compare results from the dynamic model with those of a static
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model, which is the most common model used in economic evaluations of 
infectious disease. This will illustrate how herd-immunity externalities influence 
the benefit of vaccination.
3.1 M O D ELL IN G  VACC IN E EFF ICA CY
3.1.0 BACKGROUND
In clinical trials vaccine efficacy is measured as the relative risk of infection in the 
vaccinated group compared with unvaccinated individuals (Halloran et al., 1997). 
In general, vaccine efficacy is comprised of three components (McLean and 
Blower, 1993): the proportion of individuals who acquire protection; the degree to 
which they are protected; and the duration of that protection. It can be difficult 
to estimate the contribution of each effect to the overall vaccine efficacy 
measured in controlled trials, because these often have a short time span relative 
to the period over which the vaccine is intended to offer protection (often life­
time). Clearly, however, it is critical to have good estimates of these parameters 
to allow accurate long-term predictions of the impact of vaccination programs to 
be made.
Halloran et al. (1994) attempted to estimate vaccine efficacy parameters for 
varicella zoster (VZV) vaccine by reviewing the literature available at the time and 
employing a Delphi process. These parameter values have been used in subsequent 
studies (Coudeville et al.r 1999; Lieu et al., 1994). Since many countries are in the 
process of evaluating the cost-effectiveness of varicella vaccination it is now 
timely to re-examine these estimates and amend them if necessary.
In this section, we re-evaluate Halloran et al.'s (1994) estimates in the light of 
new data. Additionally, Halloran et al. (1994) used the standard approach of
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estimating each parameter separately. This approach can result in a poor fit to 
the data when all the parameters are combined even though each individual 
estimate seems plausible. Our approach differs in that we estimate the 
parameters simultaneously from the observed breakthrough rates (varicella 
infection in seroconverted vaccinees (Halloran et at., 1994) over time.
3.1.1 METHODS
3.1.1.1 Selection of studies
Most of the published studies of vaccine immunogenicity and efficacy have 
specifically involved the Oka/Merck product (Varivax®, Merck Research 
Laboratories). Published data using the other manufacturer’s vaccines were too 
few to include in the analysis.
The pre-licensure studies of Varivax® involved four different lots prepared in 
1982, 1984, 1987 and 1991 (Arbeter et at., 1982; Arbeter et at., 1984; Weibel et 
at., 1984; Weibel et at., 1985; Arbeter et at., 1986; Johnson et at., 1989; White 
et at., 1991; Kuter et at., 1991; Clements et at., 1995; Johnson et a/., 1997). 
These lots differed in the relative amounts of both live virus and non-viable viral 
antigen as well as method of preparation. To avoid bias only studies in which 
active surveillance was carried out over time were used to analyse the base-case 
and worst-case scenarios. These included studies done with the 1987 and 1991 
lots. For the base-case scenario efficacy data for the 1991 lot were chosen since 
this study vaccine most closely resembles the currently licensed product. Based on 
previously unpublished data provided by Merck Research Laboratories, a total of 
1164 children were randomised to receive one of 5 vaccine preparations 
containing from 2900 to 9000 pfus. The mean age at vaccination of these children 
was 4.4 years and 65% of vaccinees were followed for five years post vaccination. 
For the worst-case scenario data from studies using the 1987 lot (Krause and
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Klinman, 1995) were setected since this vaccine had much higher breakthrough 
rates (modified varicella infection in vaccinees) than that observed in any other 
published clinical trial using the Oka/Merck vaccine. These studies included a 
total of 4142 children who were randomised to receive one of five vaccine 
preparations varying in potency from 1000 to 1625 pfu's per dose. The mean age 
of vaccinees was 4.0 years.
For the best-case scenario, data from the randomised placebo-controlled clinical 
trial of the 1982 lot (Krause and Klinman, 1995) containing 17,430 pfu/dose were 
used. Unfortunately only a single year of active follow-up data was available for 
this study and thus it was necessary to include data gathered by a combination of 
active and passive follow-up. The likely underestimation of the number of 
varicella-like infections occurring after immunisation due to passive reporting was 
considered acceptable for the best-case analysis since the objective was to 
estimate the parameters of the best possible vaccine.
3.1.1.2 Model
A mathematical model, similar to Halloran et c/.’s (1994), was used to simulate 
the expected number of breakthrough cases through time in a vaccine efficacy 
trial (Figure 3.1, see Appendix 1 for formal mathematical structure). Since studies 
did not include individuals who did not seroconvert, we consider only individuals 
who responded to vaccination (Krause and Klinman, 1995). There are three 
distinct classes that represent the different states of protection, which we term 
“vaccinated protected”, “vaccinated susceptible” and "immune" (Halloran et a/., 
1994). Of vaccine responders a proportion T pass into the “vaccinated protected” 
class, and 1-7 into the “vaccinated susceptible" class. These two classes differ in 
their response to exposure to infection, which occurs at a rate l  (the force of 
varicella infection, assumed to be 0.2 per year, which is the rounded average
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value of Halloran et al’s estimation for age groups 5 to 9 and 10 to 14 (Halloran et 
al., 1994)). Those in the vaccinated protected class do not develop disease 
however a proportion k are boosted into the immune class. A proportion b of those 
in the vaccinated susceptible class develop immunity after a breakthrough 
infection (b represents their susceptibility relative to unvaccinated susceptible 
individuals). There is assumed to be no sub-clinical boosting of vaccinated 
susceptibles to the vaccinated immune class (the only substantial difference 
between our model and that of Halloran et al. (1994)). We suppose that 
individuals who are vaccinated susceptible have lost their immune protection to a 
degree that effective contact with wild type virus results in breakthrough 
infection instead of sub-clinical boosting. Such an assumption has no significant 
effect on the value of the other parameter estimates. Individuals in the 
vaccinated protected class pass into the vaccinated susceptible class at the 
waning rate W; individuals in the immune class have permanent immunity.
individuals* F*°W diagram of the natural hl’story of varicella among vaccinated
The efficacy parameters were estimated by comparing the expected annual 
incidence of breakthrough infections with that observed in the vaccinated arm of 
clinical trials. The parameter values, which minimised the weighted least square,
95
were chosen (weights were proportional to the number of individuals in the study 
at each time point (t)):
d )
t
A
where, t is time, ni is number of individuals at time t, yi and y{ are the observed 
and modelled number of breakthrough cases respectively.
To reduce the number of parameters to be estimated k was set to 50% for the 
worst-case scenario and 100% for the best-case; for the base-case k was allowed 
to vary between these values. The only constraints on the remaining parameters 
were that T and b were allowed to vary between 0% and 100% and that W was 
positive.
3.1.2 VACCINE EFFICACY
Figure 3.2 shows the data and the best fit model for the best, worst and base- 
cases (best fit parameter values are given in Table 3.1). For comparative purposes 
the annual proportion of the cohort with breakthrough infections as predicted 
using Halloran et al.'s (1994) base-case and worst-case (“low-efficacy”) parameter 
combinations (see Table 3.1) are also shown in Figure 3.2. It is clear that none of 
Halloran et al.’s (1994) parameter sets fit the data: even the least optimistic 
vaccine assumptions give far fewer breakthrough cases than are observed. In order 
to fit the observed data it was necessary to adopt high values for W, T, k and b 
(Table 3.1). That is, although a number of parameter sets gave similar overall fits 
they all share the same features: vaccination seems to result in a high proportion 
of individuals who are initially totally protected, but these individuals lose this 
protection relatively rapidly (approximately 3% in the base-case lose this
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protection each year) passing into a class in which if they are exposed they have a 
high probability of developing a breakthrough infection. Furthermore, a high 
proportion of individuals who are vaccinated protected seem to become immune 
through contact with varicella (91% in the base-case) without developing a 
breakthrough infection.
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Better fits can be produced by stratifying the model to take into account changes 
in force of infection with age. If the force of infection was assumed to be a step 
function (increasing from 0.16 to 0.2 y r 1 at 2 years) the fit was improved without 
significantly changing current parameter estimates (results not shown).
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Note that the vaccine efficacy parameters (as estimated here) are independent of 
herd immunity. Herd immunity influences the post-immunisation value of X, not 
the characteristics of the vaccine.
Table 3.1. Vaccine efficacy parameters
Parameters Symbol Brisson et al. 
Best Base Worst
Halloran 
et al.
Worst
Rate at which vaccinated protected 
individuals become partially susceptible 
to varicella (1/year)
W 0.021 0.031 0.072 0.0057
Percent of individuals who become 
protected after vaccination
T 97% 97% 88% 83%
Rate of varicella acquisition of vaccinées 
compared to non vaccinées
b 50% 73% 100% 16%
Proportion of vaccinated protected 
individuals who become immune if in 
contact with varicella
k 100%* 91% 50%6 0%
“Assumed parameter values
3.1.3 DISCUSSION
This study shows that vaccine efficacy parameters should be estimated 
concurrently to take into account dependencies (inter-relationships) between 
parameters and that simple mathematical models can be useful for such 
enterprises.
We also have updated Halloran et al.'s (1994) vaccine efficacy parameters in the 
light of new data and the weak methodological approach that was used (Delphi 
process). Our approach differs in that we estimate the parameters simultaneously 
from the observed breakthrough rates over time. Our estimates yield higher 
breakthrough rates, which give a better fit to the observed data. Indeed, the 
annual number of breakthrough cases with Halloran et al.’s (1994) worst-case 
scenario is lower than that of the lowest observed breakthrough data (lot 1982,
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with passive reporting). Thus studies using Halloran et al.’s (1994) parameter sets 
may be overestimating the predicted effectiveness of varicella immunisation.
In the next section we use the vaccine parameter values estimated here to predict 
the impact of vaccination on the epidemiology of VZV at the population level 
(taking into account herd-immunity externalities).
3.2 M O DELL IN G  VACC IN E  EFFECT IVENESS
3.2.0 BACKGROUND
Some important questions remain which limit the widespread acceptability and 
implementation of the vaccine in developed countries.
• Vaccination could increase the overall morbidity due tn varirona Vaccination 
can lead to a shift in the average age at infection from children to adults 
where risk of complication is greater. Hence, by increasing incidence in adults 
varicella vaccination programs could lead to an overall reduction in public 
health (Halloran et al. (1994), Health Canada (1999), Brisson et al. (2000a)). 
Such a phenomenon has been observed with rubella vaccination in Greece 
(Panagiotopoulos etal., 1999).
• High number of varicella cases in vaccinees. A high number of breakthrough 
cases of varicella have been reported in some vaccine efficacy studies (Krause 
and Klinman, 1995). Clinical trials have shown that 0.2% to 4.5% of vaccinees a 
year develop mild breakthrough varicella (modified varicella) in the first years 
following vaccination (Krause and Klinman, 1995; Section 3.1).
• Vaccination could increase the incidence of znctw (Gershon et al. (1996), 
Garnett and Grenfell (1992), Plotkin (1994)). In section 2.4.3 we show strong 
epidemiological evidence that exposure to varicella reduces the risk of 
reactivation (zoster). If this is so, mass vaccination of varicella could increase
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the incidence of zoster by reducing the opportunity of exposure to VZV (by 
reducing chickenpox cases).
• The vaccine can establish latency (Levin et al., 1994). The likelihood and 
severity of reactivation (zoster) in vaccinees is an additional concern (Krause 
and Klinman, 2000).
Previous modelling work on the impact of VZV vaccination has focused mainly on 
the change in incidence and morbidity of varicella due to shifts in the age at 
infection (Halloran et al., 1994; Schuette et al., 1999) and the possible impact on 
zoster (Schuette et al., 1999; Garnett and Grenfell, 1992a; Garnett and Grenfell, 
1992b). The summary of epidemiological features included in published 
transmission dynamic models is presented in Table 3.2.
Impact of vaccination on varicella: Halloran et al., (1994) and Schuette and 
Hethcote (1999) predicted that vaccination of 12-month-old children would reduce 
both varicella incidence and hospitalisation in the US.
Table 3.2. Summary of epidemiological features included in previous published 
dynamic models of varicella zoster virus transmission_________
Reference Age
structure
Breakthrough
infection
Zoster
Garnett and Grenfell (1992a,b) Yes No Yes
Halloran et al. (1994) Yes Yes No
Ferguson et al. (1996) Yes No Noa
Garnett and Ferguson (1996) Yes No Yes
Shuette and Hethcote (1999) Yes Yes Yes
A l A sse ssed  the  im pact o f  zo ste r  on  va rice lla  d ynam ic s b u t  d id  no t a sse ss  the  im pact 
o f va rice lla  on  the  inc idence  o f  zo ste r
Impact of vaccination on zoster. Garnett and Grenfell (Garnett and Grenfell, 
1992a; Garnett and Grenfell, 1992b) were the first to explore the relationship 
between varicella and zoster using mathematical models. They examined the
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impact of vaccination on the long-term equilibrium incidence of these diseases 
(Garnett and Grenfell, 1992b). Furthermore, they modelled the impact of mass 
vaccination on zoster assuming varicella is eliminated at the start of vaccination. 
Thus, they did not investigate the impact of the post vaccination dynamics of 
varicella on the incidence of zoster. Ferguson et al. (1996), on the other hand, 
examined the possible influence of zoster on the transmission dynamics of 
varicella, but did not investigate the impact of vaccination on the incidence of 
zoster (their model assumes a constant background force of infection from zoster 
which remains unchanged through time). Finally, Schuette and Hethcote (1999) 
were the first to model the short to medium-term impact of varicella vaccination 
on the incidence of zoster using a dynamic framework. In the simulations, zoster 
incidence increased in the first 30 years after initiation of infant vaccination 
(Schuette and Hethcote, 1999).
However, within these studies a small number of vaccine coverages and strategies 
were investigated, vaccine efficacy parameters were optimistic (see section 3.1) 
and no sensitivity analysis was performed on the Who-Acquires-Infection-From- 
Whom matrix (WAIFW). Furthermore, parameters used to model zoster were based 
on assumptions.
In this section we use a mathematical model based on new data on vaccine 
efficacy (section 3.1) and zoster (section 2.4) to simulate transmission of varicella 
and zoster in developed countries before and after vaccination using England and 
Wales as an example. The four main questions addressed are: 1) the effect of 
vaccination in healthy children on the overall varicella morbidity; 2) the role of 
vaccine efficacy on varicella incidence and morbidity; 3) the effect of vaccination 
strategies in minimising incidence and morbidity; and 4) the impact of vaccination 
on zoster.
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3.2.1 METHODS
3.2.1.1 Population
The population of England and Wales is assumed to be stable - i.e. birth is set to 
equal death. Birth rates are assumed constant through each year. Mortality is 
assumed to be zero until 65 years and constant thereafter producing an average 
life expectancy of 75 years. The population is stratified into 66 age cohorts 
(0,1,2,3,..,65+). This type of simplified age structure is widely used and is a 
reasonable approximation of the demography of England and Wales (Office for 
National Statistics, 2000).
3.2.1.2 Model Structure
Two models were used in this study. Model 1 (Figure 3.3a) was built to assess the 
impact of varicella transmission before and after vaccination in England and Wales 
whereas Model 2 (Figure 3.3b) was built to investigate the potential impact of 
varicella vaccination on zoster. Both transmission models are realistic age- 
structured deterministic models (RAS) based on a set of ordinary differential 
equations. Similar types of models have been used in other work to study 
childhood infections such as measles and varicella (Halloran et al., 1994; Schenzle 
D, 1984; Babad et al., 1995; Bolker and Grenfell, 1993). Models 1 and 2 possess 8 
epidemiological age groups (0 to 1, 2 to 4, 5 to 11, 12 to 18, 19 to 24, 25 to 44, 45 
to 64 and 65+ years). The younger age groups represent the school structure of 
England and Wales (i.e. infant, pre-school, primary school, secondary school, 
college and university) while older age groups are stratified to better capture 
differences in varicella and zoster incidence and morbidity with age. The models 
start at the mean varicella epidemic cycle.
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Model 1 is illustrated by the flow diagram in Figure 3.3a, which characterises the 
natural history of varicella with and without vaccination (the mathematical 
structure is presented in Appendix 2). The mutually exclusive compartments 
represent the different epidemiological states of the disease and the arrows 
represent the flow of individuals between them. At 6 months of age, once 
maternal antibodies to varicella have waned, children enter the susceptible class 
(Susceptible) and if infected pass through the latent (Latent - i.e. infected but not 
infectious) and infectious (Infectious) periods before acquiring lifelong immunity 
(Immune). Following vaccination, individuals either remain in the fully susceptible 
class (Susceptible) because of complete vaccine failure (primary failure) or pass 
into one of two mutually exclusive classes: 1) a temporary protection class (V 
Protected) in which individuals are immune from infection but may lose protection 
over time; and 2) a modified susceptible class (V Susceptible) in which individuals 
retain some degree of partial protection (1-b) and if infected are likely to 
experience a less severe infection (Bernstein et at., 1993). Vaccinated protected 
individuals can also become permanently immune (V Immune) by having an 
effective contact with an infectious individual (contact which would otherwise 
lead to infection).
The age-specific varicella force of infection Ma,t) (the per susceptible rate of 
infection) is composed of the force of infection caused by varicella (X.v(a,t)) and 
by zoster (h) (see Appendix 2). The force of infection caused by varicella (X.v(a,t)) 
is a function of the age-specific number of infectious individuals and the effective 
contact rate between age groups. It is allowed to take different values in each of 
8 age groups (< 2, 2 to 4, 5 to 11, 12 to 18, 19 to 24, 25 to 44, 45 to 64 and > 65 
years). In model 1, the force of infection due to zoster is constant through time 
(Xz) - i.e. independent of the prevalence of zoster.
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Model 2, illustrated by Figure 3.3b, adds a complexity to model 1 by attempting to 
incorporate the natural history of zoster (solid bold boxes a  lines) (see Appendix 3 
for mathematical structure). Following varicella infection individuals acquire 
lifelong immunity to varicella and a temporary immunity to zoster {Immune). Once 
immunity to zoster has waned individuals become susceptible to zoster (Sus 
Boosting). Unless they die in the meantime, two events can then occur: 1) 
individuals have a reactivation episode (Zoster) and then become permanently 
immune (Zoster Immune); or 2) individuals are boosted by contacts with varicella 
and return to the temporarily immune class (Immune). Repeat cases of zoster 
were not modelled since reoccurrence is low (Levin et al., 1994). Furthermore, 
zoster was assumed not to occur in vaccinées even though studies in 
immunocompromised children have shown V2V to reactivate after vaccination. 
However, after vaccination zoster is reduced by 6 fold and cases are less severe 
(Gershon etal., 1999).
In Model 2 the force of varicella infection caused by zoster (Jiz(a,t)) is a function 
of the overall number of zoster infectives (see Appendix 3). The rate of VZV 
reactivation (p(a)) is assumed to be dependant on age (see Chapter 2 and 
Appendix 3).
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Figure 3.3. Flow diagram of varicella and zoster before and after vaccination. 
The mutually exclusive compartments represent the different varicella and zoster 
epidemiological states. Arrows represent the flow between theses states, a) Model 
1, represents the transmission dynamics of varicella, b) Model 2, represents the 
transmission dynamics of both varicella and zoster. See text and table 3.3 for 
details.
3.2.1.3 Mixing patterns - The Who-Acquired-Infection-From-Whom matrix 
The standard technique to take account of age-dependant mixing patterns of the 
population is to use a Who-Acquired-lnfection-From-Whom (WAIFW) matrix 
(Anderson and May, 1991). The WAIFW matrix represents the effective contact
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rate between age groups - i.e. the rate at which an infective of age X will infect a 
susceptible of age Y. Since the elements of the matrix cannot be observed directly 
in populations they must be estimated from the pre-vaccination force of infection. 
With such a technique a large number of possible matrix structures can be 
assumed from the same observed data. It is therefore necessary to perform a 
sensitivity analysis to assess how changes in the matrix structures influence 
results. In this study we explore the effect of five WAIFW matrices on the results. 
The chosen matrix structures are; our base matrix (base matrix); two variations on 
the base matrix (matrix 1 & matrix 2); a purely proportional (proportional 
matrix), and a highly assortative mixing matrix (assortative matrix) (see Appendix 
4 for the matrix structures).
The structure of the base matrix was chosen to reflect the importance of school 
and parent-child transmission of varicella. Contact rates within pre-school (2 to 4 
years old), primary school (5 to 11 years), secondary school (12 to 18 years), 
university (19 to 24 years) are allowed to be large. The highest contact rates are 
observed within the 19 to 24 age group, which may reflect higher contact patterns 
amongst University students (Edmunds et al., 1997). Infants (0 and 1) are 
assumed to come into contact with all other children at a similar rate and with 
adults at different rates (the highest estimated rates were with the 19 to 24 and 
25 to 44 year groups, which probably represents parent-infant contacts). Adults 
(45 to 64 and 65+) are assumed to mix with themselves and with children at 
similar rates. School-aged children (2 to 4, 5 to 11 and 12 to 18) mix with other 
children not of their own age at a unique rate.
Matrix 1 is different to the base matrix in that specific rates are added for "grand 
parent’’-child contact (0 to 1, 2 to 4, 5 to 11 with 45 to 64 and 65+) and work 
related contacts (19 to 24, 25 to 44 and 45 to 64). Matrix 2 has a similar structure
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to the base matrix but with contact rates in the 19 to 24 age group set to be 2/3 
of the base matrix. The purely proportional matrix assumes that each age group 
has a unique contact rate and the rate of effective contact between two age 
groups is dependent on the product of their respective contact rates. This matrix 
structure puts the least emphasis on mixing within age groups. Finally, the 
assortative matrix (like-with-like) implies a strong amount of within age group 
mixing. The assortative matrix has unique coefficients along the leading diagonal 
for all but the 65+ age group. It is important to note that this structure is not 
purely like-with-like since it allows a low contact rate between different age 
groups.
3.2.1.4 Model Output
Following mass immunisation, varicella cases are classified into two groups 
characterised by their degree of severity; 1) Natural (NV) and 2) Breakthrough 
varicella (BV). Natural or full-blown varicella occurs in unvaccinated individuals 
and primary failures. Breakthrough varicella, which occurs in seroconverted 
vaccinated individuals, is clinically modified and significantly less severe than 
natural varicella (Bernstein et at., 1993). Since breakthrough cases are very mild 
and are assumed to require no medical care we primarily investigate the influence 
of vaccination on natural varicella cases.
Varicella morbidity is represented by the total number of inpatient days due to 
varicella. The frequency of varicella and zoster hospitalisation and length of stay 
per admission were determined using the Hospital Episode Statistics for England 
(see Tables 2.2 and 2.4 in Chapter 2). We applied the age-specific length of stay 
per varicella case to the predicted number of natural cases of varicella. 
Breakthrough cases were assumed not to require hospitalisation. Using the 
hospital separation data might overestimate the severity of illness among older
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individuals since the validity of diagnostic codes for varicella decreases markedly 
after age 50 years (Choo et al., 1995). Furthermore, the incidence of co-morbid 
disease increases with age making it difficult to be sure that all days in hospital 
are attributable to varicella. On the other hand, our results assume that 
breakthrough varicella never requires hospital admission, which might be an 
underestimation of morbidity among older adults.
3.2.1.5 Biological parameters
The parameter definitions, values and data sources are described in table 3.3. The 
average duration of latency (1 /a) and infectiousness (1/a) for varicella is 
respectively 14 and 7 days (Beneson, 1995). Natural immunity to varicella is 
assumed to be life-long. Duration of immunity to zoster after boosting (Model 2) is 
set at 20 years (see Section 2.4 for details) but is varied in the sensitivity analysis. 
The average length of zoster infectiousness (1/az) is 7 days (Beneson, 1995).
3.2.1.6 Vaccine efficacy parameters and estimates
The waning rate (W), proportion of individuals who become temporarily protected 
after vaccination (T), residual susceptibility (b) and boosting (*) were estimated 
concurrently to take into account dependencies (inter-relationships) between 
parameters (see Section 3.1 for more details). The rate of primary vaccine failure 
(P) observed in clinical trials has ranged from 0% to 656 (Weibel et al., 1985; White 
et al., 1991; Clements et al., 1995). For the model P was set to 1% for the best 
vaccine, 456 for the base vaccine and 656 for the worst vaccine scenario. Relative 
residual infectiousness (m) is defined as the relative rate of varicella transmission 
to susceptible non-vaccinated contacts (NV) from infected vaccinees (i.e. those 
with breakthrough infection) versus that from infected non-vaccinees. M can be 
estimated epidemiologically by dividing the household secondary attack rate (SAR) 
from vaccinated to unvaccinated individuals (SARv.Nv) with the secondary attack
108
rate from unvaccinated to unvaccinated individuals (SAR*V.NV) (Halloran et at., 
1997). The observed rate for S A IW Is  86% (Ross, 1962). There are no published 
estimates for SARV.NV however the rate can be estimated from SARV.V, which has 
been reported as 5% (Weibel et aL, 1985), 8.6% (Johnson et al., 1989) and 12% 
(Watson et at., 1993) in three different vaccine trials. If we set SARV.V to equal 
8.6% and we suppose that 10% of vaccinees are susceptible to varicella infection 
then the relative residual infectiousness is close to 100% (m = [SARV.NV / SARnv.nv] = 
[(8.6%/10%) / 86%J = 100%). A second method of estimating relative residual 
infectiousness is through the ratio of lesion numbers observed in vaccinees with 
breakthrough varicella compared to unvaccinated individuals with natural 
varicella. Published reports suggest this ratio is 17% (Bernstein et at., 1993). 
Taking both methods into account, relative residual infectiousness (m) is varied 
between 20% and 100% (i.e. 20% best vaccine, 50% base vaccine and 100% worst 
vaccine).
3.2.1.7 Vaccination policies
The different vaccination strategies investigated were:
Infant: Routine vaccination at 1 year of age.
Catch-up: Infant + vaccination of 1 to 11 year old children in first year of
program.
Adolescent: Routine vaccination at 12 years.
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Model Param eters
Demographic Parameters 
England and Wales Population
Birth rate (births/year)
Mortality rates by age group (1 /year):
0-64
>65
Biologic Parameters
Force of varicella infection by age group (Xv(a,t)) 
(1/year):
Force of varicella infection due to zoster (X,) 
(1/year):
Model 1 
Model 2
Duration of varicella (days):
Duration of latent period (1 /a)
Duration of infectious period(1/a)
Proportion of effective varicella contacts that 
boost against zoster (z)
Duration of immunity to zoster after varicella 
infection (1/6) (years)
Rate of reactivation by age group (p(a)) (1/year) 
for different durations of immunity (1/6):
0-1
2-4
5-11
12-19
20-24
25-44
45-64
>65 _____________________________
Table 3.3. Model Parameters_________
Mean value Source
Data
50,000,000
667,000
(ONS,
2000)
0.0
0.1
(See
Section
2.3)
0.001
5.4e'7*Zoster Prevalence
14
7
(Appendix
2)
(Appendix
3)
(Beneson,
1995)
100%
20 (95%CI 7-41) (Section
2.4)
1/5=7
8.08e-02
7.45e-04
6.94e-03
5.06e-03
3.02e-03
4.61e-03
5.93e-03
1.73e-02
1/8=20 1/8=41 
2.0 4.0 
7.9e-02 4.51e-03 
2.0e-02 3.41e-02 
1.1e-02 2.10e-02 
6.0e-03 1.10e-02 
8.3e-03 1.44e-02 
8.9e-03 1.76e-02 
2.3e-02 5.68e-02
(Appendix
3)
3.2.2 IMPACT OF VACCINATION ON VARICELLA
3.2.2.1 Age Distribution ft Coverage.
Incidence (Infant vaccination; base matrix; base vaccine). Model 1 produces a 
yearly epidemic of varicella before vaccination (see Figure 3.4) with an average 
predicted incidence rate of 13029 cases/1,000,000 population-year and 87% of 
cases occurring in children under 15. Considering reporting rates (<50% in children 
and >90% in adults), these results are consistent with sentinel surveillance and 
medical billings data from the England and Wales (5220 per 1,000,000 year; and 
80% in under 15s respectively (section 2.3)), Canada (5110 per 1,000,000 year; and 
85% (Brisson eta/., 2001; Law et a/., 1998), France (9855 per 1,000,000 year; and
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92% (Deguen et al., 1998)) and Scotland (6205 per 1,000,000 year; and 79% 
(Fairley and Miller, 1996)).
At 30% coverage (Figure 3.4a), the number of annual cases is rapidly reduced then 
oscillates between high and low epidemic years before reaching a new 
equilibrium. A slight shift in the age distribution is predicted but the bulk (73% 
compared to 83%) of infection remains in children under 12 years of age. Such 
dynamic patterns are observed with the base-case model for levels of coverage 
under 60%. As coverage increases (between 30% and 60%) oscillations in the 
number of cases before equilibrium become more pronounced, the number of 
cases at equilibrium decrease and a greater shift in the age at infection occurs 
(results not shown).
If high coverage is achieved, as should be expected in England and Wales (and 
other developed countries), more complex dynamics are produced. As shown in 
Figure 3.4b, 90% vaccine coverage produces an immediate decline in cases, which 
lasts for more than 10 years (honeymoon period). During this time susceptibles 
(unvaccinated, primary failures and partially susceptibles) slowly accumulate. 
Once a threshold of susceptibles is surpassed an epidemic occurs (post-honeymoon 
epidemic). Thereafter, the infection settles into a new epidemic cycle and 
equilibrium. The post-honeymoon epidemic would occur primarily in individuals 
who were in age groups immediately above those who were vaccinated when 
vaccination began. The epidemic occurs mostly in the 19 to 44 year cohorts. 
Finally, at equilibrium proportionately there are more cases in adults (48% occur 
in those over 18 years of age), but the absolute number is lower than the pre­
vaccination state. The transmission dynamics shown in Figure 3.4b are similar for 
vaccine coverage between about 70% and 95%. As coverage increases the 
honeymoon period is longer, the post-honeymoon epidemic is shorter but more
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intense and the shift in the age at infection (proportion of cases in adults) is more 
pronounced (results not shown).
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M orb id ity  (Infant vaccination; base m atrix; base vaccine). Figure 3.5 
represents the estimated yearly age-specific number of inpatient days expected in 
a population of 1,000,000 at equilibrium after mass vaccination, for the base case. 
Mass vaccination seems to reduce the overall morbidity as coverage increases 
despite a shift in the average age at infection and an increase in morbidity with 
age. The overall number of inpatient days decreases less than proportionately 
with an increase in coverage for levels of coverage below about 60%. This is 
because the sharp decrease in morbidity in children (at 60% coverage an estimated 
decrease of from 125 prior to vaccination to 35 inpatient days) is offset by the 
increase in adult morbidity (84 to 126 inpatient days). Only when coverage 
exceeds 80% does vaccination seem to reduce varicella transmission sufficiently to 
reduce both adult and child morbidity. Thus, small increases in coverage between 
70% and 90% are expected to significantly reduce the overall morbidity.
0 %  10%  2 0%  3 0%  4 0 %  5 0 %  6 0 %  7 0 %  8 0%  9 0%  100%
Coverage
Figure 3.5. Age distribution & coverage. Predicted age distribution of varicella 
associated inpatient days (morbidity measure) at equilibrium by vaccine coverage 
(base case vaccine used).
113
3.2.2.2 WAIFW matrices
Incidence (Infant vaccination; 90% coverage; base vaccine). The transmission 
dynamics shown in Figure 3.4 are dependant on the age-specific mixing patterns. 
Figure 3.6 shows the age-specific number of natural varicella cases for the 
different WAIFW matrices.
The more proportional matrices (proportional matrix and matrix 2 - Figure 3.6c, 
d) do not produce a post-honeymoon epidemic. On the other hand, they induce a 
larger shift in the age at infection due to a higher degree of contact between 
children and adults (Figure 3.6e). The remaining WAIFW structures (Matrix 1 and 
the assortative matrix) produce a post-honeymoon epidemic (Figure 3.6a,b). 
Matrix 1 (Figure 3.6b) produces almost identical short-term dynamics as the base 
matrix and a similar shift in the age at infection (Figure 3.5e). Thus, with the 
estimated force of infection of England and Wales, adding specific mixing rates for 
’’grand parent” -child contact (0 to 1, 2 to 4, 5 to 11 with 45 to 6g 4 and 65+) and 
work related contacts (19 to 24, 25 to 44 and 45 to 64) does not have an impact on 
post-vaccine dynamics. Finally, the assortative matrix (3.5d) produces a larger 
post-honeymoon epidemic and a small shift in the average age of infection (Figure 
3.5e). Results indicate that unless contacts are assortative or proportional, which 
is highly unlikely, dynamics of varicella after vaccination at high levels of 
coverage should approximate those of our base case model (base matrix, base 
vaccine, 90% coverage).
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Figure 3.6. WAIFW Matrix. Estimated incidence of natural varicella cases for al 
Assortative mixing, b) Matrix 1, c) Matrix 2, d) Proportional m ix im  and M fH fi 
age distribution of infection at equilibrium by WAIFW matrix structure All 
s im u la t io n s  assume the base vaccine and 90% coverage. AU
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M orb id ity  (Infant vaccination; base vaccine). As shown by Figure 3.4a and 3.6, 
mixing patterns influence the nature and scale of the shift in the age distribution 
of infection after immunisation. Since severity of varicella changes with age 
(Section 2.3), it is essential to assess the impact different WAIFW matrices can 
have on morbidity. In doing so we can quantify the uncertainty of our base matrix 
results.
The shift in the average age at infection is smaller as mixing becomes more 
assortative (Figure 3.6). The more contact across age groups the higher the 
potential for adverse effects of vaccination on varicella morbidity. However, 
equilibrium results are similar for the different Matrices (Figure 3.7). Hence, 
results from our model are relatively insensitive to the WAIFW assumptions.
250
Coverage
Figure 3.7. WAIFW Matrix. Estimated morbidity (annual inpatient days) at 
equilibrium for the Base matrix, Matrix 1, Matrix 2, Assortative and Proportional 
matrix.
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Incidence (Infant vaccination; 90% coverage; base matrix). Figure 3.8 shows 
the predicted impact of the various vaccine efficacy scenarios on the number of 
natural and breakthrough cases of varicella for high vaccine coverage. Before 
attaining post-immunisation equilibrium, the worst vaccine (Figure 3.8c) produces 
several epidemic peaks whereas the best and base vaccines produce one small 
epidemic (Figures 3.8a, b). The continuing transmission of varicella following 
vaccination with the worst vaccine produces 80% more natural cases than the base 
vaccine over the first 30 years.
At equilibrium the base and worst vaccines are expected to produce similar 
numbers of natural varicella cases (10% and 16% of pre-vaccination state 
respectively). However, the worst, base and best vaccine scenarios are predicted 
to cause very different numbers of breakthrough infections. The worst vaccine 
scenario results in roughly twice as many breakthrough cases at equilibrium as the 
base vaccine. Thus, if breakthrough cases are taken into account, 90% coverage 
with the worst vaccine is expected to reduce the number of total cases of 
varicella by only 25% in contrast to 60% for the base vaccine.
3.2.2.3 Vaccine efficacy
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Figure 3.8. Vaccine efficacy. Predicted incidence of natural & breakthrough varicella cases over time (90% infant coverage) with a) best case 
vaccine, b) base case vaccine, c) worst case vaccine; and d) estimated morbidity (annual inpatient days) at equilibrium for the base, worst, 
and best vaccine.
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Morbidity (Infant vaccination; base matrix). Figure 3.8d represents the 
estimated yearly number of inpatient days at equilibrium after routine mass 
immunisation with different levels of coverage and vaccine efficacy. 
Paradoxically, the worst vaccine results in fewer inpatient days than the best 
vaccine at all levels of coverage below about 80% coverage. This occurs because 
the best vaccine is more effective in reducing varicella transmission and thus 
produces greater shifts in the average age at infection. It should be stressed that 
the results shown in Figure 3.8d are at equilibrium and will not be seen for many 
years after the start of vaccination (the precise time to equilibrium will depend on 
many factors such as the efficacy of the vaccine and vaccination coverage).
3.2.2.4 Vaccination strategies
Incidence (90% coverage; base matrix; base vaccine). As already presented 
above vaccination at 12 months of age with no catch-up campaign is expected to 
produce a post-honeymoon epidemic among individuals who were 1 to 11 years old 
when the immunisation programme began (Figures 3.4, 3.6 and 3.8). Introducing a 
catch-up strategy for all children between 1 and 11 years can eliminate the post­
honeymoon epidemic (Figure 3.9a). Following the first year of vaccination the bulk 
of susceptibles in the population (over 85%) would be immunised. This practically 
eliminates transmission. Accumulation of susceptibles is slower and creates a 
longer honeymoon period (20 years). However, the annual number of cases of 
varicella at equilibrium (long-term) is identical for the infant and any catch-up 
strategy. Coverage and vaccine efficacy influences the number of cases at 
equilibrium whereas catch-up programs do not.
Vaccination at 12 years of age (adolescent strategy) is the least effective strategy 
producing only a slight decrease in the annual number of natural cases (Figure 
3.9a). Vaccinating 12-year-old children with the base vaccine and 90% coverage is
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predicted to reduce the total number of natural varicella by only 13% at post­
immunisation equilibrium. This is because by age 12 more than 85% of children 
have developed varicella. However, this strategy is expected to prevent 93% of 
adult cases at equilibrium.
Morbidity (90% coverage; base matrix; base vaccine). Figure 3.9b represents 
the estimated yearly age-specific number of inpatient days expected in a 
population of 1m following mass vaccination with 90% coverage and the base 
vaccine. Initially, infant and catch-up strategies are expected to significantly 
reduce morbidity (Figure 3.9b). However, in the long-term (after 80 years) 
inpatient days are expected to be reduced by only 50% with 90% vaccine coverage. 
This is because the sharp decrease in morbidity in children (234 to 16 inpatient 
days per 1m population-year) is partially offset by the increase in adult morbidity 
(86 to 150 inpatient days per 1m population-year).
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Figure 3.9. Vaccine strategy. Estimated a) varicella incidence and b) inpatient 
days due to varicella over time by vaccine strategy (90% coverage, base vaccine).
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3.2.3 IMPACT OF VACCINATION ON ZOSTER
In this section, we examine the potential impact of childhood vaccination on 
zoster (Model 2). Unless stated, zoster results are presented assuming that 
exposure to varicella results in 20 years of immunity, as estimated in section 2.4.
The model produces similar annual zoster incidence rates (3176 new 
cases/1,000,000 population-year without repeat cases) to observed data from 
Canada (3212 new cases/1,000,000 population-year without repeat cases (Brisson 
et al., 2001)) and England and Wales (3730 new cases/1,000,000 population-year 
with repeat cases) (section 2.3). The age distribution of cases is also similar to 
observed data from industrialised countries (Brisson et al., 2001, Edmunds et al., 
2001). The pre-vaccination and post-vaccination varicella dynamics produced by 
Model 2 are nearly identical to Model 1.
Incidence (Infant vaccination; 90% coverage; base matrix; base vaccine). We 
used the model to estimate how the incidence of zoster would evolve over time 
following introduction of mass varicella vaccination (Figure 3.10a). The base case 
model (1/o=20 years, 95% Cl, 7-41yrs) predicts that zoster cases will increase for 
the first 15 to 20 years after the start of vaccination, peaking at an incidence 39% 
(95% Cl, 25-42%) higher than the pre-vaccination level. The incidence of zoster 
will then gradually decrease as the vaccinated cohorts begin to reach the age at 
which most zoster occurs, but will remain above the pre-vaccination level until 40 
years (95% Cl, 30-44 years) after the introduction of vaccination (Figure 3.10a).
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Figure 3.10. Dynamics of zoster. Estimated a) incidence and b) morbidity (annual 
inpatient days) over time after the introduction of vaccination for the Base case 
model (11o=20 years) and the 95% confidence bounds of 1/c (7 and 41 years). The 
no vaccination scenario is represented by the red line.
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The more effective vaccines or effective programs against varicella will produce 
the greatest increases in zoster cases (Figure 3.11a,c). For example, the number 
of cases of zoster after vaccination is lower for the worst vaccine than more 
efficacious ones (Figure 3.11c).
In the long-term, once individuals from every cohort in the population have been 
vaccinated, zoster incidence will decrease if the vaccine virus reactivates at a 
lower rate than the wild-type (Figure 3.10a). Here, we assume that the vaccinees 
do not develop zoster.
Morbidity (Infant vaccination; 90% coverage; base matrix; base vaccine). 
Figure 3.10b shows the predicted increase in zoster morbidity due to varicella 
vaccination. The model predicts that, infant varicella vaccination with 90% 
coverage will increase zoster morbidity for over 60 years (Figure 3.10b). Such an 
increase would offset the gain in reduction of varicella morbidity from 
vaccination. Under base assumptions (base vaccine, infant strategy, 90% coverage, 
20yrs immunity), vaccination would prevent 0.5m inpatient days due to varicella 
over 60 years (Figure 3.9b) but would generate an extra 1.1m inpatient days due 
to zoster in a population of 50m (Figure 3.10b). More effective programs in terms 
of varicella reduction (i.e. higher coverage, better vaccines or catch-up 
strategies) would produce even greater increases in zoster incidence and 
morbidity (Figure 3.11b,d).
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Figure 3.11. Zoster incidence and morbidity. Estimated zoster a) incidence and b) morbidity (annual inpatient days) over time following 
the introduction of vaccination (at year 0) for different vaccine strategies. Estimated zoster c) incidence and d) morbidity (annual inpatient 
days) following the introduction of vaccination for different vaccine efficacy.
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3.2.4 DISCUSSION
The model suggests that the overall varicella incidence of infection (natural a 
breakthrough) and morbidity (measured by inpatient days) will more than likely be 
reduced by mass vaccination of 12-month-old children in England and Wales. 
However, the overall level of effectiveness of routine immunisation depends 
highly on the level of coverage, the type of vaccination strategy, the efficacy of 
the vaccine and the relationship between varicella and zoster. Importantly, the 
most effective programmes at reducing the incidence of varicella result in the 
biggest increase in zoster cases.
It seems unlikely that infant vaccination will shift the average age at infection to 
such an extent that the net outcome (in terms of inpatient days due to 
chickenpox) is worse than the pre-vaccination state. Using our base case 
assumptions regarding vaccine efficacy then, of the scenarios tested, no matrix 
resulted in a long-term increase in varicella morbidity. It should be noted, 
however, that an increase in adults cases would be expected although this is 
counterbalanced by the important decline in child cases. Whilst not predicted to 
cause harm to public health, there are many (more likely) scenarios in which 
vaccination at intermediate levels of coverage results in only marginal long-term 
benefits. Indeed, the more efficacious the vaccine (higher degree of individual 
protection), and the more contact that occurs between adults and children the 
more likely that infant vaccination at intermediate levels of coverage will result in 
few health benefits at the population level. On the other hand, varicella morbidity 
is eventually expected to decrease significantly for all scenarios if coverage is high 
(greater than approximately 70%-see Figures 3.7 and 3.8d). To limit the risk of 
adverse effects and significantly increase the effectiveness of varicella 
vaccination (at preventing varicella), programmes should aim at achieving a higher
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coverage than 70%. Such levels of coverage might be difficult to achieve in some 
countries. Only 60-70% of mothers say they would definitely, or probably have 
their children vaccinated against chickenpox in England (Health Education 
Authority, 1998).
If high levels of coverage (over 70%) are attained post-honeymoon epidemics are 
expected to occur, unless there is very little within-group mixing, or the vaccine 
has very low efficacy. Such epidemics have been observed after measles (1989- 
1990) and mumps (1970-1980) vaccination programmes in the United-States 
(Atkinson et al., 1992; Cochi et al., 1988) and elsewhere (Chen et al., 1994). The 
use of catch-up campaigns can reduce these epidemics as well as minimize the 
overall number of varicella cases after vaccination. It should be stressed, 
however, that although catch-up programs have a major impact on the short-term 
dynamics of infection, they do not influence the long-term effectiveness of the 
program.
As expected, the higher the vaccine efficacy the more mass vaccination reduces 
the incidence of varicella infection. On the other hand, lower vaccine efficacy 
reduces the shift in the average age at natural infection by allowing a certain 
number of cases to occur every year. Thus, paradoxically, for intermediate levels 
of coverage, lower efficacy vaccines could be more effective in reducing 
morbidity than better vaccines, particularly if exposure to varicella does boost the 
immune response to zoster. However, less efficacious vaccines are expected to 
result in a significant number of breakthrough cases even at high levels of 
coverage. Although breakthrough cases are mild and are assumed, here, to require 
no medical care, such a high number of cases in vaccinées may have an impact on 
vaccine acceptance.
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Since the number of breakthrough cases of varicella might be significant even at 
high levels of coverage, elimination is unlikely to be a goal of routine 
immunisation. Given the mild nature of breakthrough varicella, reduction of 
morbidity of chickenpox is a more realistic target. If morbidity reduction is the 
goal of vaccination then using a vaccine with lower efficacy could actually be 
more effective than the use of higher efficacy vaccines. These results might 
provide some reassurance to concerns that, in the field, the vaccine would lose 
potency because it requires freezing.
If vaccination is highly effective against varicella, as it is likely to be with high 
coverage (Vazquez et al., 2001, Clements et al., 2001, Seward et al., 2001), and 
exposure to varicella is protective against zoster (section 2.4, Thomas et al., 
2001), then an increase in zoster will occur after infant vaccination. Because the 
burden of zoster is high compared to varicella, such an increase might render 
infant immunization highly cost-ineffective and could lead to adverse public 
health consequences. These predictions depend on one main assumption. That 
exposure to varicella boosts against zoster. The longer the period of immunity 
after boosting the greater the increase in zoster after vaccination. Therefore, our 
results may overestimate the impact of vaccination on zoster if the period of 
immunity conferred by exposure is shorter than 20 years. However, as shown in 
figure 3.10 the duration of immunity is likely to be long enough to produce a 
significant increase in zoster after vaccination. It should be noted that, in the 
long-term a reduction of zoster cases will occur provided vaccine recipients are 
less likely to develop zoster than individuals who acquire natural infection 
(Garnett and Grenfell (1992)). However, if zoster can occur in a high proportion of 
vaccinées and varicella can boost immunity against zoster there is a risk that
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incidence of zoster could increase in the long-term (Garnett and Grenfell, 1992). 
This scenario is unlikely. Studies in immunocompromised children have shown a 6- 
fold reduction in zoster after vaccination (Gershon et al., 1999). Thus it seems 
likely that in the long-term the incidence of zoster will decrease following the 
introduction of childhood vaccination, though a short to medium term increase in 
incidence of the possible size shown in Figures 3.10 and 3.11 could have a 
negative effect on public health and confidence in immunisation.
The model presented here differs and extends that of Halloran et al. (1994), 
Schuette and Hethcote (1999) and Garnett and Grenfell (1992) in several ways. 
First, improved vaccine parameter estimates, based on up-to-date data from 
clinical trials were used. Secondly, the age-structure of the model more 
accurately reflects school aged mixing patterns. Thirdly, we assessed the 
sensitivity of our results to different age-dependent mixing patterns and discussed 
which of the patterns are more likely given available evidence on observed mixing 
patterns. Fourthly, Halloran et al. (1994) did not attempt to assess the possible 
effect of VZV vaccination on the incidence of Herpes zoster. Finally, although 
previous models have suggested that a rise in zoster incidence may occur following 
mass infant varicella vaccination (Schuette and Hethcote, 1999; Garnett and 
Grenfell, 1992), these studies relied on assumptions for key parameters such as 
the period of boosting. The model presented here is more rigorous and better 
parameterised since it is based on the analysis of a large, population based survey 
(see section 2.4), thus its predictions should be more robust.
In conclusion, the overall effectiveness of infant varicella vaccination depends on 
the impact it will have on zoster. Further work is necessary in this area. In the 
mean time, sensitive surveillance of zoster incidence should be a priority in
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countries where immunization is underway. In countries where vaccination has yet 
to be implemented, pre-adolescent vaccination is a safe alternative to infant 
vaccination, since it carries no risk of increasing the age at infection or the 
incidence of zoster.
In the next section we illustrate why dynamic models, such as the one presented 
above, are important in the context of the economic evaluation of vaccination 
programmes.
3 .3  COM PARISO N BETW EEN DYNAM IC AND  STAT IC M ODELS: TH E  
IM PACT OF H ERD-IM M UN ITY
3.3.0 BACKGROUND
As described in Chapter 1, although there are many types of models that are used 
to predict the impact of vaccination they can be broken down into two main 
categories: 1) dynamic and 2) static. The major difference between these types of 
analysis is that in dynamic models the rate at which susceptibles become infected 
is dependant on the number of infectious individuals in the population (thus the 
system is inherently non-linear) (Edmunds et al., 1999; Anderson and May, 1991; 
Nokes and Anderson, 1988), whereas static models treat this rate as a fixed 
parameter (Edmunds et al., 1999). Since mass vaccination results in fewer 
infectious individuals in the population, under the dynamic framework the rate at 
which susceptibles become infected will decline, whereas under a static 
framework this rate remains unaltered (though there may be fewer susceptibles to 
act on due to vaccination). Thus dynamic models capture herd-immunity effects, 
whereas static models omit them.
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Currently, because of its relative simplicity compared to dynamic models, the bulk 
of economic evaluations of vaccination programmes continue to use static models, 
such as decision analysis Markov models and cohort models, and therefore do not 
take into account the indirect effects produced by herd-immunity. Furthermore 
authors using static models occasionally claim to be taking account of herd- 
immunity effects (Rothberg et al., 2002). This comes from a misunderstanding of 
what herd-immunity is, what its effects are, and how to incorporate it into 
decision analyses.
In this section we illustrate and describe the effect of herd-immunity on the 
dynamics of infection using routine varicella vaccination as an example. We 
compare results from a dynamic model with those of a static model to illustrate 
and quantify the impact of incorporating herd-immunity externalities. It should be 
noted that results from the dynamic model used here is a simplified version of the 
one used in section 3.2. These simplifications are made for ease of exposition.
3.3.1 METHODS
3.3.1.1 Mathematical Models
The dynamic model used here is the realistic age-structured deterministic model 
of varicella presented in section 3.2 (see Appendix 5 for a description of the 
model). The single difference between the static model and the dynamic model, 
used here, is that the force of infection (per-susceptible rate of infection, 
sometimes termed the attack rate) in the static model remains constant through 
time, whereas in the dynamic model the rate at which susceptibles become 
infected is assumed to be a function of the number of infectious individuals in the 
population at a given point in time, multiplied by the effective contact rate 
between susceptibles and infectious individuals. That is:
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X = fixed (static)
X(t) = pi(t) (dynamic)
where X is a (1*Ac) vector representing the force of infection in each of the k age 
groups, p is a k*k matrix representing the effective contact rate between 
individuals by age group, and l(t) gives the number of infectious individuals in 
each age group at time t. Static models are usually applied to a single ageing 
cohort (Sonnenberg and Beck JR, 1993), whereas dynamic models are run for many 
years to allow the full effects of the intervention to become apparent. For 
comparability the static model presented here is applied to multiple cohorts. It 
should be noted that in a cohort model, since the force of infection is constant 
with respect to time, the cost-effectiveness results are identical for single or 
multiple cohort models provided that all cohorts are followed for the same length 
of time (usually until death) (Edmunds et al., 1999).
3.3.1.2 Parameter Estimates
Simulations were performed for a population with characteristics similar to 
England and Wales. The population and average life expectancy was assumed to 
be 50m and 75 years respectively. The age-specific force of varicella infection 
(the per susceptible rate of infection) in England and Wales was taken from pre- 
vaccination data (Chapter 2).
The different health outcomes were taken from Chapter 2. The predicted number 
of cases of varicella was estimated directly from the models. The estimated 
varicella case-fatality was applied to the predicted number of cases. For simplicity 
we assume that vaccine is perfect: that is, all vaccine recipients will derive life­
long immunity after a single dose.
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3.3.1.3 Vaccination programmes
AU simulations are with 80% coverage unless otherwise stated. The different 
vaccination strategies investigated were:
• Routine vaccination at 1 year of age (Infant vaccination) and,
• Routine vaccination at 11 years (Adolescent vaccination).
3.3.2 THE DYNAMICS OF VACCINATION
The introduction of routine infant mass vaccination typically produces dynamical 
effect which are composed of three phases (Figure 3.12a):
• Honeymoon period: Shortly after the start of vaccination (at high levels of 
coverage), the number of susceptibles falls to such low levels that continued 
endemic transmission is no longer possible. This results in a period of very low 
incidence, which is commonly called the ’’honeymoon period” .
•  P o s t - honeymoon epidemic: Over time, the low incidence of infection allows 
susceptibles (here, individuals who have not been vaccinated) to accumulate 
via births. Once a threshold of susceptibles is surpassed an epidemic occurs 
which is called the "post-honeymoon epidemic” .
• Post-vaccination endemic equilibrium: After the post-honeymoon epidemic 
infection settles into a new equilibrium with much lower incidence than before 
vaccination.
Such dynamics have been observed following measles and mumps vaccination 
(Atkinson et al., 1992; Cochi et al., 1988; Chen et al., 1994). Static models cannot 
c a p t u r e  th e se  d y n a m ic s ;  in s t e a d  th e  incidence of infection steadily declines as the 
number of cohorts vaccinated increases in the population (Figure 3.12b). Figure 
3.12c shows the predicted incidence of varicella following vaccination using both
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the static and dynamic model. The impact of herd-immunity on the incidence of 
infection can be visualized as the difference between the dynamic (full line) and 
the static model (dotted line). Quantitatively, with the infant strategy (80% 
coverage), herd-immunity (difference between the two models) is estimated to 
prevent 10m cases of varicella over the first 80 years of vaccination in a country 
similar to England and Wales (50m).
The extent of protection conferred by herd-immunity depends on the amount of 
continuing infection in the community. If only a small proportion of the population 
is immunized (low coverage and/or targeted vaccination and/or poor vaccine 
efficacy) then vaccination confers little or no herd-immunity since the force of 
infection acting on those who remain susceptible remains relatively unchanged. 
Here, we illustrate this point using adolescent vaccination against varicella as an 
example. The predicted number of cases of varicella over time is similar using the 
dynamic and static approaches (Figure 3.12c). This is expected since the bulk of 
cases (85%) are in children under 11 years, thus vaccinating 11 year olds has little 
effect on the overall force of infection of varicella (i.e. the risk of children getting 
chickenpox).
3.3.3 SHIFT IN THE AGE AT INFECTION AND MORBIDITY OF DISEASE
Routine infant vaccination will cause the average age at infection to rise 
(Anderson and May, 1991). The shift in the age at infection is due to two factors:
• Cohort effect: For routine infant immunisation, as vaccinated cohorts age, 
infection becomes concentrated in the older unvaccinated cohorts. This cohort 
effect can be clearly seen with the static model (Figure 3.12b) since herd- 
immunity effects do not confound it. In Figure 3.12b, incidence first declines 
in children while it is constant in the older age groups. Hence, the proportion
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of adult cases increases. Only when all cohorts are vaccinated does this effect 
disappear.
• Herd-immunity effect: Vaccination at high levels of coverage leads to reduced 
circulation of infection. As a result, susceptibles are less likely to come into 
contact with infectious individuals and therefore tend to be older when they 
eventually become infected. The shift in the age at infection can clearly be 
seen in Figure 3.12a. The number of cases of varicella in adults over 45 years 
of age is expected to increase by more than three fold after vaccination. Note 
that here the number of adult cases increases, not just the proportion. Also 
remember that there is no waning immunity: waning vaccine-induced 
immunity is not necessary to induce an increase in the number of adult cases.
An increase in the number of adult cases can lead to a rise in mortality and 
morbidity if disease severity increases with age at infection. Many viral infections 
are more severe if contracted as adults; examples include polio, hepatitis A virus, 
and mumps, and such perverse outcomes arising from mass infant vaccination 
have been observed for rubella in Greece (Panagiotopoulos et al., 1999) (rubella is 
a benign childhood infection, which can have devastating effects on the foetus if a 
mother contracts the virus during pregnancy). These shifts in the age at infection 
can also have beneficial effects if disease is most severe in young children - e.g. 
pertussis and measles in developing countries.
Since static models cannot predict an absolute increase in adult cases, the choice 
of model can have an important impact on the overall assessment of the benefit 
of vaccination. We illustrate this by comparing the predicted number of varicella 
deaths in England and Wales following vaccination using the dynamic and static 
models (Figure 3.13). Varicella deaths are used as an example since varicella-
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associated case-fatality increases dramatically with age. The dynamic model 
initially produces a rapid decrease in deaths following vaccination (Figure 3.13a). 
However, after 50 years the number of deaths due to varicella rises and surpasses 
the pre-vaccination level due to the increase in the number of cases in adults. In 
contrast, using the static model the number of deaths falls as the number of 
cohorts that are vaccinated increases (Figure 3.13b). Over the first 80 years of 
vaccination, the dynamic model predicts that vaccination will produce 315 deaths 
over the pre-vaccination level while the static model predicts that 765 deaths will 
be prevented. Thus, herd-immunity (difference between the two models) is 
estimated to cause 1,080 deaths over the first 80 years of vaccination in England 
and Wales.
The extent to which the average age at infection will rise following routine infant 
vaccination depends on the amount of continuing infection in the community. As 
the proportion of immunized individuals increases in the population so does the 
average age at infection due to increased herd-immunity. To illustrate this, in 
Figure 3.14 we present the estimated number of varicella deaths in England and 
Wales at post- vaccination equilibrium by vaccine coverage. Here, coverage is 
equal to the proportion immunized since the vaccine is assumed to be perfect. For 
the dynamic model the proportion of deaths in adults increases between 0 and 
60% coverage (Figure 3.14a). Furthermore, only when coverage exceeds 80% does 
vaccination seem to diminish varicella transmission sufficiently to reduce adult 
mortality to levels below the pre-vaccination state. In contrast, without herd- 
immunity (Figure 3.14b), the number of deaths decreases linearly with increased 
coverage and there is no shift in the age distribution of deaths - e.g. 50% coverage 
will reduce the number of deaths by 50% in all age groups. This leads to our final 
point, for the static model the number of cases or deaths prevented per
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immunised individual is independent of the overall number of individuals 
vaccinated (coverage). This means that the cost-effectiveness ratio is independent 
of coverage (overall size of the vaccine programme), assuming there are no fixed 
or constant marginal costs associated with setting up the programme. However, 
Figure 3.14a clearly shows that if herd-immunity is taken into account, the size of 
the programme has a major impact on effectiveness and thus cost-effectiveness.
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Figure 3.13. Pre and Post vaccination dynamics of varicella infection Estimated age-specific mortality due to varicella in England and 
Wales after the introduction of infant vaccination using a) a dynamic and b) a static model. (80% coverage, perfect vaccine).
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Figure 3.14. Post vaccination equilibrium. Predicted age distribution of varicella associated deaths in England and Wales at equilibrium by 
vaccine coverage using a) a dynamic and b) a static model (perfect vaccine).
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3.3.4 DISCUSSION
The aim of this section was to illustrate the importance of incorporating herd- 
immunity externalities when assessing the health benefits of vaccination 
programmes. To do this, we compare two methods of estimating the benefits of 
routine mass vaccination, one that includes herd-immunity (dynamical approach) 
and one that does not (static approach). We show that because they take into 
account herd-immunity effects, dynamic models:
• Produce non-linear dynamics following vaccination (Figure 3.12a)
• Predict a higher number of cases prevented by vaccination (Figure 3.12c)
• Produce proportional and absolute shifts in the age at infection (Figure 3.13a)
• Can predict increases (or decreases) in morbidity and mortality due to shifts in 
the age at infection following vaccination (Figure 3.13-3.14).
These dynamical effects are dependant on the extent to which vaccination 
prevents transmission of infection in the population. If only a small proportion of 
the population is immunized (low coverage or targeted vaccination) or the vaccine 
does not prevent the circulation of the pathogen (as occurs with some vaccines) 
then herd-immunity effects are negligible (Figure 3.12, 3.14). Under such 
conditions static and dynamic model produce similar results (Edmunds et al., 
1999). Static models may also be used as a tool to estimate the worst-case 
scenario when herd-immunity externalities cannot produce negative effects 
(disease severity does not increase with age). In other circumstances dynamic 
models should be used.
These results can be used to clarify a number of misconceptions, which are 
common in the literature concerning herd-immunity and dynamical effects 
produced by models:
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• Herd-immunity is always a good thing: We show that herd-immunity can cause 
the age at infection to increase, which can cause serious deleterious 
consequences (Figure 3.13-3.14). It is not always a conservative assumption to 
ignore herd immunity effects. Indeed, a static model may grossly overestimate 
the effectiveness of mass vaccination at preventing serious disease if the risk 
of developing complications increases with age at infection, as is shown here 
for chickenpox.
• Waning vaccine-induced immunity is necessary to cause an increase in adult 
cases. While waning vaccine-induced immunity can exacerbate increases in the 
average age at infection it is not necessary, as we have demonstrated here.
• Static models can give rise to shifts in the age at infection: If a static model is 
applied to successive cohorts then the models can produce a temporary shift in 
the age at infection. These shifts are due to a cohort effect (the vaccinated 
cohorts make up the younger age groups) and not herd-immunity. Once all the 
cohorts have been vaccinated the age distribution of infection will be identical 
to the pre-vaccination state. Furthermore, this will only produce a temporary 
proportional increase in adult infections (as opposed to absolute increases) as 
the rate of infection in the older (unvaccinated) cohorts remains the same as it 
was before vaccination. Hence, static models cannot investigate whether shifts 
in the age at infection following vaccination will produce increases (or indeed 
decreases) in morbidity.
There is a large literature on models of infectious disease transmission dating back 
to Bernouilli in the 18th century (for a comprehensive textbook on the subject see 
Anderson and May (1991) or Bailey (1975)). Analysts who ignore this literature 
(because of complexity) and assume that the disease in question is not infectious 
(as static models implicitly assume) do so at the risk of biasing results of economic 
analysis and can mislead public health decision makers.
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3.4 SUMMARY
First, in this chapter we examined the potential impact of varicella vaccination on 
VZV disease. As described in Chapter 2, mass vaccination has two dangers; it could 
increase the number of varicella cases in adults, where severity is greater, and 
increase cases of zoster. A deterministic realistic age-structured model (RAS) was 
built to study these concerns. Model parameter estimates were derived from a 
literature review and surveillance data from England and Wales. Different vaccine 
efficacy scenarios, vaccine coverages and vaccination strategies were 
investigated. The model predicts that, although an upward shift in the age at 
infection occurs resulting from more cases in adults, the overall morbidity due to 
varicella is likely to decrease following mass infant vaccination. On the other 
hand, cases of zoster may significantly increase in the first 50 years following 
vaccination.
Secondly, we illustrated the importance of incorporating herd-immunity 
externalities when assessing the effectiveness of vaccination programmes. To do 
this, we compared two methods of estimating the benefits of routine mass 
vaccination, one that includes herd-immunity (dynamical approach) and one that 
did not (static approach). Finally, we used the results to clarify a number of 
misconceptions, which are common in the literature concerning herd-immunity 
and dynamical effects produced by models. These results show that, in certain 
circumstances, ignoring the herd-immunity externality can lead to gross 
miscalculations of the effectiveness and thus the cost-effectiveness of vaccination 
programmes.
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Chapter 4
Valuing the Benefit of Vaccination 
Programmes
4.0  INTRODUCTION
The specific objectives of chapter 4 are to:
1) Estimate the willingness to pay for varicella vaccination and the Quality Adjusted 
Life-Years (QALY) lost due to chickenpox and shingles using different elicitation 
techniques,
2) Examine and compare the different elicitation techniques and their outcomes,
3) Assess the importance of the different attributes of immunisation,
4) Examine how individual preferences can be aggregated to estimate the overall 
population’s value of the benefit of vaccination taking into account externalities 
and non-health effects.
In the first section, we examine what are individual’s preferences regarding 
chickenpox vaccination and how they can be measured and valued (individual 
perspective). We estimate the average willingness to pay for varicella vaccination 
and the QALY lost due to chickenpox (no such information exists within the 
international literature). We then attempt to identify what attributes of vaccination 
are important to vaccinees and what elicitation technique can capture these 
components.
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In section 2, we examine how to measure the benefit of vaccination at the 
population level (population perspective). That is, we explore different methods of 
aggregating individual revealed preferences to the population level taking into 
account externalities (herd-immunity and zoster, see Chapter 3) as well as the non­
health benefits of vaccination (estimated in the first section of this Chapter).
Results from this chapter should provide a better understanding of how the choice of 
valuation technique, outcome measure and method of aggregation can affect the 
results of economic evaluation of vaccination programmes and therefore influence 
resource allocation decision-making.
4.1 VA LU E OF VAR ICELLA  VACC INAT IO N  - IND IV IDUAL  
PERSPECTIVE
4.1.0 BACKGROUND
In order for economic evaluation of health programmes to be comparable, a 
common methodology must be used to estimate benefits. However, there is no 
consensus on the technique that should be used. This stems, in part, from a 
theoretical disagreement on how economic analysis should be performed. There 
are two competing views on economic evaluation in health care: Welfarism and 
extra-welfarism (Tsuchiya and Williams, 2001; Brouwer and Koopmanschap, 2000). 
The first is based on the theory of welfare economics, on which the theoretical 
foundation of economic evaluation was built. Welfarism is the perspective where 
the benefit of an intervention depends solely on individuals’ self-assessed 
preferences (Brouwer and Koopmanschap, 2000; Johansson, 1991). Welfarists 
believe that Cost-Benefit analysis with monetary valuation of benefits should be 
used. The second view, extra-welfarism, is that other types of measure can be 
used, and may be more pertinent, than individual preferences in the context of
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resource allocation in health care (Culyer, 1990; Wagstaff, 1991; Brouwer and 
Koopmanschap, 2000). Extra-welfarists believe that the benefits of health 
interventions should be based on quantifiable and comparable effectiveness 
measures such Life-years and QALYs gained (McGuire, 2001) and therefore that 
Cost-Effectiveness or Cost-Utility analysis should be performed. It has been argued 
that QALYs do not only measure health outcomes but can measure preferences 
(utilities) and that Cost-Utility analysis (Cost per QALY-gained) can be consistent 
with Cost-Benefit under certain assumptions (Bleichrodt and Quiggin, 1999). These 
theoretical issues have been extensively debated in the literature (Blomqvist, 
2002; Dolan and Edlin, 2002; Bleichrodt and Quiggin, 1999; Garber and Phelps, 
1997; Johannesson, 1995). The aim of this section is not to study under which 
theoretical assumptions Cost-Utility and Cost-Benefit would yield different or 
similar resource allocation or what theoretical perspective should be taken as the 
correct basis for judging the benefit of health interventions. Rather, the aims of 
this section are to compare various valuation techniques and examine empirically 
what attributes of health intervention they can capture. That is, we focus on 
empirical problems rather than theoretical issues. This, in the context of 
vaccination.
Most elicitation techniques have been developed for interventions that treat 
chronic diseases in adults. Vaccination has different characteristics, which may 
have an impact on which measures of benefit should be used when assessing the 
impact of immunisation campaigns. Vaccination is different from most health 
interventions found in the literature because: 1) it is a preventative intervention 
(in contrast to curative), 2) it protects against infectious disease, 3) the diseases 
it prevents are usually short-lived and self-limiting (and can be mild), 4) most 
vaccines are given to young children from whom it is very difficult to elicit
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health/program preferences. Because of its unique characteristics, vaccination 
may possess its own specific benefits. At the time of this study, to our knowledge 
no study has attempted to measure the different attributes of the benefit of 
vaccination.
It has been argued that health is not the only source of well being derived from 
public health interventions (Mooney, 1994; Birch et al., 1999; Olsen and Smith, 
2001). For vaccinees, the overall benefit of vaccination can be separated into 4 
possible dimensions: 1) the direct effect on health, 2) caring (altruism), 3) 
security (reduction of uncertainty), and 4) productivity effects.
Direct effect on health. The principal benefit that can be derived from 
vaccination is that it prevents the vaccinee from acquiring disease and thus losing 
health related quality of life. Health related quality of life being defined as a 
state of physical, mental and social well-being and not merely absence or 
presence of disease (World Health Organisation, 1947). Other direct effect on 
health could be the side-effects related to the vaccine itself.
Caring externality (Altruism). Preventing (or treating) infection in a proportion 
of individuals in the population offers a degree of protection to others in the 
population. Because of this, the vaccinee (or vaccinees parent) may derive benefit 
from the knowledge that by being vaccinated they will not infect other children 
(e.g. their siblings and friends). Such a benefit can be called caring (paternalistic 
or altruistic Altruism). In this section, altruism indicates paternalistic or altruistic 
altruism.
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Security (Insurance type benefits). Immunisation offers protection against the 
uncertain future event of catching disease and its consequences. In these terms, 
being vaccinated can be viewed as taking insurance against disease. Because 
individuals are generally risk averse (afraid to take risks) in relation to health, 
they may find an added benefit in the knowledge that they are protected against 
disease.
Productivity effect (Work loss). Individuals may also find benefit in that 
vaccination can also prevent them missing time off work or other inconveniences 
and welfare enhancing activities.
In this section we examine three different valuation techniques to measure the 
benefit of varicella vaccination: 1) Contingent valuation (Monetary value), 2) 
Standard Gamble (QALY) and the Health Utilities Index mark 2 (HUI2) 
questionnaire (QALY).
Monetary value of health outcomes has gained renewed interest in recent years 
with the increased popularity of Contingent Valuation (CV) and the Willingness to 
pay (WTP) measure (Olsen and Smith, 2001; O’Brien and Gafni, 1996; Klose, 1999; 
Diener et al., 1998; Johannesson, 1993). The main arguments to CV’s superiority, 
as a measure for health intervention, is that it is theoretically correct, because of 
its base on economic theory (welfare economics) and that it values benefits in the 
same unit as the costs and therefore allows direct comparison (Olsen and Smith., 
2001, Birch et al., 1999, Bala et al., 1998; O’Brien and Viramontes, 1994; O’Brien 
and Gafni, 1996; Klose, 1999). Other aspects/qualities of CV and WTP are 
particularly appropriate for evaluating the benefit of vaccination (Birch et al., 
1999). First, it is a method of valuation that is sensitive to small changes in well­
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being at the individual level. Many vaccines that are now available prevent self- 
limiting, short lasting and/or mild diseases (e.g. varicella and influenza). Second, 
it imposes no restrictions on which dimensions of a vaccine programme individuals 
are allowed to express a value for. That is, theoretically, WTP should be capable 
of capturing the different non-health benefits of vaccination described above 
(altruism, uncertainty, work loss). On the other hand, the principal disadvantage 
of the CV and other WTP techniques is that the hypothetical WTP is usually found 
to be higher than the actual WTP and may be oversensitive to small changes in 
health or programme benefits (Seip a Strand, 1992; Duffield and Patterson; 1991, 
Clarke, 2002) (see Chapter 1 for further detail on WTP and CV).
QALYs are the most used method for measuring outcomes (Elixhauser et al., 
1998), mainly because of the widespread reluctance of clinicians and policymakers 
in the healthcare sector to evaluate health changes in monetary terms (Drummond 
et al., 1997; Johannesson, 1996; Brouwer and Koopmanschap, 2000). The concept 
of QALY was developed to capture simultaneously gains from reduced morbidity 
and reduced mortality, and to combine these into a single measure. It has been 
suggested that QALYs cannot capture non-health benefits (Olsen and Smith, 2001; 
Donaldson et at., 1997). Here, we test this hypothesis using two very different 
methods of estimating QALYs. First, we use the standard gamble (SG) because it is 
a standard technique that has a basis in economic theory (i.e. based on von 
Neumann-Morgenstern utility theory (von Neumann and Morgenstern, 1944). 
Second, it is similar to the CV in that it uses the economic concept of opportunity 
costs under uncertainty. For the SG, individuals are asked to trade-off probability 
of survival or risk of returning to a worse health state (in contrast to money with 
WTP) in return for health improvement. The main disadvantage of using SG for 
vaccine preventable disease is that many are acute and/or mild and therefore the
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risks individuals must trade-off are too small for them to comprehend. The use of 
SG and TTO to value morbidity for acute diseases has well documented 
measurement and evaluation problems (Bala, and Zardin, 2000; Bala et al., 1999; 
Stalmeier et al., 1996; Gafni, 1994; Dolan and Gudex, 1995; Stiggelbolt, 1995; 
Bleichrodt, Johannesson; 1997). Furthermore, SG has shown to be insensitive to 
small changes in health status (De Wit et al., 2000). The main reasons for choosing 
SG over TTO was that it resembles more the CV technique (uses the concept of 
opportunity costs under uncertainty) and that it has the potential of measuring 
non-health benefits of vaccination. Within the TTO framework it would have been 
very difficult to include scenarios that are close to vaccination. Within the TTO 
framework trade-offs are made between durations of current health states 
without the concept of uncertainty. On the other hand, a vaccine scenario is 
easily included in the SG framework. That is, the respondent can be asked to 
choose the probability of immediate death (or some other outcome worse than the 
one being valued) they are prepared to accept from vaccination to avoid the 
chance of acquiring the future disease being valued. Furthermore, SG can capture 
risk aversion, which is the basis of the insurance type benefit and the disutility 
related to insecurity about potential vaccine adverse events. As stated below due 
to ethic committee concerns a vaccination scenario was not included in the final 
questionnaire. Nevertheless, the SG technique was chosen here as the electronic 
questionnaires were programmed and the insights gained by using the SG 
technique will be used for future work on measuring the (dis)utility related to risk 
aversion of vaccine adverse events and non-health benefits.
The second technique used to measure QALYs lost due to chickenpox is the health 
status index (Health Utilities Index mark 2 (HUI2)) (see Chapter 1 for description). 
Multi-attribute health status indices, such as HUI2, are a simple alternative to the
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complex task of measuring preference through SG (or other similar techniques). 
Furthermore, it can capture small changes in heath status (De Wit et aL, 2000; de 
Vries et aL, 1998), which is of particular interest for vaccine preventable 
diseases.
The feature that distinguishes between techniques of economic evaluation is the 
way in which the benefits of health care programmes are valued. Surprisingly, 
only very few studies have directly compared WTP and QALYs (Bala et aL, 1998; 
O’Brien and Viramontes, 1994; Stavem K, 2002). The results raise questions as to 
whether QALYs and WTP would lead to similar decisions concerning the allocation 
of health resources. Furthermore, no study has compared QALYs and WTP for 
immunisation, small changes in well-being or have examined if QALYs are truly 
incapable of measuring individuals non-health benefits.
The objectives of this section are threefold: 1) to estimate willingness to pay for 
varicella vaccination and the Quality Adjusted Life Years (QALY) lost due to 
chickenpox, 2) to compare results, and 3) identify what attributes of vaccination 
(i.e. direct health effect, non-health effects, spill over effects) these elicitation 
techniques can capture.
4.1.1 METHODS
4.1.1.1 Ethical approval
Because it was the intention to interview mothers of healthy young children in 
health care settings in which they ordinarily would make the decision to 
vaccinate, it was felt necessary to seek approval from an ethics committee even 
though no medical intervention or invasive procedure was being proposed. Ethical 
approval was initially sought from the Camden and /s//ngion Community Health
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Services NHS trust in July 2001. The project was rejected by the Deputy Director 
of Primary Care in Camden and Islington in October 2001 and thus was not 
reviewed by the ethics committee. The questionnaires were slightly different at 
this stage. We intended to elicit the impact of vaccine adverse events into the CV 
questionnaire. The main reason for refusal was that, because of the anxiety about 
the Measles-Mumps-Rubella (MMR) vaccine, ’’parents may confuse some of the 
‘risk’ themes of the project with other immunisations that their children are 
receiving” .
The questionnaire was revised and questions relating to the risk of vaccination 
were removed. In October 2001, application for ethical approval was sent to the 
PHLS ethics committee and the Barnet, Enfield and Haringey Local Research Ethic 
Committee. In June 2002, ethical approval was granted from both committees. 
Ethical approval was difficult to obtain primarily because CV and SG questionnaire 
were new to the members of the various ethical committees.
4.1.1.2 Sampling and survey design
The study population consists of parents. Parents were used as proxies for their 
children since at the time of chickenpox vaccination (or disease) the child is too 
young to reveal his/her preferences (incapable of answering the valuation 
questionnaires (Friedman, 1990; Torrance, 1986; Vogels et al., 1998)). 
Furthermore, it is the parent who decides whether or not their child is vaccinated. 
We recruited all parents regardless of whether or not their children had prior 
history of varicella. For ethical reasons, the only inclusion/exclusion criteria was 
age greater than 18 years.
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Parents and caregivers were recruited from primary Health Centres in Enfield, 
London at the time of routine infant and child check-ups. Parents were 
approached in the waiting room where they were given an information leaflet (see 
Appendix 6) and asked to participate in the study. Those consenting to participate 
were given a computer active interview. The interview took place at the moment 
of consent.
4.1.1.3 Questionnaire and experimental design
The computerised questionnaire was programmed in Visual Basic within Microsoft 
Access (the questionnaire was programmed by Richard Bois and Marc Brisson).
Before the start of the main study, a pilot study was conducted to finalize the 
questionnaire. The computer active pilot questionnaire was administered to 89 
parents (20 SG and 69 CV). From the pilot we concluded that respondents had 
little difficulty answering the questionnaires and that the bidding scales used 
produced adequate distributions. This lead to some changes in wording. The final 
computer active questionnaire is structured into 3 parts (see Appendix 7, 8, 9 and 
10 for questionnaires).
Part 1: Socio-demographic questionnaire. In part 1, respondents are asked 
standard socio-demographic questions such as their age, sex, level of education 
and annual income (see Appendix 7). Other questions are more specific to 
chickenpox vaccination. Respondents are asked whether their children are fully 
vaccinated for their age in order to have an idea of the parent’s general attitude 
towards vaccination; if they need to take time off work when their child is sick, 
and whether any of their children have had chickenpox.
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Part 2: Contingent Valuation or Standard Gamble questionnaire. In part 2, 
respondents are given one of two different types of questionnaire: 1) CV 
(Appendix 8) and 2) SG (Appendix 9). Each parent or caregiver responded to only 
one type of question. Interviews using the CV and SG questionnaires were given on 
different days.
Contingent Valuation: The respondents are given a description of the health 
profile of a child with chickenpox (the description of chickenpox was written in 
collaboration with Natasha Crowcroft, PHLS Consultant Epidemiologist - see 
Appendix 8 part 1). In a first instance we ask respondents to assume that their 
child has chickenpox and that a drug exists which can cure their child 
immediately. We then elicit the maximum the respondent is willing to pay for the 
drug. In the second section of the CV questionnaire, respondents are asked the 
maximum they are willing to pay to vaccinate their child against chickenpox (i.e. 
to prevent their child having chickenpox sometime in the future). With CV, there 
are two measures of utility change: compensating variation and equivalent 
variation. Under compensating variation individuals are maintained on the initial 
level of utility before the health intervention whereas equivalent variation keeps 
the individual at the new level of utility attained after the intervention 
(Johansson, 1991). Here, compensation variation was used since the questionnaire 
measures the maximum amount that must be taken from the gainer to maintain 
the level of utility he/she had before the health intervention. We used the ex-post 
user-based perspective (respondents are asked to assume they are at the point of 
intervention) for comparability with the standard gamble, which has a similar 
perspective. However, as mentioned earlier, immunisation offers protection 
against the uncertain future event of catching disease. In this respect, the second 
section (vaccination question) has also characteristics of insurance-based
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questions (i.e. respondents are at the point of intervention (vaccination) but not 
in the disease state). Table 4.1 presents a summary description of the CV 
questionnaire, used here, following O’Brien and Gafni’s (1996) conceptual 
framework.
Table 4.1. Description of CV questionnaire
Question Consideration
What question do we want to Problem Definition:
answer? Project appraisal for resource allocation. 
Current Status of Prosram:
Program does not currently exist 
(Dis)Utilitv of program to respondent: 
Gain in utility from program
What type of measure is used? Monetary measure of utility change: 
Compensating Variation 
“Direction” of measurement:
Willingness to pay
What is asked of whom? Externality and option value:
Diseased (Treatment)
Non-diseased: At future risk (Vaccination) 
Framing of program consumption and payment:
Ex-post user-based question
What characteristics of the Program outcome description:
program are important for Certain outcomes (Efficacy 100%)
determining how it is valued? Uncertain outcomes (Efficacy 85%)
What question format was used? Valuation scenario:
Scenarios are holistic and decomposed. 
Value elicitation method:
Bidding Games
Adapted from O’Brien and Gafni (1996)
Respondents were given randomly one of 4 different contingent valuation 
questionnaires (Appendix 8). The questionnaires differ in their description of the 
effectiveness and consequences of the intervention. Table 4.2 describes the
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different components included in the 4 questionnaires. By comparing the 
willingness to pay between and within the different questionnaires it is possible to 
estimate the value parents place on vaccination and its different attributes.
Overall benefit of chickenpox vaccination in vaccines: Clinical trials and post 
vaccine surveillance have shown the varicella vaccine to be 85% effective 
(Vazquez et al., 2001). Therefore, the overall benefit of chickenpox vaccination in 
vaccinées is estimated by assessing the average willingness to pay for chickenpox 
vaccination when efficacy is 85% (Appendix 8 part 2 and 3).
Attributes of vaccine programmes: The direct health effect of preventing a case 
of chickenpox will be measured by estimating the average willingness to pay for 
chickenpox treatment when efficacy is 100% (Appendix 8 part 4). It should be 
pointed out that, due to ethical reasons, parents were told that vaccination and 
treatment had no side effects. The value parents’ put on preventing their child 
infecting others (altruism) is measured by comparing the WTP from questionnaires 
highlighting/stressing this effect (Appendix 8 part 2 and 4) to those in which the 
effect is not mentioned (Appendix 8 part 3 and 5). The benefit of security 
(insurance type benefit) will be measured by comparing the difference in parent’s 
willingness to pay for treatment and vaccination. Finally, the value of parental 
work loss will be measured by estimating whether parents who must take time off 
work when their child is ill are willing to pay more to prevent chickenpox than 
those who do not, controlling for factors such as household income. It should be 
noted that many adults will not lose financially from being off work although their 
employers will. Therefore, WTP will only capture a portion of the welfare losses.
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Table 4.2. Attributes varied in the CV questionnaires
Efficacy
100% 85%
Altruism
Appendix 8 part 2 X X
Appendix 8 part 3 X
Appendix 8 part 4 X X
Appendix 8 part 5 X
X indicates that the attribute is included in the description of the intervention
Standard Gamble: A separate group of respondents were asked to imagine that 
their child is in an imaginary health state for 15 years (see Appendix 9 part 1 for 
description). The duration of 15 years was chosen so that parents would trade 
risks of death for intervention and it is the time-span of childhood. Apart from the 
duration of disease, the health profile is identical to the description of 
chickenpox, though the patients were not told that the disease in question was 
chickenpox. Interviews using the CV and SG questionnaires were given on different 
days so that parents could not compare questions and thus associate the disease 
description in the SG questionnaire to chickenpox.
The SG questionnaire asks the parent what risk of death they would theoretically 
be willing to take to cure their child. Respondents are given randomly one of 2 
different SG questionnaires (see Table 4.3 and Appendix 9). The only attribute 
varied in the SG questionnaire was altruism. Altruism is included by specifying 
that treatment will prevent the child from giving the disease to other children. 
Probabilities were presented numerically and visually to make clear the risks that 
were being traded-off (see Appendix 9 Part 2 and 3). Visual aids were similar to 
those presented by Appel et al. (1990).
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Table 4.3. Attributes varied in the SG questionnaires
Altruism
Appendix 9 part 2
Appendix 9 part 3 X
X indicates that the attribute is included in the description of the intervention
The experimental design used, here, is a combination of conjoint analysis and CV 
or SG. That is, we present individuals with various scenarios that include different 
attributes (conjoint analysis) and from which we obtain preferences using CV or 
SG. Such a technique has been used to estimate the value of product attributes 
for antihistamine drugs (Reardon and Pathak, 1990). We did not ask parents to 
value directly the different attributes to prevent warm glow effects (Olsen, 1997).
Respondent’s maximum WTP or maximum acceptable risk to return to perfect 
health (SG) is assessed using bidding algorithms. Bidding algorithms is a standard 
approach in which the interview (computerized in this case) follows a pre­
programmed search strategy of probing accept/reject/indifferent questions at 
different bids, each one conditional on the person’s previous response (O’Brien 
and Gafni, 1996). Starting point bias has been identified in such algorithms 
(O’Brien and Viramontes, 1994; Stalhammar, 1996). To test and control for 
starting point bias, we used three randomised starting bids for the CV and SG 
questions. The starting point and bidding algorithms, for both the CV and SG 
questionnaires, are presented in Table 4.4.
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WTP SG Bid Bid Bid
Table 4.4. Bidding Scales and Bidding algorithms for WTP and SG questions
Bid Scale Bid Scale Algorithm 1 Algorithm 2 Algorithm 3
£0 0.1%
£10 0.5%
£25 1%
£50 2%
£75 5%
£100 10%
£150 15%
£200 20%
Y, willing to accept the bid, N not willing to accept the bid.
Y
Y
Y
Y
For SG, if a person is indifferent we stop the bidding.
Part 3: Health Utilities Index mark 2 (HUI2) questionnaire. In part 3 we ask the 
respondents to rate the health state that has been described to them (chickenpox 
(CV) or the imaginary disease (SG)) using an existing generic health status index 
(Health Utilities Index mark 2 (HUI2)). This enables us to estimate the QALY loss 
due to chickenpox as well as validate the WTP and SG responses. Preferences for 
the HUI2 scoring function were measured on a random sample of parents of 
schoolchildren in the City of Hamilton (Canada) and surrounding district using both 
the SG and a visual analogue score (Torrance et al., 1996). Because it was 
developed for childhood diseases using parents as proxies and utilities were 
derived using SG, HUI2 is an ideal tool to compare responses from Part 2 (CV and 
SG questionnaires).
4.1.1.4 Data Analysis
CV and SG model. The respondents’ answers to the questions do not directly 
reveal their maximum WTP (CV) or their maximum acceptable risk to return to 
perfect health (SG). The responses only provide bounds. For example, a 
respondent who responds yes to £100 but no to £150 is assumed to have a WTP 
value between £100 and £150. Furthermore, the data is both right and left
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censored. That is, the lowest bid for WTP is £0 (0.1% for SG) and highest is £200 
(20% for SG).
Interval regression was used here because it can estimate models for point, 
interval and censored data. Using this method we estimate the average WTP for 
chickenpox treatment and vaccination (CV) and average acceptable risk (SG). 
Furthermore, we test which intervention and respondent attributes affect the 
results as well as whether there is starting point bias. The variables and attributes 
included in the regression are listed and described in Table 4.5.
Interval regression can be described as follows. Let au and aut be the lower and 
upper bounds for each respondent and y, represents the true WTP or risk (SG). We 
assume that yi is represented by the following function:
y = xp + e (1)
Where, x is the vector of variables, p is the vector of regression coefficients and s 
is the error term. The model assumes that e ~ A(0,ct2I). The probability of y, falling 
between the lower and upper bounds is:
Prlau^a^PrKat,- x,p< e, < aui- x,p)] (2)
The log likelihood function, derived from this, is (StataCorp, 2002):
L  =
-1 /2 Z -
JeC . <y )
\ 2
+ log2;rcr2> +
JeL
yLj-xP'
a
+ g l o g j l  -  + 1  l o g W ^ ^ j  -
(3)
where observations jeC are point data (y,), jeL are left-censored (y, < yLi), jeR are 
right-censored (y, < yRi) and jel are interval data (ati<yi<aUi).
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Analyses were carried out in Stata v.7.0. (StataCorp, 2002). Regression was 
performed using the intreg function. The data generated from the study sample 
was re-weighted (using the pweight function) to be representative of the 
population of parents with children of vaccine age in England. Weights for the CV 
and SG analyses are presented in Tables 4.6 and 4.19 respectively.
The final multivariable models used to estimate the average WTP and SG and to 
identify significant variables were selected using the following method. Firstly, 
univariable analyses identified variables that were significant (p<0.2 level) for 
inclusion in the multivariable models. Secondly, the identified variables were 
added to the model and retained if they remained significant (p<0.1 level). 
Finally, the variables that were excluded at the univariable stage were included 
one by one to assess whether they became significant.
Residuals were tested for normality. Furthermore, we compared the log 
likelihoods for the interval regression and the ordered probit regression (oprobit 
command, stata v.7.0) since both model interval and censored data and their 
likelihoods are discrete.
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Table 4.5. Variable specification
Variable Description
Gender
Age
Degree
Work
Vaccinated
0=female, 1=male 
age in years 
0=degree, 1=no degree 
0=does not work, 1 =works
0=children are fully vaccinated for their age, 1 children are not 
fully vaccinated, 9=don’t know or did not answer
Work loss 0=Need to take time off work when child is sick, 1=Does not need 
to take time off work
Children 1=1 child, 2=2 children, 3=3 children, 4=4 or more children, 9=did 
not answer
Chickenpox* 0=at least one child has had chickenpox, 1=no child has had 
chickenpox, 9=don’t know or did not answer
People 1=1 person in the household, 2=2 people in the household, 
3=3people in the household, 4=4 people in the household, 5=5 
people in the household, 9=did not answer
Income 0=annual household income before tax is less than £15,000,
1 =£15,000-24,999, 2=£25,000-39,999, 3=£40,000-59,999, 4=more 
than $60,000, 9= did not answer
Altruism6 
Efficacy*’6 
HUI26 
Start Bid
0=altruism, 1=no altruism 
0=100% efficacy, 1=85% efficacy
QALY weight of chickenpox as measured by the HUI2 system 
0= start bid is £25 (CV) or 1% (SG), 1= start bid is £50 (CV) or 2% 
(SG), 2= start bid is £75 (CV) or 5% (SG)
A. Not included in the SG analysis (see Appendix 7). B. Not included in the HUI2 
analysis.
Analysis of refusals. In the CV questionnaire respondents have the option to 
refuse chickenpox treatment and vaccination for their children (that is, would not 
accept the intervention even if cost was zero). We used logistic regression (Stata 
v.7.0, logistic function) to examine which variables determined whether or not 
parents refused intervention. In the analysis, the dependant variable is 0 if the 
respondent refused intervention and 1 otherwise with independent variable 
presented in Table 4.5.
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QALY-weisht estimation from SG. As described above, the average maximum risk 
of instant painless death (P) parents are willing to accept for their children is 
estimated using interval regression. From this a QALY-weight can be estimated. 
The standard gamble questionnaire elicits the probability P that makes the 
respondent indifferent between the current condition:
Q *T  + 1 * (L- T) (3)
and the expected benefit of treatment:
(1-P) * L  *  1 + P *0  (4)
where, Q. is the QALY-weight, T is duration of disease (15 years in the SG 
questionnaire), co is the current life expectancy of the child (we assume 75 years) 
and P is the probability of instant painless death following the intervention. From 
equations 3 and 4 we have:
Q={(L*(1-P))-(L-T)}/T  (5)
We do not use discounting, here, because it is inconsistent with the QALY utility 
model (Mehrez and Gafni, 1989; Johannesson et al., 1994). Furthermore, these 
equations assume constant-proportional trade-off (Pliskin et al., 1980).
QALY-weisht estimation from HUI2. QALY-weights can directly be measured 
from the HUI2 system using the scoring formula published by Torrance et al. 
(1996). The overall average QALY-weight and significant variables will be assessed 
using linear regression (Stata v.7.0, reg function). The variables included in the 
regression are listed and described in Table 4.5. Both responders to the CV and 
the SG filled in the HUI2. The description of disease was identical in the two 
questionnaires apart from duration, that is in the CV questionnaire the disease is
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assumed to be for a week and In the SG it is assumed to last for 15 years (see 
Appendices 8 and 9 for descriptions). In this section, we term HUI2-CV and HUI2- 
SG the health state described to CV and SG respondents respectively. By 
comparing HUI2-CV and HUI2-SG we test whether duration of disease has an 
impact on HUI2, which it should not if the SG QALY model works.
4.1.2 WILLINGNESS TO PAY - CV QUESTIONNAIRE
4.1.2.1 Characteristics of respondents
Table 4.6 shows the characteristics of respondents to the CV questionnaire. Two 
hundred parents answered the questionnaire, 91% of whom were women. Because 
the setting was in baby clinics, the parents interviewed had very young children 
(53% were younger than 1 year, 36% between 1 and 4 years). This was intended, as 
we sought to recruit parents of children that were close to the age of vaccination 
and who were susceptible to chickenpox. Compared to ONS statistics
, the parents of the sample were older, more educated 
and had a higher household income than average (see Table 4.6 for details). This 
is controlled for in the WTP analysis.
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Table 4.6. Characteristics of respondents - CV questionnaire________
Study ONS Under-representation
__________________________ N %  % ____________________
Gender
Male 18 9%
Female 183 91%
Age (years)
< 20 5 2% 8%A 0.3120-29 65 32% 47% 0.6830-39 124 61% 43% 1.43
40+ 8 4% 2% 1.98
Degree
Yes 96 48% 28%B 1.70
No 106 52% 72% 0.73
Work
No 84 42% 46% c 0.90
Yes 118 58% 54% 1.07
Number of children
1 123 61%
2 63 31%
3 14 7%
4+ 2 1%
Age of children (years)
0 149 53%
1-4 100 36%
5+ 32 11%
Children fully vaccinated
yes 186 92% 86-94%°
no 9 4%
don’t know or n.a. 7 3%
Work loss when child is sick
yes 83 41%
no 119 59%
Child with chickenpox
yes 42 21% 23%E 0.90
no 157 78%
don’t know or n.a. 3 1%
Number of people in household
1 1 0%
2 14 7%
3 102 50%
4 65 32%
5+ 19 9%
na 1 0%
Household income before tax
<£15,000 19 9% 12%F 0.78
£15,000-24,999 27 13% 17% 0.79
£25,000-39,999 51 25% 31% 0.81
£40,000-59,999 47 23% 17% 1.37
£60,000+ 36 18% 12% 1.49
na
A. Birth Statistics. 1999: aae of mother: 1 ix
22 11% 11% 1.00
i 25-44; C. Labour
_ iia iu s ui women; Dy marital status and children aged less than 5 years;
ru,v'  - Proportion of fully vaccinated children by
24 months in UK; E. Predicted *  of seropositive children using the sero-profile estimated in Chapter 2; F. Family 
Expenditure Survey 1999-2000 - Characteristics of households: by children aged less than 5 years.
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4 . 1 . 2 . 2  D i s t r ib u t io n  o f  W T P  r e s p o n s e s
All respondents to the CV questionnaire (202 parents) were asked their WTP for 
both chickenpox vaccination and treatment. The distribution of WTP responses is 
presented in Figure 4.1. Twenty-nine and 31 parents said they would not have 
their child treated and vaccinated, respectively, even if it was free. Of the 
parents who were willing to have their children both treated and vaccinated, 49 
were WTP more for vaccination, 5 were WTP more for treatment and 111 provided 
identical WTP (Figure 4.2). Using McNemar’s test for paired data, the WTP for 
vaccination was found to be significantly higher than for treatment (x2=34, p- 
value<0.0001). This suggests that parents find an added benefit in prevention - 
i.e. that insurance type benefits exit.
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Figure 4.2. WTP response frequency for vaccination and treatment. The size of 
the dots is a function of the frequency of responses.
4.1.2.3 WTP analysis
The WTP analysis is divided into 3 sections. First, we analyse the complete dataset 
assessing the average overall preference of young parents taking into account 
those who would refuse the intervention even if it were free (i.e. those who have 
zero or negative WTP). In the second section, we examine the variables, which 
determine whether or not parents refuse chickenpox treatment or vaccination. 
Thirdly, we analyse the WTP of parents who desire chickenpox treatment and 
vaccination for their children.
A. WTP analysis with refusals.
Empirical results. The significant parameters identified by the univariable 
analysis are presented in Table 4.7.
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Table 4.7. Univariable analysis - significant parameters (p<0.2)
WTP Treatment
(p-value)
WTP Vaccination
(p-value)
Work 0.001 0.001
Vaccinated 0.018 0.008
Work loss 0.004 0.008
Chickenpox NS 0.150
Income 0.075 0.199
HUI2 0.004 0.025
Start Bid 0.092 0.033
NS: Not significant (p<0.2)
Work was excluded from the multivariable analysis since it is significantly 
correlated with Work loss (p<0.05). Furthermore, work loss was considered the 
more informative variable since with it we can determine whether missing time 
off work is a determinant in parents WTP for chickenpox treatment and 
vaccination.
Results from the interval regression model are presented in Tables 4.8 and 4.9. 
Significant variables (p < 0.05) for both the WTP for treatment and vaccination 
were Vaccinated, Work Loss, Income, HUI2 and Start Bid. Parents of children who 
are fully vaccinated for their age (Vaccinated*0) are willing to pay £107 and £134 
more for chickenpox treatment and vaccination, respectively. Furthermore, 
controlling for other variables, parents who must take time of work when their 
children are sick (Work loss*0) are WTP £32 (£38) more for treatment 
(vaccination). Results also suggest there is starting point bias. WTP for treatment 
and vaccination is significantly higher for respondents who were given the £75 
starting bid (start bid: p<0.05 Tables 4.8 and 4.9). Finally, as expected by theory, 
WTP increases with the household income (income: p<0.05) and with perceived 
severity of chickenpox (HUI2: p<0.05). It should be noted that altruism and 
efficacy were not found to be significant factors in parents WTP for chickenpox 
treatment and vaccination.
169
Residuals from the interval regression were normally distributed (see Appendix 
11). Ordered probit regression (oprobit command, stata v.7.0) was performed to 
validate model results since, as interval regression, it can model interval and 
censored data and their likelihoods are discrete. The ordered probit models 
produced the same significant variables and similar log likelihoods to the interval 
regression models (-391 and -392 for treatment and vaccination respectively). We 
chose interval regression although it produced slightly lower log likelihoods 
because coefficients are in natural units and, contrary to oprobit, it is possible to 
measure mean WTP.
Table 4.8. WTP for treatment - Interval regression model with refusals
Coef [95% Cl] P>|z|
Constant 169.44 (89.48 to 249.39) 0.000**
Vaccinated 0.009**
0 0 Baseline
1 -107.36 (-173.68 to -41.04)
9
Work loss
-53.61 (-139.89 to 32.66)
0.023**
0 0 Baseline
1
Income
-31.55 (-58.78 to -4.32)
0.062*
0 0 Baseline
1 13.44 (-41.48 to 68.36)
2 35.29 (-14.02 to 84.60)
3 66.81 (16.95 to 116.67)
4 58.51 (5.23 to 111.79)
9
Start Bid
44.38 (-14.14 to 102.91)
0.037**
0 0 Baseline
1 -2.55 (-34.69 to -29.58)
2 35.10 (2.64 to 67.56)
HUI2 -131.11 (-213.35 to -48.86) 0.002**
<j 89.18 (77.52 to 100.83)
Log likelihood -408.63
Null Log-likelihood -430.06
LR x2(12) 42.83 0.000**
Sample size 202
rx^ A AC* Significant at p<0.1; ** Significant at p<0.05
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Table 4.9. WTP for vaccination - Interval regression model with refusals
Coef [95% Cl] P>|z|
Constant
Vaccinated
187.39 (87.02 to 287.77) 0.000”
0.012”
0 0 Baseline
1 -134.24 (-220.12 to -48.36)
9
Work loss
-55.45 (-161.18 to 50.28)
0.028”
0 0 Baseline
1
Income
-38.12 (-72.11 to -4.12)
0.098*
0 0 Baseline
1 18.15 (-50.13 to 86.43)
2 41.50 (-19.64 to 102.63)
3 74.16 (11.92 to 136.40)
4 64.64 (-2.01 to 131.30)
9
Start Bid
34.04 (-39.11 to 107.18)
0.014”
0 0 Baseline
1 -28.50 (-68.81 to 11.83)
2 30.87 (-9.55 to 71.28)
HUI2 -130.44 (-233.61 to -27.27) 0.013”
CT
Log likelihood 
Null Log-likelihood
109.75
-395.26
-414.02
(94.00 to 125.50)
LR x 2(12) 
Sample size
37.52
202
0.000**
* Significant at p<0.1; * ’Significant at p<0.05
Table 4.10. Average WTP for treatment and vaccination - Interval regression
model with refusals
Average WTP [95% Cl]
Treatment
Sample 98.38 (83.95 to 112.81)
England* 90.08 (75.21 to 104.95)
Vaccination
Sample 105.42 (87.58 to 123.26)
England* 96.16 (78.92 to 113.41)
A. Data generated from the study sample re-weighted to represent the population of 
parents with children of vaccine age in England. Weights used are presented in Table
4.6.
WTP estimates. Table 4.10 presents the estimated average WTP for chickenpox 
treatment and vaccination for the study sample and the population of England. 
The sample has a higher WTP because it has a higher income, higher level of 
education and older population. The difference between vaccination and 
treatment is approximately £8. Even though, in Table 4.10, the 95% confidence
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intervals of WTP for treatment and vaccination overlap, results from the paired 
test presented in section 4. 1.2.2 show that the difference is significant
(p<0.0001).
B. Analysis of refusals.
Tables 4.11 and 4.12 report the results from the logistic regression of 
acceptance/rejection of chickenpox treatment and vaccination. Significant 
variables are Vaccinated, Work and HUI2. Parents of children who are fully 
vaccinated for their age (Vaccinated=0) are estimated to be 6 (1/0.16) fold more 
likely to accept treatment or vaccination. Furthermore, parents who work 
(Work=i) were 3 times more likely to accept intervention against chickenpox. 
Finally, those who accepted treatment or vaccination thought chickenpox to be 
more severe then those who did not.
Table 4.11. Wanted treatment - Logistic regression model
Odds Ratio [95% Cll P>|z|
Vaccinated 0.034“
0 1 Baseline
1 0.16 (0.03 to 0.83)
9 0.25 (0.03 to 1.99)
Work 0.010“
0 1 Baseline
1 3.29 (1.41 to 7.68)
HUI2 0.001 (0.00 to 0.08) 0.002“
Log likelihood -74.08
Null Log likelihood -89.93
Model %z(4) 30.99 0.000“
Sample size 200
* ‘Significant at p<0.05
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Table 4.12. Wanted vaccination - Logistic regression model
Odds Ratio [95% cn P>|z|
Vaccinated
0 1 Baseline
0.003**
1 0.16 (0.04 to 0.72)
9 0.11 (0.01 to 0.79)
Work
0 1 Baseline
0.004**
1 2.93 (1.39 to 6.20)
HUI2 0.07 (0.00 to 1.04) 0.041**
Log likelihood 
Null Log likelihood 
Model x2(4)
-90.86
-103.26
23.87 0.000**
Sample size 200
* *Significant at p<0.05
C. WTP analysis without refusals
This section analyses the WTP of parents who desired chickenpox treatment or 
vaccination for their children.
Empirical results. The significant parameters identified by the univariable 
analysis are presented in Table 4.13. Work was excluded from the multivariable 
analysis since it is significantly correlated with work loss.
Table 4.13. Univariable analysis no refusals-significant parameters (p<0.2)
WTP Treatment
(p-value)
WTP Vaccination
(p-value)
Degree 0.059 0.171
Age 0.087 0.173
Work 0.037 0.117
Work loss 0.007 0.011
Income 0.003 0.001
HUI2 NS 0.184
Tables 4.14 and 4.15 report the results from the interval regression model of WTP 
values for treatment and vaccination. Significant variables for both the WTP for 
treatment and vaccination were Work Loss and Income. Controlling for other 
variables, parents who must take time of work when their children are sick (Work
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/oss=0) are willing to pay £26 (£24) more for treatment (vaccination). 
Interestingly, the perceived severity of chickenpox was not significant in the 
amount parents were WTP. Thus, perceived severity seems to be a significant 
factor in whether or not parents would want their child to be treated (or 
vaccinated - Tables 4.11 and 4.12) against chickenpox but not the amount they 
are WTP (Tables 4.14 and 4.15). Once parents have decided they were willing to 
treat (or vaccinate) their children, the most important factor in their maximum 
WTP for intervention is their income (i.e. their capacity to pay). Altruism and 
efficacy were not found to be significant factors in parents WTP.
Table 4.14. WTP for treatment - Interval regression model no refusals
Coef [95% Cl] P>|z|
Constant 88.28 (48.05 to 128.512) 0.000“
Work loss 
0 0 Baseline
0.050“
1 -26.15 (-49.95 to -2.36)
Income
0 0 Baseline
0.010“
1 22.89 (-24.51 to 70.29)
2 44.07 (2.36 to 85.77)
3 61.49 (19.77 to 103.21)
4 60.09 (14.94 to 105.24)
9 84.90 (34.02 to 135.79)
a 73.73 (64.06 to 82.68)
Log likelihood 
Null Log-likelihood
-354.54
-365.71
LR x 2(6) 22.34 0.001“
Sample size
* if  r \ s ( \
173
* ‘Significant at p<0.05
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Table 4.15. WTP for vaccination - Interval regression model no refusals
Coef [95% Cl] P> zI
Constant 97.24 (52.28 to 142.21) 0.000“
Work loss
0 0 Baseline 0.074*
1 -24.41 (-51.17 to 2.34)
Income
0 0 Baseline 0.005“
1 34.16 (-18.8 to 87.15)
2 42.20 (-3.81 to 88.21)
3 79.58 (32.38 to 126.77)
4 82.13 (30.40 to 133.86)
9 84.19 (27.06 to 141.33)
<j 79.43 (68.50 to 90.37)
Log likelihood
Null Log-likelihood 
LR x 2(6)
-320.63
-332.27
23.28 0.001“
Sample size 171
* ‘Significant at p<0.1; * ‘Significant at p<0.05
Table 4.16. Average WTP for treatment and vacdnation - Interval regression 
model no refusals 5 U l
Mean WTP S.E. [95% Cl]
Treatment
Sample 121.61 6.23 (109.39 to 133.81)
England* 104.63 7.85 (89.25 to 120.01)
Vaccination
Sample 140.45 7.16 (126.42 to 154.50)
England* 120.21 8.69 (103.18 to 137.24)
A. Data generated from the study sample re-weighted to represent the population 
of parents with children of vaccine age in England. Weights used are presented in 
Table 4.6.
WTP estimates. Table 4.16 reports the descriptive statistics about the WTP for 
varicella treatment and vacdnation. The average WTP values reveal the same 
pattern as results that included those who refused intervention. The WTP for 
chickenpox vaccination is significantly greater than for treatment (£18 for the 
sample and £16 for England) suggesting that insurance type benefits exist. 
Furthermore, the average WTP for the sample is higher than for England.
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Table 4.17. Mean average value of vaccination attributes (£).
England Sample
Direct Health Benefit 93.81 110.89
Altruism 0.00 0.00
Insurance Type Benefit 15.68 18.84
Parental Work loss 10.72 10.72
From Table 4.14, 4.15 and 4.16 it is possible to estimate the monetary value of 
the various attributes of varicella vaccination. Altruism was not significant in the 
WTP models. In our sample, the insurance type benefit is estimated to be £18.84 
(£140.45 - £121.61, Table 4.16). Furthermore, the average value of parental work 
loss in the sample was £10.72 (£26.41‘Proportion of parents who do not take time 
of work (41%), Table 4.6 and 4.14).
4.1.3 QUALITY-ADJUSTED LIFE-YEARS - SG QUESTIONNAIRE
4.1.3.1 Characteristics of respondents
Because, there were fewer attributes tested in the SG questionnaire, the sample 
size (63) was lower than the CV questionnaire. Table 4.18 presents the 
characteristics of the 63 respondents to the SG questionnaire and how they 
compare to women with children under 5 years in the general population of 
England. The characteristics of parents who responded to the SG questionnaire 
(Table 4.18) were similar to those who responded to the CV questions (Table 4.6). 
Compared to ONS statistics , the parents of the SG sample
were older, more educated, worked more and had a higher household income (see 
Table 4.18 for details). This is controlled for in the SG analysis.
176
Study ONS Under-representation
____ __________________________N % %_______________________
Gender
Table 4.18. Characteristics of respondents - SG questionnaire___________
Male 
Female 
Age (years)
< 20 
20-29 
30-39 
40+
Degree
Yes
No
Work
No
Yes
Number of Children 
1 2 
3
4+
Age of Children (years)
0
1-4
5+
Children fully vaccinated 
yes 
no
don't know or n.a.
Work loss when child is sick 
yes 
no
don’t know
Number of people in household 
1 2
3
4 
5+ 
na
7 11%
56 89%
2 3% 8%A 0.40
25 40% 47% 0.84
31 49% 43% 1.14
5 8% 2% 3.97
31 49% 28%b 1.76
32 51% 72% 0.71
22 35% 46% c 0.76
41 65% 54% 1.21
43 68%
15 24%
4 6%
1 2%
43 48%
33 37%
13 15%
56 89% 86-94%°
5 8%
2 3%
30 48%
28 44%
5 8%
1 2%
3 5%
35 56%
17 27%
6 10%
1 2%
Household income before tax 
<£15,000 2 3% 12%E
£15,000-24,999 10 16% 16%
£25,000-39,999 22 35% 30%
£40,000-59,999 12 19% 16%
£60,000+ 8 13% 12%
na 9 14% 14%
0.27
0.97
1.17
1.16
1.10
1.00_____  >  I  w v  I  I / U
A. Birth Statistics, 1999: age of mother: Live births; B. Labour Force Survey, 2000 - women aged 25-44; C. Labour 
Force Survey, 2000 - Economic activitv status of women: by marital status and children aged less than 5 years;
• Proportion of fully vaccinated children by 
24 months in UK; E. Predicted *  of seropositive children using the sero-profile estimated in Chapter 2; F. Family 
Expenditure Survey 1999-2000 - Characteristics of households: by children aged less than 5 years.
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4.1.3.2 Distribution of SG responses
The distribution of risk of instant death elicited from the SG questionnaire is 
presented in Figure 4.3. The most prevalent response was a 10% risk of death.
16 -
<0.1 0.1 0.5 1 2 5 10 15 20+
SG Risk Bin
Figure 4.3. Response frequency to the SG questionnaire.
4.1.3.3 SG analysis
The SG analysis is divided into 2 sections. First, we present the average risk 
parents are willing to accept to return their children to normal health and 
investigate whether SG can capture non-health benefits. In the second section, we 
present the average QALY-weight estimated from the SG questionnaire.
Empirical results. Table 4.19 reports results from the interval regression model 
of parents’ maximum acceptable risk. The significant variables of this model are 
Gender, Decree and Altruism. Fathers were willing to take, on average, a 5% 
greater risk of death for their child to return to normal health than mothers. 
Furthermore, respondents without a degree were, on average, willing to take a 6% 
higher risk than those with a degree. Parents who were told their child could
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transmit the imaginary disease to other children were willing to accept a 5% 
greater risk of death than those who did not.
Table 4.19. SG - Interval regression model
Coef [95% Cl] P>|z|
Constant
Altruism
10.05 (4.34 to 15.77) 0.000**
0 0 Baseline 0.009**
1
Gender
4.96 (1.23 to 8.70)
0.016**
0 0 Baseline
1
Degree
-7.27 (-13.20 to -1.35)
0.001**
0 0 Baseline
1 6.12 (2.49 to 9.75)
CT
Log likelihood 
Null Log-likelihood
7.10
-158.17
-166.72
(5.64 to 8.55)
LR %2(3) 
Sample size
17.08
63
0.001**
* ‘Significant at p<0.05
QALY-weight estimates. The average risk accepted by respondents was 9% (95%CI 
7%-11% - Table 4.20). This corresponds to a QALY-weight of 56% (95% Cl: 45%-66%). 
The average risk of death that would be acceptable to parents is predicted to be 
higher for England (14%), and therefore produce a lower QALY-weight (31%). This 
is because the study sample has a high proportion of parents with a degree.
Table 4.20. Average risk of death - Interval regression model
Mean Risk [95% Cl]
Sample 8.88 (6.80 to 10.95)
England* 13.74 (8.43 to 19.05)
A. Data generated from the study sample re-weighted to represent the population 
of parents with children of vaccine age in England. Weights used are presented in 
Table 4.18.
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4.1.4 QUALITY-ADJUSTED LIFE-YEARS - HUI2 QUESTIONNAIRE
4.1.4.1 Distribution of HUI2 responses
The distribution of QALY-weights estimated from the HUI2 responses are very 
different between respondents who were given the CV and SG questionnaires 
(Figure 4.4a). This, despite the fact that the description of disease was identical 
except for duration, and in the CV questionnaire we specify to parents that they 
are valuing chickenpox (see Appendices 8 and 9). Furthermore, of those who 
responded to the CV questionnaire, the distribution of QALY-weights elicited 
differed between parents whose children have had chickenpox and those who have 
not.
4.1.4.2 HUI2 analysis
Tables 4.21 and 4.22 report results from the regression model of QALY-weights 
elicited from respondents of the CV and SG questionnaires, respectively, using the 
HUI2 system. For respondents of the CV questionnaire, the single significant 
variable was Chickenpox. Respondents whose children never had chickenpox 
(Chickenpox=1) believed chickenpox to be more severe (lower QALY-weights). For 
respondents of the SG questionnaire, Altruism was the lone significant variable. 
Parents who were given the altruistic questionnaire had a significantly lower 
QALY-weight.
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Figure 4.4. QALY-weight distribution elicited from HUI2. a) Distribution of 
QALY-weights elicited from CV and SG respondents, b) Distribution of QALY- 
weights elicited from CV respondents stratified into whether or not the parent has 
a child with a previous history of chickenpox.
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Table 4.21. HUI2 - CV questionnaire - Regression model 
~  Coe? [95% Cl] M i j
Constant 0.824 (0.777 to 0.872) 0.000"
Chickenpox 0.008"
0 0 Baseline
1 -0.077 (-0.130 to -0.023)
9 -0.188 (-0.371 to -0.004)
Sample size 202
* ‘Significant at p<0.05
Table 4.22. HUI2 - SG questionnaire - Regression model
Coef [95% Cl] P>|z|
Constant 0.608 (0.546 to 0.670) 0.000"
Altruism 0.034*
0 0 Baseline
1 -0.101 (-0.194 to -0.008)
Sample size 63
•Significant at p<0.1; "Significant at p<0.05
For the sample, the standard gamble and HUI2-SG produced identical QALY- 
weights (56%). However, this is significantly different to the 76% (95% Cl: 74%-78%) 
calculated from HUI2-CV.
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Table 4.23. Average QALY-weight for chickenpox from HUI2
Mean QALY [95% Cl]
HUI2-CV 
All children
Sample 0.76 (0.74 to 0.78)
England6 0.75 (0.72 to 0.78)
Children with history of chickenpox
Sample 0.82 (0.77 to 0.87)
England6 0.81 (0.75 to 0.87)
HUI2-SGC
Sample 0.56 (0.52 to 0.61)
England6 0.57 (0.48 to 0.66)
SG questionnaire
Sample 0.56 (0.45 to 0.66)
England6
A. Data cenerated from the studv samole re-wei(
0.31
3hted to rpnrpçpnt th,
(0.05 to 0.58)
parents with children of vaccine age in England. Weights used are presented in"Table 4 6- 
B. See Appendix 8 part 1 for description of chickenpox; C. See Appendix 9 part 1 for ’ 
descrition of imaginary disease.
4.1.5 DISCUSSION
In this section we used various elicitation techniques (CV, SG and HUI2) to 
estimate parent’s WTP for varicella vaccination and the QALY lost due to 
chickenpox and to identify the different attributes of vaccination.
Conjoint valuation. The average WTP for parents who desired varicella 
vaccination, corrected to represent the population of England, was £120.21. Three 
attributes of vaccination were measured: 1) direct health benefit, 2) insurance 
type benefit, and 3) parental work loss (Table 4.17). The direct health benefit, 
insurance type benefit and work loss represented 79%, 13% and 8% of the average 
WTP for vaccination respectively. To our knowledge, this is the first study to 
show, empirically, that individuals prefer vaccination (prevention) to treatment 
and that quantifies parent’s WTP to prevent work loss.
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WTP for vaccination was significantly greater than for treatment indicating that 
individuals find an added benefit in the security that their child will not develop 
chickenpox (insurance type benefit). In theory, this is expected since individuals 
are risk averse and therefore there exists a potential for improving welfare by 
reducing or eliminating uncertainty. Previous studies have shown that the 
expected WTP assuming risk neutrality (WTP to treat, ex post, multiplied by the 
risk of the event) is lower than the elicited WTP using the ex ante insurance-based 
question (O’Brien et al., 1998; Neumann and Johannesson, 1994). Here, there is a 
difference in that both the treatment and vaccination questions are ex post user- 
based. Furthermore, the risk of acquiring chickenpox is 100%. Hence, contrary to 
previous studies (O’Brien et al., 1998; Neumann and Johannesson, 1994), the 
insurance type benefit that is quantified cannot be biased because of differences 
in the valuation perspective (ex ante vs ex post) or individuals misunderstanding 
of the prior risks of disease they have been presented. It should be pointed out 
that, in our calculation of the insurance type benefit, we do not take into account 
discounting, which would render the added benefit of vaccination greater. Since 
chickenpox occurs on average at 6 years of age, the present value of treatment 
(assuming discounting) will be lower than the elicited WTP, which supposes the 
child is currently diseased.
Work loss was a significant factor in parents WTP for vaccination after controlling 
for other factors such as income. Prevention of parental work loss thus seems to 
be a benefit of preventing children having disease. This raises questions of 
whether prevention of work loss should be included in the denominator of CB ratio 
(is a benefit), should be included in the numerator (is a societal productivity gain) 
or both. Care must be taken when conducting Cost-benefit analysis not to double 
count these cost/benefits.
184
Although other studies have found evidence of altruism (Johannesson et al., 1993; 
Onwujekwe et al., 2002; Arana and Leon, 2002), it was not identified as a 
significant variable in this study. Previous studies measured altruism by comparing 
private versus public WTP for an intervention (Johannesson et al., 1996b). That is, 
they measured respondent’s preference for subsidizing fellow citizens’ health care 
(caring externality - Olsen, 1997). Here, we attempted to measure a different 
type of altruism, which is specific to vaccination (or prevention) of infectious 
disease. We estimated whether individuals derive benefit from not infecting 
others (i.e. family and friends) because they are immunized. Here, this type of 
altruism may not have been detected because of the lack of power of the study to 
measure very small differences in WTP, chickenpox is too mild to produce such 
altruistic benefits or because this particular type of altruism does not exist. The 
interval regression coefficient for altruism was £1 (95% Cl, -£33 to £35) for the 
WTP for vaccination and £1 (95% Cl -£27 to £28) for the WTP for treatment, which 
suggests that the value of altruism is very small or does not exist for chickenpox. 
Although inconclusive, this study is the first to attempt to measure altruism 
related to vaccination. Further research is needed to examine if such altruism 
exists or is measurable for diseases with greater severity.
As expected by economic theory, WTP increased with perceived severity of 
disease (HUI2) and income. That richer people are WTP more than poorer people 
for a programme which provides the same level of well-being could lead to 
inequalities in the distribution of heath care if CBA is used by policy makers. That 
is, CBA based on CV can potentially bias towards programmes that treat/prevent 
diseases that typically affect richer individuals in society (men vs. women, older 
vs. younger adults).
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Finally, from the CV questionnaire it is possible to estimate the uptake of varicella 
vaccination if it was covered by the NHS (free at point of consumption). Of the 
202 parents who answered the CV questionnaire, 85% said they would vaccinate 
their child against varicella if it were free. Thus, the expected uptake of varicella 
vaccination would be 85%. This is similar to a recent study in Australia, which 
estimated the average coverage of varicella to be 88% using stated preference 
discrete modelling (Hall et a/., 2002). Such levels of coverage would produce very 
similar dynamics to those presented in Chapter 3, where 90% coverage was used as 
a base case scenario. Parents who desired vaccination had a positive attitude 
towards vaccination in general (their children were fully vaccinated for their age), 
thought chickenpox to be more severe (higher QALY-lost weight as measured by 
the HUI2 system) and worked (Table 4.11-4.12). These results are coherent with 
the literature (Bennett and Smith, 1992; Bond et al. 1998). However, contrary to 
other studies, effectiveness of the vaccine was not found to be a significant factor 
in parent’s decision to vaccinate (Streefland, 2001; Bond et al. 1998). This is most 
likely because parents were told that although the vaccine had 85% vaccine 
efficacy, cases among vaccinated children were very mild. However, the interval 
regression coefficient for efficacy was -£11 (95% Cl, -£37 to £14) for the WTP for 
vaccination, which suggests that the sample size may have been too small to 
assess a significant difference.
Validations of CV studies are very difficult due to the hypothetical nature of the 
questions (Drummond, 1997; O’Brien and Viramontes, 1994). Ideally, results 
should be compared to actual market observations (criterion validity). This is very 
difficult in the UK and other countries where the population do not pay directly 
for health care (i.e. where the market does not actually exist). Because of this 
problem, other validation tests have been suggested. First, construct validation
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consists of examining whether the CV results are consistent with economic theory 
(Drummond, 1997; O’Brien and Viramontes, 1994). This usually consists of testing 
whether WTP increases with income but eventually at a decreasing rate (positive 
income elasticity). The NOAA recognized validity problems with CV studies and 
recommended the use of test of scope in their guidelines (National Oceanic and 
Atmospheric Administration, 1993). The test of scope consists of assessing whether 
increase in benefit relates to an increase in WTP. In this study, responses to the 
CV questionnaire were consistent with expected theory. WTP for vaccination (and 
treatment) increases with income until a point at which it starts to decline 
(construct validity - Tables 4.8, 4.9, 4.14 and 4.14). Secondly, the perceived 
severity of disease as measured by the HUI2 system significantly affected parents 
overall WTP for chickenpox vaccination and treatment, which demonstrates 
convergent validity and that WTP increases with perceived benefits (Tables 4.8 
and 4.9). Tests of reliability were not performed. However, test-retest reliability 
of CV has been shown to be comparable to other preference measures (O’Brien 
and Viramontes, 1994).
Standard Gamble. The average QALY-weight estimated from the SG analysis is 
56% for the sample and 31% for England.
Work loss was not found to be a significant factor of the SG. This result is 
consistent with the general belief that QALYs cannot capture non-health benefits 
(Olsen and Smith, 2001; Donaldson et al., 1997).
The effect of Altruism, Gender and Degree were significant (Table 4.19). The 
QALY-weight elicited from parents who were told that intervention would prevent 
their child giving the disease to other children was 0.25 lower than those who did
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not have this attribute. This may be an altruistic or a paternalistic externality or 
a direct health valuation. That is, parents may be willing to take a greater risk to 
protect their other children (paternalistic externality), protect other individuals 
(altruistic externality) or believe, with this added attribute, that the disease is 
more severe (e.g. child is more isolated). We show in section 4.1.5.2 that parents 
who were given the altruistic scenario believe that the disease was more severe 
(the QALY-weight derived from the HUI2-SG questionnaire was significantly higher 
(Table 4.22)). Hence, it is more likely that the SG did not capture externalities 
but actual valuations of health.
Fathers were willing to take greater risks to return their children to normal health 
(QALY-weights were 0.35 lower than for mothers). This is consistent with other 
studies, which show that for an identical health state QALY-weights elicited from 
women are higher (Jacobs et al., 2002; Dolan et al., 1996). Finally, having a 
degree was found to be significant, which suggests that understanding of risk may 
be an important factor in standard gamble elicitation despite the fact that visual 
aids, similar to those presented in Appel et al. (1990), were used (see Appendix 
9). This corroborates a previous study, which suggested that risk misunderstanding 
was associated with respondents’ educational attainment (O'Brien et al., 1998). 
That gender and level of education influence SG responses is a concern for 
resource allocation (raises equity concerns). If these results are generalisable then 
disease interventions, which affect men and individuals with lower education will 
have lower Cost-Utility ratios (if QALYs are based on SG questionnaires) - i.e. 
diseases in men and people with less education will be valued as more severe.
Health Utility Index mark 2. The QALY-weight distributions estimated from the 
HUI2 system are very different between HUI2-CV and HUI2-SG questionnaires. The
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HUI2-SG produced a much lower average QALY-weight (0.56 vs. 0.76 - Table 4.22). 
The only difference between the CV and SG disease descriptions were that 
duration of disease was extended to 15 years in the SG questionnaire (in order for 
parents to trade-off probabilities that they could understand). Furthermore, 
parents who were given the CV questionnaire were told they were valuing 
chickenpox. The average QALY-weight from HUI2-SG and SG questionnaires were 
similar. This suggests that, as expected, SG and HUI2 elicit similar QALY-weights 
for a same disease state.
Difference between the QALY-weight elicited from HUI2-CV, HUI2-SG and the SG 
questionnaires illustrate the measurement problems of estimating QALY-weights 
for acute diseases using SG and similar elicitation methods. The main problem is 
that, for acute and mild diseases, such as chickenpox, the rational risk that 
individuals should be willing to trade-off is too small for most to comprehend. To 
get around this we can increase the duration of the disease state, assuming 
constant proportional trade-off (U(H)T = U(H,T) (Pliskin et al., 1980), while 
keeping the same health state description, that is increasing T but keeping H 
constant. Here, this technique does not seem to work. This can be due to two 
reasons. Firstly, the proportional trade-off assumption may not hold. Many studies 
in the literature show that, the QALY-weight is dependant on the time individuals 
are in the disease state (i.e. duration of disease has an impact on individual’s 
perception of severity (Stalmeier, 1996; Dolan and Gudex, 1995; Bala and Zarkin, 
2000; Gafni, 1994; Bala et al., 1999)). The second problem is that by increasing 
duration of disease and refraining from mentioning chickenpox, individuals are 
actually rating an imaginary disease that they have difficulty understanding. That 
is, parents are rating a different disease. This seems to be the case as HUI2-CV 
and HUI2-SG give different QALY-weights. It should be pointed out that chained
189
methods have previously been used to address the problem of assessing QALYs for 
temporary health states within the SG framework (Jansen et al., 1998). However, 
to our knowledge none have been used for health states that are as short and as 
mild as chickenpox. Because the duration of varicella is very short, chaining will 
be difficult (e.g. use of many anchor levels) and the opportunity of including bias 
will be large. Nevertheless, in future work chained procedures should be 
considered as an alternative to the method chosen here.
As mentioned earlier, the HUI2 system and other multi-attribute health status 
classification systems have two major advantages over SG when estimating the 
morbidity of infectious disease: 1) they are simple to understand and answer and, 
2) they can capture small changes in heath status (De Wit et al., 2000; de Vries et 
al., 1998). In this study individuals who responded to the HUI2-CV had little 
difficulty responding to the questionnaire. This was aided by the fact that 
chickenpox was known to most parents. Despite this, QALY-weights were 
significantly higher for parents of children with positive history of the disease 
(Table 4.23), which raises the question about who should be answering elicitation 
questionnaires. Should it be those who are at risk or affected by the disease or the 
general public. De Wit et al. (2000) consider this question in detail.
Limitations of the analysis. The analysis presented here has four main a priori 
limitations: 1) it uses parents as proxies, 2) a bidding algorithm was used, 3) the 
impact of vaccine side effects and risk of disease on WTP and SG were not directly 
elicited, 4) a vaccination scenario was not included in the SG questionnaire.
Parents are used as proxies. Vaccination is mainly carried out on very young 
children, from whom it is impossible to elicit preferences. We used parents as
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proxies as they are the ones who are responsible for the health of their children 
and decide whether they receive vaccination. A number of problems have been 
observed when using parents as proxies (Petrou, 2003). Firstly, for multi-attribute 
health systems, although results are correlated between parents and children, 
parents report a greater effect of illness on the quality of life of their child (Eiser 
and Morse, 2001; Ennett ei al., 1991; Graham et al., 1997; Theunissen, 1998). 
This has also been observed to be true when comparing elicitation techniques 
between patients and other proxies (De Wit et al., 2000). On the other hand, 
parents may be more risk averse for their children than for themselves. Hence, SG 
using parents as proxies is likely to underestimate the QALYs lost. Secondly, if 
parents are used as proxies, QALY and WTP measures may integrate to some 
degree the indirect effects on the parents (e.g. psychological, monetary). A good 
example of this is that parents who must take time off work are willing to pay 
more for vaccination. See Petrou (2003) and Eiser and Morse (2001) for more 
information on the methodological issues raised by preference based approaches 
to measure the health status of children.
Impact of vaccine side effects and risk of disease on coverage and WTP. Decision 
to immunise or not is influenced by individuals’ fear of side effects and the 
severity of disease (Hall et al., 2002). However, as mentioned above, we could not 
measure the extent to which these factors have an effect on vaccine coverage and 
WTP for vaccination because of ethical considerations. Although varicella vaccine 
side-effects are rare and mostly mild (Krause and Klinman, 1995; Krause and 
Straus, 1999; Wise et al., 2000), results from the CV may overestimate parents 
WTP for vaccination.
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It has also been suggested that perceived risk or prevalence of disease can have an 
important impact on demand of prevention programmes of infectious disease 
(Geoffard & Phlipson, 1996; Geoffard & Phlipson, 1997; Philipson, 2000). The 
central assumption is that high levels of coverage are difficult to maintain because 
demand for vaccine is correlated with prevalence of disease (e.g. if disease 
prevalence decreases demand for vaccine decreases). However, analysis of 
vaccine coverage data from the UK clearly shows that while incidence of pertussis 
and diphtheria have virtually been eliminated, the coverage of these diseases has 
remained relatively constant (see Figure 4.5). In Figure 4.5, the drop in pertussis 
coverage during late 1970s was due to a scare about the safety of the vaccine, 
which suggests that perceived risk of vaccination is as mentioned above, 
important in vaccine uptake.
To test the relationship between the demand for vaccine and perceived risk of 
disease, we imbedded into our study, a small pilot study eliciting parents’ 
maximum WTP for vaccination for different base-line risks of varicella infection. 
This was done using a similar computer active CV questionnaire to the one 
presented in the methods section (see Appendix 12 for questionnaire). Although 
not statistically significant, parents’ average WTP for vaccination was £109 (n=16, 
Standard Deviation=61), £97 (n=16, Standard Deviation=79) and £102 (n=16, 
Standard Deviation=79) assuming their children’s lifetime risk of chickenpox 
without intervention was 100%, 50% and 25% respectively. Hence, results suggest 
that WTP for varicella vaccination is not a function of the risk of disease. Clearly, 
more work is needed in this field.
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Year
F ig u r e  4 . 5 .  Pertussis and diptheria notifications and vaccine coverage England 
and Wales 1940-1999. The blue and red lines represent diptheria and’pertussis 
respectively. Full-lines represent notification rates (Figure courtesy of the Public 
Health Laboratory Service).
Bidding game. To increase precision and the power of our study to detect 
attributes, we used a bidding game (iterative-close ended questioning approach) 
to elicit maximum WTP. This method has been shown to induce starting-point bias 
in environmental economics (Rowe et al., 1980; Brookshire et al., 1980; Boyle, 
1985), and in health economics (Stalhammar, 1996; Dalmau-Matarrodona, 2001; 
Eastaugh 2000). Starting point-bias was identified in the WTP for vaccination and 
treatment (when including responses of those who refused intervention) against 
chickenpox for their children. Those who were given a starting point of £75 gave, 
on average, responses that were approximately £30 hirer than those who were 
given starting bids of £25 and £50 (Tables 4.8 and 4.9). It should be noted that 
starting-point bias was controlled for when estimating the values of the different 
attributes of vaccination. Furthermore, starting-point bias was not a significant 
factor when assessing the maximum WTP for vaccination or treatment when 
excluding responses of those who refused intervention.
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A vaccination scenario was not included in the SG questionnaire. We did not 
include a vaccination scenario in the SG questionnaire because of ethical reasons. 
When ethical approval was originally sought (in 2001), vaccine coverage had 
dropped in the UK due to a scare about the safety of the MMR vaccine. Including a 
scenario in which vaccination could cause death in a high proportion of children 
could have provoked more worry in parents and have had deleterious 
consequences on vaccine coverage.
Sample size. Although the sample size was 63 for the SG questionnaire, it can be 
seen by Figure 4.3 that responses had a clear distribution. Furthermore, 
significant variables were as expected by the literature.
Strengths of the analysis. The analysis presented here expands the health 
economic literature of infectious disease prevention in two major areas. We 
present for the first time empirical evidence that individuals prefer vaccination to 
treatment (insurance type benefit exist) and that in their decision to treat or 
vaccinate their children parents value the benefit of preventing time off work 
(work loss benefit). This study is also the first to assess, using empirical results, 
the advantages/disadvantages of different elicitation techniques in the context of 
valuing the benefit of vaccination.
For the CV questionnaire we follow Carson et al.'s (1991) conditions for a valid CV 
scenarios and NOAA recommendations (National Oceanic and Atmospheric 
Administration, 199). The CV scenario is theoretically accurate, policy relevant, 
understandable by the respondent as intended, plausible to the respondent and 
meaningful to the respondent. As recommended by the NOAA panel we use face- 
to-face interviews, remind respondents that the money is from their own
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disposable income (out-of-pocket), use a binary CV format and demonstrate 
sensitivity of scope.
In the next section, WTP and QALY values estimated here will be aggregated to 
assess the overall population value of vaccination.
4.2 ESTIM ATION OF W TP AND Q ALY VALUES FOR ZO STER AND  PHN
4.2.1 WTP FOR ZOSTER TREATMENT
4.2.1.1 Method
We used a convenient sample of individuals who work at the Public Health 
Laboratory Service in London. Individuals were asked to participate in the study. 
Those consenting to participate were given a computer active interview.
We adapted the computerised CV questionnaire of varicella treatment and 
vaccination presented in Chapter 4. The questionnaire is structured into 3 parts. 
In part 1 (see Appendix 13 Part 1), respondents are asked a combination of 
standard socio-demographic questions (e.g. age, gender) and zoster specific 
questions (e.g. have you had shingles). In part 2, respondents are randomly given 
a description of mild or severe zoster (the health profile descriptions are identical 
to those presented in Bala et al. (1998) - see Appendix 13 Part 2A,B). We then 
elicit the maximum the respondents would be willing to pay to for a drug that 
would cure them of zoster (Appendix 13 Part 2D). In part 3, we elicit the 
willingness to pay for a drug that would cure PHN (see Appendix 13 Part 3). 
Respondent’s maximum WTP is assessed using bidding algorithms. As in Chapter 4, 
interval regression was used here to estimate the average WTP for mild and severe 
zoster and PHN.
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4.2.1.2 Results
The number of respondents was 38. Results from the interval regression model are 
presented in Tables 4.24 and 4.25. Men were WTP significantly more for zoster 
and PHN treatment (£190 and £862 more respectively). Furthermore, as expected 
by theory, WTP increased significantly with zoster severity. Using this model, the 
average WTP for mild and severe zoster and PHN is £201, £352 and £1369 
respectively. The average willingness to pay for a case of zoster, £236, was 
calculated by using the proportion of zoster cases that experience mild (77%) and 
severe pain (23%).
Table 4.24. WTP for zoster treatment - Interval regression model
Coef [95% Cl] P>|z|
Constant 335.44 (215.60 to 455.28)
Gender 0.003“
0 0 Baseline
1 -191.46 (-316.52 to -66.41)
Severity 0.029“
0 0 Baseline
1 113.88 (19.34 to 282.94)
CT 177.68 (128.87 to 226.50)
LR x2(12) 13.27 0.001“
Sample size 38
* Significant at p<0.1; “ bignificant at p<0.05
Table 4.25. WTP for PHN treatment - Interval regression model
Coef [95% Cl] P>|z|
Constant 1892.48 (1409.50 to 2375.47)
Gender 0.005“
0 0 Baseline
1 -862.49 (-1468.25 to -256.52)
o 887.92 (652.55 to 1123.28)
LR X2(D 7.28 0.007“
Sample size 38
* ‘Significant at p<0.05
4.2.1 QALY WEIGHTS FOR ZOSTER AND PHN
QALY estimates for zoster were estimated from the literature. Bala et al. (1998) 
estimated the utility, or QALY-weight, of pain due to zoster. They interviewed 114
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65-70 year olds, and elicited their QALY-weights using standard gamble 
techniques. The two disease states the respondents were asked to consider were: 
mild zoster pain, described as “A tingling, burning, pin-prick sensation in the 
affected area. Any contact with the affected area is uncomfortable”; and severe 
zoster pain, described as “A constant, excruciating pain, like an electric shock. 
Patients often cannot sleep, concentrate, or perform common household tasks”. 
The resulting mean QALY weights they obtained were 0.73 (95% Confidence 
Interval 0.68-0.78) for mild pain and 0.47 (95% Cl 0.41-0.53) for severe pain. Bala 
et al.’s results cannot be used directly to estimate the average QALY loss from 
zoster, as they did not measure what proportion of zoster patients would have 
severe and mild pain as they define it. However, Mauskopf et al. (1994) report the 
proportion of zoster patients who fall into four definitions of pain that can be 
dichotomised into two categories which are very simitar to those used by Bala et 
al. Namely, “Pain can be ignored” (43% of individuals with pain) and “Pain cannot 
be ignored but has no effect on activities” (34 %) can be regarded as mild pain (as 
defined by Bala et al., see above); and “Pain interferes with sleep and 
concentration” (19%) and “Pain interferes with all activities” (4%) taken together 
are very similar to Bala et al.’s definition of severe pain (see above). Thus, for the 
base-case, we assumed that 77% (43%+34%) of those with pain would have “mild 
pain” and 23% (19%+ 4%) would have "severe pain”. We assume that the same 
proportion of zoster patients as PHN patients experience “mild” and “severe” pain 
with equal QALY weights to PHN patients. Finally, to estimate the number of 
QALYs lost per acute zoster and PHN case we multiply the QALY-weights by the 
average length of time that patients spend in these health states (see Chapter 2 
for duration of zoster and PHN). The parameter values are given in Table 4.26.
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Table 4.26. QALY estimates
Parameter Value Data Source
Mean length of zoster 2 weeks Paparatti et al., 1999
Mean length of PHN 1.4 years Chapter 2
Average QALY lost zoster 0.01
Average QALY lost PHN 0.46
4.3 VALUE OF VAR ICELLA  VACC INAT IO N  - POPULATION
PERSPECTIVE
4.3.0 BACKGROUND
Economic evaluation involves comparing the total costs of a programme with total 
benefits (WTP, QALYs gained, Life-years gained). To estimate total benefit of a 
programme, individuals’ welfare/utilities/health gains must be aggregated to the 
population level. There are many techniques available/used to aggregate benefits, 
each with their own theoretical and empirical problems.
The social welfare function (SWF), introduced by Bergson (1938) and Samuelson 
(1947), provides the conceptual framework of aggregating individual’s benefits. 
The aim of economic analysis is to maximise the utility functions of all individuals 
in society (SWF) subject to a budget constraint. However, Arrow (1950, 1951) 
showed that the only possible way to use the SWF was to assume that individuals’ 
utilities are cardinal and comparable (Arrow Impossibility Theorem). The Arrow 
impossibility theorem has been extensively examined and it has been suggested 
that weaker forms of comparability can permit making consistent social welfare 
judgements, satisfying all of Arrow’s requirements (Sen, 1977; Sen, 1999).
Aggregation of WTP (Welfarism). The change in SW can be assessed by adding 
individual’s maximum WTP (CV), adjusted for individuals’ marginal utility of 
income and multiplied by equity weights placed on these individuals’ marginal
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utilities (Johansson, 1995). Although WTP is measurable, the welfare weight that 
society attributes to each household in the economy and marginal utility of 
income are generally unobservable. To overcome this, it is assumed that if the 
government can redistribute incomes over individuals so that the social marginal 
utility of income becomes equal for all individuals (assuming conversion of 
potential Pareto improvement (Hicks, 1939; Kaldor, 1939) is possible) the 
unweighted sum of WTP can lead to SW maximisation. In this section we aggregate 
the unweighted WTP estimated of vaccination from section 4.1.
Aggregation QALY and Life-years gained (Extra-welfarism or efficiency health 
maximisation). There are two distinct views of QALYs: 1 ) as a utility, and 2) as a 
measure of health (Wagstaff, 1991). Utilitarians believe that QALYs are a measure 
of utility and seek to maximize the sum of utilities whereas others believe QALYs 
to be a measure of health and seek to maximize the population’s health (Culyer, 
1990).
To be considered as a measure of utility, QALYs must first satisfy the assumptions 
of expected utility theory (i.e. Neumann-Morgenstern axioms (von Neumann and 
Morgenstern, 1947)): 1) independence, 2) desire for high probability of success, 
and 3) compound probabilities. Pliskin et al. (1980) identified further assumptions 
necessary for QALYs to be a valid utility function: 1) health states worse than 
death do not exist, 2) mutual utility independence (i.e. utility in one time period 
is independent of previous utility), 3) constant proportional trade-off, 4) risk 
neutrality and constant relative risk-aversion (Liljas and Lindgren, 2001). The 
literature shows that these assumptions are violated too often for QALYs to be 
considered a valid utility and to be included into a utilitarian SWF framework 
(Blomqvist, 2002; Dolan and Edlin, 2002; Bleichrodt and Quiggin, 1999; Garber and
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Phelps, 1997; Johannesson, 1995; Dolan and Stalmeier, 2003).
It has been argued that components such as health (QALYs or Life-years gained) 
can be separated from utility measures and be considered in isolation when 
aggregating benefits of intervention (Culyer, 1990, Wagstaff 1991). Wagstaff 
(1991) shows that maximisation of QALYs gives rise to a SWF that resembles the 
utilitarian SWF, which meets the requirement of comparability and cardinality. 
Similarly to aggregation of unweighted WTP this can lead to distributional 
concerns. Here, we use this conceptual framework of health maximisation when 
aggregating the benefits of vaccination in terms of QALYs and Life-years gained.
The aim of this section is not to examine the above-mentioned theoretical 
assumptions related to aggregation. Rather, we aim to examine the empirical 
problems related to the aggregation of WTP, QALYs and Life-years gained in the 
context of immunisation, using varicella vaccination as an example. Firstly, for each 
outcome measure we intend to examine how externalities and non-health benefits 
can be aggregated using the dynamic model presented in Chapter 3. Secondly, we 
compare results, from different outcome measures, to better understand the 
implications of omitting external effects and non-health benefits from economic 
analysis. This, to gain a better understanding of how the choice of valuation 
technique, outcome measure and method of aggregation can affect the results of 
economic evaluation of vaccination programmes and therefore influences resource 
allocation decision-making.
Externalities can be classified into two broad categories: selfish and altruistic 
(Labelle & Hurley, 1992; Johannesson, 1996). Selfish externalities exist when 
individual A cares about individual B’s consumption of health services because B’s
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consumption of health services affects A’s (expected) health status (the classic 
example is herd-immunity). Altruism occurs when individual A cares about 
individual B's consumption of health care and/or health status enters A 's utility 
function (individuals may find benefit in vaccination because it prevents them 
infecting others). We focus our analysis on two spill-over effects of varicella 
vaccination. The first is herd-immunity, which is the classic example of a selfish 
externality (Weisbrod, 1961). As shown in Chapter 3, herd-immunity can produce 
both positive and negative effects (e.g. protects non-vaccinated susceptibles 
against infection but can increase overall morbidity and mortality by shifting the 
age at infection). The second externality examined, here, is the impact of 
varicella vaccination of children on the incidence of zoster in adults who have not 
been vaccinated. As described in the first section of this chapter, it is possible 
that vaccination can produce altruistic externalities if vaccinees derive benefit 
from the knowledge that they will not infect others because they are immunized. 
In the case of WTP for varicella vaccination, although altruism was not found to 
be significant in section 4.1, we examine how it can be incorporated into the 
aggregation functions. We also formalise how direct health effects, insurance type 
benefits and work loss benefits can be aggregated at the population level.
4.3.1 METHODS
4.3.1.1 Aggregation of WTP
We use the utilitarian-type social welfare function where social welfare (W/t) in 
state of the world i and time t is given by:
N
Wit =  Y a iVm (P » y M l  ( l+  ^ 0 for j=1,...., N individuals at timet. (4)
7=1
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where aj is the welfare weight that society attributes to individualy, Vitj(p,y,h,k) 
is the level of utility experienced by individualin state i at time t; V is a function 
of prices (p), post-tax income (y), health (h), and non-health outcomes (k)\ d is 
the discount rate.
Given that the willingness to pay for an intervention, which moves individuals 
from state 0 to state 1, using compensating variation can be defined as 
(Johannesson, 1996):
V y & y - W T P , ^ )  =  V 0 J t ( p , y , h v , k 0 )  (5)
The present value of the overall benefit of intervention (S) over ( years can be 
described as follows:
~ K ) = ) -  T Y ^ a x  jp ,
1=0 1=0 1=0 j =1 <=o j=i
where r*=1 /(Ud)(. Substituting (5) into (6) yields:
B = y y / a iVUt(p,y,zl,kl) - Y & a j W p . y -  W T ^ k , ) = y y fJa,viWTP (7)
t= O j= l t= 0 j= l f=0 j= l  i '
where vj is the marginal utility of income of individual;.
Assuming that society weights all individuals equally {a}= 1) and marginal utility of 
income is the same for all individuals (y, =1), the present value of the benefit of 
an intervention can be described as follows:
I  N  l
B  =  a jVj^TPj ~  N 'W T P  for j=i,.„M Ntindividuals at time t. (8)
t=o j =1 i=0
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where WTP is the average willingness to pay for the intervention.
As shown in Chapter 3, varicella vaccination not only protects vaccinated 
individuals but also those who are not vaccinated. Furthermore, varicella 
vaccination increases the incidence of zoster in non-vaccinees. The total benefit 
of vaccination (B) should thus be the sum of the direct health and non-health 
benefits of preventing chickenpox in vaccinées (Bvoc) and non-vaccinees (Bnvac) as 
well as its negative effect on zoster (B*).
B = B vac+Bnvac+ B z (9)
From equation (8) we can formalise the present value of the overall benefit of 
varicella vaccination over l years in vaccinées:
= W T F acY / tK c (10)
1=0
where, AT^t is the number of individuals vaccinated at time t. WTPvac is the 
average willingness to pay for varicella vaccination among those who would accept 
the vaccine. Here, we assume that WTPvac is the sum of the direct health benefit 
on chickenpox (WTPhealth), the insurance type benefit (WTPlns), prevention of work 
loss (WTP*0* ) and altruism (WTP°lt), which were estimated in section 4.1 (see 
Table 4.27 for values and sources, it should be noted that we reduce the WTP 
values elicited in section 4.1 and Appendix 13 by 50% as recommended by the 
NOAA panel (NOAA, 1993)). The NOAA recommendation mainly stems from a study 
conducted by Dickie et al. (1987) and re-analysed by Diamond et al. (1992), which 
found that, for ordinary market goods, the CV approach tended systematically to 
overestimate actual quantities demanded at each price, sometimes by as much as 
50% (http://www.darp.noaa.gov/pdf/cvblue.pdf). Hence, to be conservative in
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our results we reduced WTP estimates by 50% (in the economic analysis (Chapter
5) extensive sensitivity analysis is performed on this assumption).
Estimating the benefit of vaccination in non-vaccinated individuals (Bnvac) is more 
complex, which is why these benefits are rarely included in cost-benefit analysis 
of vaccination programmes. The overall benefit of herd-immunity (health benefits 
in individuals who are not vaccinated) can be expressed as follows:
t=0 /=0 7=1
By comparing Vijt and Vojt (state of the world with and without vaccination) to a 
state of the world where there is no chickenpox (i=2), we can estimate the benefit 
of herd-immunity:
B nvac= y  y y  ^ { P i y ^ k 2 )~ v ^ { P i y i Z ^
Ü  j=i l - ^ 2 j X p ^ y > z 2,k2+) - V 0jl(p ,y ,z 0,k0))\
B ~ h h r _ - (V2j>(P’y ’Z2’k2 ) ~ V2j>(P’y ~ WTP0j’Z2’k2))
(12)
By substituting (5) into (12).
B nvac =  É  S  r !c Z cW T lteahh ~ £  E  r ,cZ“cWTP£ea,th
t- 0 a  /=0 a
j^ nvac nvac 
0at
1=0 a
nvac\ 
at )
(13)
where, C ™ c is the number of predicted chickenpox cases among non-vaccinees of 
age a, at time t, in state of the world i. We assume that only infected people are 
willing to pay for chickenpox treatment. Hence, the summation of benefits can be 
over varicella cases in non-vaccinees rather than all individuals who are not
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vaccinated. Y/TPhealth is used here as a proxy for the value of not getting 
chickenpox (see Table 4.27 for values and sources).
Similarly to (13), the impact of varicella vaccination on zoster can be estimated as 
follows:
(14)
where, C(*t is the number of predicted zoster cases in individuals of age a, at
time t and in state of the world i. WTP* is the value of preventing zoster (see 
Table 4.27 for values and sources).
Table 4.27. Average WTPA used for aggregation of overall benefits 
___________ (£)___________ (Source)
Varicella
WTPVac 60.10 (Section 4.1, Table 4.10)yfj-phealth 46.59 (Section 4.1, Table 4.17)
WTPns 7.84 (Section 4.1, Table 4.17)
yfj-pwork 5.36 (Section 4.1, Table 4.17)
WTP*“ 0.00 (Section 4.1, Table 4.17)
WTPfreat
Children8 46.59 (Section 4.1, Table 4.10)
Adultsc 100.64 Assumption0
Zoster
WTP1 117.79 (Section 4.2, Table 4.24)
PHN
WTPphn 684.72 (Section 4.2, Table 4.25)
A. We reduce the WTP values elicited in section 4 1«? hw snv ..
NOAA panel (N0AA,1993) 4.1 2 by 50% as recommended by the
B.
C.
D.
Children are aged between 0 and 15 years.
Here, adults are considered to be 15 years and older. 
We assume that the WTP for the treatment of varicella 
treatment of mild zoster in adults as both have similar
in adults is equal to the WTP of 
duration and severity.
Aggregation of QALYs and Life-years gained
To aggregate QALYs and Life-years (LY) gained we use the health maximisation 
approach (Wagstaff, 1991). That is, we assume that health can be separated from
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the social welfare utility function and be considered in isolation when aggregating 
benefits of intervention. Here, we assume that benefits are additive.
The present value of Quality-Adjusted Life-Years (QALY) lost due to disease (X) at 
time t in state of the world i can be expressed as follows:
where, C iat is the number of cases of disease x in individuals of age a during time 
t, Q*a is the QALY-weight associated with disease x in individuals of age a, pxa is 
the case-fatality ratio of disease X  in age a. Finally, LYLa is the present value of 
the expected life years lost of an individual who dies at age a. Assuming m is the 
average life expectancy at birth, LYLa is:
The total QALYs gained from an intervention can thus be estimated as follows:
where, QALY*, and QALY*0 are the predicted number of QALYs lost due to disease x 
in a population with and without the intervention respectively.
In Chapter 3 we show that varicella vaccination can have an impact on the 
incidence of varicella and zoster. This should be taken into account when 
assessing the total impact of varicella vaccination on health. In the analysis, the 
total impact of vaccination on health can be expressed as:
(15)
a
(16)
i=1
Q A L Y ^ ained= Q A L Y 0x - Q A L Y * (17)
Q A L Y gained= Q A L Y ™ ned+ Q A L Y &
rn va c
gained + Q a l y ^ (18)
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From equations (15) and (16), the QALYs gained attributed to varicella in 
vaccinées (QALY™ned ) and non-vaccinees (QALY™anced), and zoster (QALY*ained) 
can be expressed as follows:
e^ & = É Z r'c;(ar+prin1)-ÎZ'-'c.-fer+irii’4) <«)
f=0 a t=0 a
qalyzz.=tiyqrfor +ptlyl,) <»»
fas0 a t=0 a
/»0 a t=0 a
where, Q ™r are the age specific QALY lost associated with a case of varicella;
Q * , is the age specific QALY lost due to a case zoster; p v°r is the age specific
varicella case-fatality ratios, and; p* is the age specific zoster case-fatality ratio.
As explained in Chapter 3, cases of varicella in seroconverted vaccinated 
individuals, which we term breakthrough varicella, are less severe and therefore 
assume they produce a QALY loss equal to 0. Further, we assume that 
breakthrough cases do not result in death and that vaccinated individuals do not 
develop zoster. The overall QALY gained from varicella vaccination can be 
expressed as follows:
Q A L Y gained =  Y L r>
1=0  a
( l ( r ,vac (~ivac\ , s/~wvac_s^nvac\)ls-\var
V'.t-'Oitt '“'laf )  +  t'-'Oat '-'1 at ) f ^ a
A c l , - c ; J q : + p :l y l 1,)
+ P 7 L Y L ')
(22)
The case-fatality ratios (px) for variella and zoster are presented in Chapter 2. For 
life-years lost (LYL) calculations we assume that life expectancy at birth is 75 
years. The base case average QALY (Qvar) lost due to chickenpox in children was
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taken from the 42 parents of children with prior history of chickenpox who 
answered the HUI2 questionnaire in Chapter 4 (Table 4.10). We used QALY-weights 
elicited using HUI2 results because they were more realistic than those produced 
by the SG question (see section 4.1.7 for discussion). Furthermore, we chose the 
valuation of parents with children who had previously had chickenpox since they 
should have a greater understanding of quality of life lost due to the disease. The 
quality of life weighting of adults with chickenpox was assumed to be similar to 
that of mild zoster. The estimation of QALY-weights associated with zoster and 
PHN is described in Section 4.2 (see Table 4.26 for values). The average QALY lost 
per case (without LY lost) is the sum of the QALY-weight times the duration of 
disease. We assumed that duration of varicella, zoster and PHN were 1 week 
(Beneson, 1995), 2 weeks (Beneson, 1995) and 1.4 years respectively (Chapter 2).
We use the base-case dynamic model presented in Chapter 3 to estimate the age- 
specific number of cases of varicella and zoster over time with and without 
vaccination. The strategy investigated here is infant vaccination at 90% coverage. 
Unless stated otherwise, benefits are discounted at 3% per year and aggregated 
over 80 years.
4.3.2 VALUE OF A CASE OF VARICELLA AND ZOSTER
Figure 4.6a,b shows the average age specific £ (WTPa), Life-years lost (paLYU) and 
Quality-Adjusted Life-years lost (Q,) due to varicella and zoster. LYs and QALYs 
lost due to varicella and zoster increase dramatically with age. LY lost due to 
zoster are lower than those for varicella as case-fatality for zoster is low and life- 
years remaining are small since zoster occurs mostly in the elderly. QALYs lost due 
to zoster are very high mainly because of the impact of PHN (see Appendix 13).
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WTP is the outcome measure, which is the least sensitive to age at the time of 
disease and, proportionally, has the least difference between valuation of 
varicella and zoster. That is, WTP is least sensitive to severity of disease. This is 
illustrated in Figure 4.6c, which shows that WTP increases as QALYs increase but 
at a decreasing rate. For example, individuals are willing to pay up to 3 times 
more to prevent PHN than zoster even though QALYs lost due to PHN are 
estimated to be more than 30 times greater (Figure 4.6c).
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Age group
Figure 4.6. Average £, Life-year and Quality-Adjusted 
Life-year lost per case of a) varicella and b) zoster, c) 
Willingness to pay per Quality-adjusted life-year lost. 
The blue dots represent the average WTP per QALV loss 
for different levels of zoster severity (Bala et al.,
1998). Red circles represent the average WTP and QALY 
loss due to varicella in children and adults, zoster in 
adults and PHN (see section 4.1 and Appendix 13).
4.3.3 VALUE OF VARICELLA  VACCINATION
Table 4.28 and Figures 8-9 show the predicted effectiveness of infant varicella 
vaccination at 90% coverage using different outcome measures with and without 
the indirect impact of herd-immunity and zoster.
Indirect effects have the least impact on overall effectiveness when using WTP. 
Including the impact of herd-immunity and zoster effects changes results by 2% 
(Table 4.28 and Figure 4.7). On the other hand, using QALYs as the outcome 
measure, varicella vaccination varicella is estimated to be highly effective when 
excluding indirect effects but produces an increase in morbidity when including 
the increase in zoster (Table 4.28 and Figure 4.8). This is because, as seen in 
Figure 4.6, zoster is estimated to produce much greater losses in QALYs than 
varicella. It should be noted that the shift in the age at infection has a significant 
effect on overall effectiveness when using Life-years gained as the outcome 
measure (Table 4.25 and Figure 4.8). Overall effectiveness is reduced from 19,400 
to 14,200 life-years gained (27%) when including the indirect effect of vaccination 
on non-vaccinees.
Table 4.28. VZV Vaccination EffectivenessA (3% discount rate, 80 year time
horizon)_________________________ _______________
LYs gained QALYs gained £gained
Benefit RR Benefit RR Benefit RR
Varicella in vaccinées only 19,400 Base 59,400 Base 1,073 Base
Varicella overall 14,200 0.73 80,200 1.35 1,286 1.20
Varicella and Zoster 10,000 0.52 -54,400 -0.92 1,035 0.98
A. Base-case model, 
parameter values).
infant vaccination, 90% coverage (see Chapter 3 for
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Figure 4.7. Benefit of varicella vaccination (no discounting), a) Benefit (tmillion) vaccination among vaccines (Bvac), b) Benefit of 
reducing varicella in non-vaccinees (Bnvac), c) impact of vaccination on zoster (Bz) and , d) overall benefit of vaccination with and without 
externalities over time.
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a)
Years after start of vaccination
Years after start of vaccination
Figure 4.8. Lys and QALYs gained from varicella vaccination (no discounting), a) QALYs-gained by vaccination among vaccines 
( QALY™cned ), b) QALYs-gained by reducing varicella in non-vaccinees ( QALY™?nced ), c) impact of vaccination on zoster ( QALY*ained ) and, d) 
overall QALYs-gained by varicella vaccination with and without externalities over time.
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4.3.4 DISCUSSION
First, in this section we illustrated formally how different outcome measures can 
be aggregated from the individual to the population level taking into account 
herd-immunity externalities using dynamic mathematical models.
Secondly, we used the dynamic model presented in Chapter 3 and the different 
outcome measures estimated in section 4.1 to demonstrate how the choice of 
valuation technique, outcome measure and method of aggregation can affect the 
overall measure of vaccination effectiveness. We show that the choice of 
valuation technique/outcome can produce conflicting results when all benefits 
(including indirect effects) are aggregated to the population level. That is, we 
estimate that varicella vaccination will results in an overall loss of Quality of Life 
(measured by QALYs) in England and Wales but would be beneficial in monetary 
units (using WTP values). As seen in Chapter 3, varicella vaccination is predicted 
to increase the age at infection from children to adults and increase the incidence 
of zoster. Because, WTP is less sensitive to increases in severity than QALYs 
(Figure 4.6), the shift in the age at infection and increase in zoster have less of an 
impact on overall vaccination effectiveness (Figure 4.7-4.8). The fact that WTP is 
capped by ability to pay seems to explain results showing that WTP increases as 
QALYs increase but at a decreasing rate Figure 4.6c). This has been previously 
observed by Bala et al. (1998) and has produced concern among health economists 
about using the welfarist framework as a basis for the allocation of health care 
resources (Weinstein and Manning, 1997). Our results suggest that, under current 
elicitation techniques, QALYs and WTP are not interchangeable/comparable 
preferenced-based measures and that caution should be exercised in interpreting 
them as such. Furthermore, if we assume QALYs adequately measure disease 
severity, results suggest that using WTP as the outcome measure may bias
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resource allocation towards less severe diseases, which may, as illustrated in this 
chapter, lead to reduction in overall quality of life thus justifying extra-welfarists’ 
concerns.
In the next chapter we illustrate how, concretely, the choice of outcome measure 
can affect cost-effectiveness results and thus resource allocation decisions.
4.4 SU M M ARY
First, in this chapter we estimated, using electronic questionnaires, parents 
willingness to pay for varicella vaccination and the QALY lost due to chickenpox. 
Different attributes of vaccination were identified. Using the (CV) method we 
demonstrate, for the first time, that vaccination possesses different non-health 
attributes such as insurance type benefits (i.e. individuals prefer vaccination to 
treatment). Furthermore, we show that prevention of work loss is an important 
intervention attribute for parents. Finally, results elicited using the CV 
questionnaire were found to possess construct validity. On the other hand, 
consistent with economic theory, QALYs did not capture non-health benefits. 
However, for a given health state description, QALYs elicited from Standard 
Gamble and HUI2 produced similar results.
Secondly, we illustrated formally, for the first time, how individual preferences or 
health outcomes can be aggregated to estimate the overall population’s value of 
the benefit of vaccination taking into account externalities and non-health 
benefits. Results suggest that WTP and QALY are not interchangeable and that this 
can produce conflicting results when all benefits are aggregated to the population 
level taking into account externalities.
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Chapter 5
Economic Analysis of Vaccination 
Programmes
5.0 INTRODUCTION
The specific aims of chapter 5 are to:
1) Estimate the cost-effectiveness, cost-utility and cost-benefit of varicella 
vaccination,
2) Examine and compare the results from the different economic evaluation 
techniques, and
3) Illustrate the importance of model and methodological assumptions on the 
economic desirability of vaccination (in particular, the choice of outcome 
measure and the impact of including externalities).
First, in this chapter, we estimate the cost-effectiveness (cost per life-years 
gained), cost-utility (cost per QALY gained) and cost-benefit (cost per benefit (as 
a measured by WTP)) of varicella vaccination. To our knowledge this is the first 
work that estimates the economic desirability of an intervention using the three 
major evaluation techniques. Secondly, we compare the different types of 
economic evaluation to illustrate how the different technique might affect 
resource allocation. Finally, we use univariate and multivariate sensitivity analysis 
to assess the impact of model and methodological assumptions on the results of
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economic evaluation. Here, we focus on the impact of using dynamic models 
(including herd-immunity) and, the choice of discount rate and time frame of 
analysis. This should allow decision makers and health economists to better 
understand how the results of economic evaluation of vaccination programs are 
influenced by the methods used.
5.1 ECO NO M IC  ANALYSIS O F VAR ICELLA  VACC INATION
5.1.0 BACKGROUND
As mentioned in Chapters 2 and 3, three main public health concerns have limited 
the widespread introduction of the vaccine. First, vaccination could lead to an 
upward shift in the average age at infection, which could result in increasing the 
overall morbidity due to varicella (Health Canada Proceedings of the National 
Varicella Consensus Conference, 1999). Secondly, a high proportion of 
breakthrough cases of varicella (modified varicella in immunized individuals) have 
been reported in vaccine efficacy trials (Krause and Klinman, 1995; Brisson et al„ 
2000). Most importantly, mass vaccination will increase the incidence of zoster if 
exposure to varicella reduces the rate of reactivation by boosting immunity to VZV 
(Garnett and Grenfell, 1992a; Garnett and Grenfell 1992b). These concerns were 
investigated in Chapter 3. The dynamic model of VZV indicates that, although a 
shift in the average age at infection is likely to occur, the overall incidence and 
morbidity of varicella is expected to decline after mass vaccination of 12-month- 
old children. On the other hand, varicella vaccination is estimated to increase the 
incidence of zoster in the short to medium term. Due to the higher severity of 
zoster, a small increase in zoster incidence could counterbalance the reduction in 
varicella morbidity compromising the effectiveness and cost-effectiveness of 
varicella vaccination. As seen in Chapter 4, the choice of outcome (£ (WTP),
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QALY-gained, LY-gained) has a major impact on the overall benefit of varicella 
vaccination.
Many economic evaluations of routine childhood varicella vaccination have been 
published (see Table 5.1 for description of studies). Previous economic evaluations 
have shown varicella vaccination to be either marginally cost-effective (Lieu et 
al., 1994; Beutels et al., 1996) or cost-ineffective (Getsios et al., 2002; Brisson et 
al., 2002) from the health care payers perspective, though cost saving from the 
societal perspective (Lieu et al., 1994; Beutels et al., 1996; Getsios et al., 2002; 
Scuffham et al., 1999; Scuffham et al., 2000; Diez Domingo et al., 1999; Preblud, 
1985; Huse et al., 1994; Banz et al., 2003). However, only Brisson et al. (2002) has 
addressed all three principal dangers of varicella vaccination as mentioned above. 
Lieu et al. (1994), Coudeville et al. (1999), Brisson et al., (2002) and Banz et al. 
(2003) incorporated herd-immunity into their analyses. However, with the 
exception of Brisson et al. (2002), these studies used the optimistic vaccine 
efficacy parameters estimated by Halloran et al. (1994 - see Chapter 2) and, more 
importantly, did not model the possible impact of varicella vaccination on the 
incidence of zoster. All other previous economic analyses did not incorporate herd 
immunity effects (such as a shift in the average age at infection) and are 
therefore of limited value as aides to decision-making (as shown in Chapters 3 and
4).
Furthermore, all previous economic evaluations of varicella vaccination have used 
either direct cost, cost-consequence and/or cost-effectiveness analysis (Table 
5.1). That is, no cost-benefit or cost-utility analysis has been performed for 
varicella vaccination. Since varicella is a mild disease, which causes little 
mortality and the vaccine is effective against complications, the main goal of
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varicella vaccination is reducing morbidity. Therefore, it could be argued that a 
more appropriate (pertinent) outcome for the economic evaluation of VZV 
vaccination should be cost per quality-adjusted life years (QALY) gained or cost- 
benefit (using WTP).
In this section, we use the dynamic mathematical model of VZV transmission 
developed and presented in Chapter 3 to explore the possible economic 
desirability of different routine varicella immunization programs in English and 
Welsh children. To do so, we use the three major economic evaluation techniques 
(cost-effectiveness, cost-utility and cost-benefit). Furthermore, we use sensitivity 
analysis to illustrate the importance of model and methodological assumptions on 
the economic desirability of vaccination.
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Table 5.1. Summary of methods and results included in published economic evaluations of infant routine varicella vaccination - Costs 
are in 1997 $US (modified from Thiry et al. (2003))_________________________________________________
Reference Study design Vaccination” Results”
Country Perspective Discount Time Outcome Study Model Zoster Cost Coverage HCP Societal
rate (%) Horizon Measures Type0 type (%)
Preblud et USA HCP Cost: 5 30 None Cost Static No 23 90 BCR: 0.3 BCR: 6.9
al. (1985) Societal Ben; NA
Huse et al. USA Societal Cost: 5 25 None Cost Static No 56 Not Stated NA BCR: 2.4
(1994) Ben: NA
Lieu et al. USA HCP Cost: 5 30 Life-years CEA Dynamic No 48 97 CER: $19,288/LYS
(1994) Societal Ben: 0,5 saved CC CCR: $5/CA
Consequences Cost BCR: 0.9 BCR: 5.4
Beutels et Germany HCP Cost: 5 70 Life-years CEA Static No 41 70 CER: $11,897/LYS
al. (1996) Societal Ben: 0,5 saved CC CCR: $11/CA
Consequences Cost BCR: 0.8 BCR: 4.6
Diez Spain Not Stated Cost: 5 20 None Cost Static No 30 95 BCR: 0.5 BCR: 1.6
Domingo et 
al. (1996)
Ben: NA
Coudeville France Patient Cost: 5 30 None Cost Dynamic No 15 80 NA NA
et al. Societal Ben: NA
(1999)
Scuffham New HCP Cost: 5 30 Consequences CC Static No 43 80 CCR: 558/CA
et al. Zealand Societal Ben: 0,5 Cost BCR: 0.7 BCR: 2.8
(1999)
Scuffham Australia HCP Cost: 5 30 Consequences CC Static No 40 80 CCR: 549/CA NA
et al. Ben: NA Cost BCR: 0.2
(2000) 
Brisson et Canada HCP Cost: 5 30 Life-years CEA Dynamic Yes 50 90 CER:
al. (2002)* Societal Ben: NA saved CC $99,31 8/LYSe
Consequences Cost CCR: $15/CA 
BCR: 0.6
BCR: 5.2
Getsios et Canada HCP Cost: 5 70 Life-years CEA Static No 55 90 CER: $71,021/LYS
al. (2002) Societal Ben: NA saved CC CCR: $35/CA
Consequences Cost BCR: 0.6 BCR: 1.7
Banz et al. Germany HCP Cost: 5 30 Consequences Cost Dynamic No 50 85
(2003) Societal Ben: NA BCR: 1.7 BCR: 4.1
A.HCP: Healthcare Provider, B. Vaccine efficacy was similar in all studies, between 90 and 95% (Thiry et al., 2003). C. Cost: Benefit to Cost ratio (Dollars saved per dollars invested in
vaccination program); CC: Cost-Consequence analysis (Cost per health outcome avoided); CEA: Cost-Effectiveness analysis (Cost per life-year saved). D. Results are discounted. E. CER with 
the impact of zoster; BCR and CCR without the impact of zoster.
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5.1.1 METHODS
5.1.1.1 Model and methodological assumptions.
We compare three different vaccination strategies to no vaccination. The 
strategies are:
1 ) infant strategy, routine mass infant vaccination at 90% coverage,
2) catch-up strategy, infant strategy with catch-up (at 80% coverage) targeted at 
susceptible 2-11 year olds in the first year and;
3) adolescent strategy, routine vaccination of 11 year old susceptibles (at 80% 
coverage).
To assess the impact of vaccination on varicella and zoster, we used the model 
described in Section 3.2. Unless stated otherwise simulations are performed using 
the base-case estimates presented in Table 5.2 of Chapter 3.
We performed the economic analysis from the perspective of the health provider 
(NHS) and of society. The primary viewpoint is that of the health provider because 
data from this perspective is more complete for the UK. This perspective includes 
all direct medical costs including physician contacts, hospitalisations and 
prescription medications. The societal perspective includes all medical and work 
loss costs as well as household expenditures. Future costs and outcomes are 
discounted at 3% per year (Gold et al., 1996). In the sensitivity analysis, results 
are presented with alternate discount rates, including those recommended in the 
UK (6% per annum for costs and 1.5% for health benefits (Department of Health, 
1995)). Costs and benefits are presented over a 80-year time horizon.
Cost, cost-effectiveness, cost-utility and cost-benefit analysis are chosen as 
analytic techniques. The Departments of Health of England and Wales do not
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recommend a specific cut-off value for cost-effectiveness and cost-utility analysis. 
On the other hand, the National Institute for Clinical Evidence (NICE) have stated 
that their ‘range of acceptable cost effectiveness’ is between £20,000 - £30,000 
per QALY gained (NICE 2002,
. However, Devlin and Parkin
have analyzed decisions made by NICE and suggest 
that their cost-effectiveness threshold is slightly higher (between £35,000 and 
£40,000 per QALY gained). In this analysis we take the conservative value of 
£20,000 per QALY or life-year gained as being the limit below which vaccination is 
regarded, here, as being cost-effective. As a range of cost-effectiveness results 
are presented others can choose alternative threshold values. The outcomes 
measured are cases, consultations, hospitalizations, deaths, life-years gained, 
QALYs gained and monetary outcomes (i.e. £). The summary measures are the cost 
per life-year gained, cost per QALY gained and cost benefit (£).
5.1.1.2 Vaccine efficacy and epidemiological estimates
The vaccine efficacy parameters are presented in section 3.1. The different health
outcome values and data sources are presented in Table 5.2.
We estimated the predicted number of cases of natural and breakthrough 
varicella, and zoster directly from the model. The estimated age-specific 
proportion of physician consultations, length of stay and deaths per case of 
varicella and zoster were applied to the predicted number of cases by age and 
time.
Natural varicella and zoster. The age-specific number of episodes of varicella 
and zoster which result in a consultation with a general practitioner (GP) and the
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average (age specific) number of consultations per episode were taken from the 
Royal College of General Practitioners (RCGP) Weekly Returns Service data for 
1991-2000 (see Chapter 2). Age-specific hospitalisation rates and length of stay 
data were taken from the Hospital Episodes Statistics for 1995-96, which covers all 
NHS inpatient episodes in England (numbers were multiplied up by the additional 
population size to include Wales) (see Chapter 2). The average number of deaths 
in England and Wales attributed to chickenpox and herpes zoster over the period 
1993-2000 were used to calculate age-specific case-fatality ratios (Table 2.2 - see 
Chapter 2 for details).
Breakthrough infections and vaccine associated adverse events. Breakthrough 
cases were assumed to visit a physician at the same rate as natural varicella cases 
(Izurieta et al., 1997), to have a 5-fold lower risk of hospitalisation (Beneson et 
al., 1995) and not to result in death. We excluded adverse events from our 
analysis since they are rare (Wise et al., 2000) and thus would not contribute 
significantly to the overall burden of the vaccine.
The age-specific population size was taken from the Office for National Statistics 
(ONS) estimates for mid 1998 (Office for National Statistics, 2000). We used the 
population distribution of mid-1998 and assumed that the birth and death rates 
will remain constant in the future.
5.1.1.3 Outcome measures
Table 5.2 presents the health outcome estimates included in the analysis. The 
outcome measures and their method of aggregation are described in detail in 
Chapter 4 (see section 4.2). It should be stressed that in the Cost-Benefit analysis, 
the WTP values elicited in Chapter 4 were reduced by 50% as recommended by the
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NOAA (National Oceanic and Atmospheric Administration, 1993) to take into 
account the worry that WTP from CV overestimates actual WTP.
Table 5.2. Health Outcome estimates
Parameters All 0-4 5-14 15-44 45-64 65+ Source
%  cases consult GP
Natural Varicella 45% 45% 72% 82% 100% Chapter 2
Breakthrough Varicella 45% 45% 72% 82% 100% [1]
Zoster 100% 100% 100% 100% 100% Chapter 2
Number of visits per consultation
Natural Varicella 1.18 1.24 1.29 1.40 1.43 [2.3]
Breakthrough Varicella 1.00 1.00 1.00 1.00 1.00 Assumption
Zoster 1.07 1.18 1.36 1.43 1.68 [2,3]
Hospitalisations per case
Natural Varicella 0.37% 0.14% 0.62% 1.38% 3.14% Chapter 2
Breakthrough Varicella 0.07% 0.03% 0.12% 0.28% 0.63% Chapter 2
Zoster 1.12% 0.66% 0.50% 0.60% 2.28% Chapter 2
Length of Stay
Natural Varicella 2.22 2.96 3.97 5.77 10.57 Chapter 2
Breakthrough Varicella 2.22 2.96 3.97 5.77 10.57 Chapter 2
Zoster 3.53 3.35 4.58 5.23 13.54 Chapter 2
Case-Fatality
Natural Varicella 0.001% 0.001% 0.009% 0.073% 0.689% Chapter 2
Zoster 0.000% 0.001% 0.002% 0.002% 0.061% Chapter 2
VZIG per Case 0.2% 0.2% 3.3% 0.2% 0.2% Chapter 2
PHN per Zoster case 
Duration of PHN (Days) 511
0% 1% 4% 11% 31% [4]
[4]
QALY Lost per case
Natural Varicella 0.004 0.004 0.005 0.005 0.005Chapter 4, [5]
Breakthrough Varicella
Zoster
PHN
0.010
0.462
0.001 0.001 0.001 0.001 0.001 Assumption
[4]
[4]
Value (£) of a case or vaccination
Vaccination* 60.10 Chapter 4
Varicella8
Zoster
PHN
- r  1 1 _ann7. M l Di
117.79
684.72
rrr%
46.59
M l r\rt
46.59 100.64 100.64 100.64 Chapter 4 
Chapter 4 
Chapter 4
—  [11 Izurie ta  e t  al. 1997; [2] RCGP, 1999; [3] RCGP, 2000; [4] Edm unds e t  a l., 2001; [5] Ba la  
e t  al.\ A. W TP  fo r  va rice lla  vacc ination ; B .Va lue  o f  a  case  o f  varice lla .
5.1.1.4 Cost data and assumptions
All costs are in £’s sterling and given in 2001 real prices as shown in Table 5.3. 
Costs estimated in previous years are inflated to 2001 values by the use of the
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Hospital and Community Health Services (HCHS) Pay and Prices Index (NHS 
Executive, 2001).
Direct costs. The average cost per inpatient day and the average cost per GP 
consultation were taken from Unit Costs of Health and Social Care (Netten and 
Curtis, 2001). Varicella zoster immunoglobulin (VZIg) in England and Wales is 
administered by the Public Health Laboratory Service. Data from 2000 were used 
to estimate the average number of VZIg doses administered annually: 5426. 
Pregnant women given VZIg (4166 vials) were assumed to be 15 to 44 years. Each 
vial of VZIg costs £240 (Dr. Elizabeth Miller, Head of the Immunisation division, 
PHLS, personal communication).
Wreghitt et al. (1996) estimated the cost of infection control measures for a 
sample of 70 hospitalised patients with either varicella or zoster. Measures 
included serological diagnosis, staff exclusion, the use of VZIg and antiviral drugs 
and patient isolation. We assume that these measures result in an average fixed 
cost associated with each hospitalised patient (i.e. independent of their length of 
stay). Excluding the cost of administration of VZIg (to avoid double counting) this 
amounts to £722 per patient (in 2001 £), two thirds of which is due to staff 
exclusion. In all analyses it is assumed that contact with a breakthrough case by 
an at-risk susceptible would be as likely to result in the use of VZIg as contact with 
natural varicella.
The 1998 Prescription Cost Analysis for England (Department of Health Statistics 
Division, 1999) was used to estimate the cost of community prescribed drugs for 
treatment of varicella and zoster (the cost of hospital prescriptions being included 
in the study by Wreghitt et al. (1999)) using assumptions described by Edmunds et
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al. (2001). The average prescription cost per consultation for varicella and zoster 
is estimated to be £2 and £35 respectively.
In our base case analysis, we assumed the vaccine costs £30 per course. This is
varied in the sensitivity analysis since in the UK the cost of the vaccine is
unknown. For the infant strategy, we assume that varicella vaccination would be 
administered concurrently with MMR at 12-15 months and therefore will not incur 
additional costs such as practice nurse consultations. For the catch-up and the 
susceptible adolescent programmes, it is assumed that each susceptible that is 
targeted is vaccinated at an additional cost of £10 over that of an infant course to 
cover the cost of a practice nurse consultation (Netten and Dennet, 1999) and 
extra administration costs. For the catch-up and adolescent stratesies only 
children with negative or uncertain history of varicella are vaccinated. In our base 
case scenario, the positive and negative predictive value of determining a
person’s varicella history at 11 years was estimated to be 97% and 70%
respectively (Beutels et al., 1996). This is varied in the sensitivity analysis.
Indirect costs. There are no published estimates of absenteeism caused by 
chickenpox in the UK, although estimates exist from other industrialised countries 
(Lieu et al., 1994; Saddier et al., 1998; Fornaro et al., 1999; Sulivan-Bolyai et al., 
1987; Law et al., 1999; Coudeville et al., 1999; Domingo et al., 1999; Beutels et 
al., 1996, Beutels et al., 2000). The average number of workdays lost per case of 
varicella that does not require hospitalisation was taken to be 0.6 for children, 
the value found in most studies conducted in European countries (Fornaro et al., 
1999; Coudeville et al., 1999; Domingo et al., 1999; Beutels et al., 1996; Beutels 
et al., 2000). For adults with varicella an estimate of 5.7 days off work was used 
(Coudeville et al., 1999; Beutels et al., 2000; Lieu et al., 1994). In the base case,
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we assume that breakthrough cases will also result in parents taking 0.6 days off 
work. In a study of varicella in a day-care centre the median period of 
absenteeism was 1 day for breakthrough cases (Izurieta et at., 1997). Since there 
are no published estimates of absenteeism caused by zoster, the number of days 
off work was assumed to be the average age-specific duration of disease 
multiplied by the proportion of workdays in a week.
Work loss from hospitalised cases due to varicella and zoster were assumed to be 
twice the average age-specific length of stay multiplied by the proportion of 
workdays in a week to take into account pre and post-hospitalisation work loss.
To calculate the average cost of work loss, the average period of adult absence 
due to chickenpox or shingles in children was multiplied by the average daily 
female wage in 25-34 year olds (weighted by the proportion in full and part-time 
employment) (ONS New Earnings Survey, 1998). For adult cases, the average 
period of absence was multiplied by the age-specific average daily wage. It was 
assumed that there were no work loss costs caused by illness in those over 65 
years of age. Household expenditures (e.g. non-prescription medications and 
babysitting) were based on literature from North America (Lieu et al., 1998; Law 
et., 1999a; De Wals et al., 2001) since no published data exists for the UK.
5.1.1.5 Sensitivity Analysis
The sensitivity of the results to variation in input parameters was explored by 
performing a probabilistic multivariate sensitivity analysis (uncertainty analysis). 
Input parameters were assigned probability distributions and combinations of 
these parameter values were drawn using Latin Hypercube Sampling assuming that 
they are independent of each other. For each vaccination scenario, the model was
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run 1000 times to generate distributions of outcome variables using ©risk Version 
4 (Palisade Corporation, New York) running within Microsoft Excel. The parameter 
values and the assumed input distributions are given in Table 5.4. All input 
distributions were assumed to be triangular. Results are presented with 90% 
Credibility intervals (Crl), which show the 5th and 95th percentile of the outcome 
distributions. Univariate sensitivity analyses, in which parameters were varied one 
at a time, holding other parameter values at the base-case level, were also 
performed.
Table 5.3. Cost Estimates
Parameters A ll N a tu ra l
V a r ice lla
B re a k th ro u g h
V a rice lla
Z o ste r  S o u rc e
Vaccination Costs
Cost of vaccine course 30
Extra cost per course for adolescent and 
catch-up 10
Self-reported history of chickenpox 
Sensitivity 97%
Specificity 70%
Direct Costs
Cost GP consult 22 22 22
Treat Cost GP consult 2 . 35
Cost Inpatient day 219 219 219
Av Treat Cost Hospitalisation 
Cost Vzig 
Indirect Costs 
Not Hospitalised 
Work days lost per case
722
240
722 875
0-15 0.6 0.6 10
16+
Hospitalised 
Work days lost
5.7 5.7 10
0-4 3.17 3.17 5.04
5-14 4.22 4.22 4.79
15-44 5.67 5.67 6.54
45-64
Cost of a Work Day Lost
8.24 8.24 7.47
0-15
16-17
18-20
21-24
25-29
30-39
40-49
50-59
60-64
Household expenditures 
0-15
16+______________
[1] Beutels et al
30
15
23 
32
51 
61 
63
52
24
15
35
Assumption
Assumption
[1-3]
[1-4]
[5]
[6]
15]
[7]
[ 8]
[1.8.9]
[1.8.9]
[1,8]
Assumption
Assumption
Assumption
Assumption
[11]
[11]
[11]
[11]
[ 11]
[ 11]
[11]
[ 11]
[ 11]
[3.12.13]
[3.12.13]
1994, [2] Beutels et al. 2002, [3] Lieu et al., 1998; [4] Kelley et al., 1991- rsi 
Netten and Dennnet, 1999; [6] Department of Health Statistics Division, 1999; [7] Wrechitt et al 
1996; [8] Dr. Elizabeth Miller, Personal communication; [9] Coudeville et al., 1999; [10] Fornaro et 
al. 1999; [11] Office for National Statistics, 2000; [12] Law et al., 1999a; [13] De Waîs et al 2001
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Table 5.4. Input values for the multivariate analysis
Parameter Minimum (source)_______
% cases consult CP  * «■ —
Maximum (source)
Varicella: 0-4
5-14 
15-44 
45-64 
65+
Hospitalisation per case
Varicella’: 0-4
5-14
15-44
45-64
65+
Zoster*: 0-4
5-14 
15-44 
45-64 
65+
Length of Stay
Varicella’: 0-4
5-14
15-44
45-64
65+
Zoster®: 0-4
5-14 
15-44 
45-64 
65+
Case-Fatality
Varicella0: 0-4 
5-14 
15-44 
45-64 
65+
Zoster0: 0-4
5-14
15-44
45-64
65+
PHN per Zoster case 
0-4 
5-14 
15-44 
45-64 
65+
Duration of PHN
Value (£) of a case or vaccination
36% RCGP 48%
26% RCGP 45%
30% RCGP 72%
48% RCGP 100%
57% RCGP 100%
0.4% HES 0.5%
0.1% HES 0.2%
0.6% HES 0.8%
1.4% HES 1.9%
3.1% HES 5.8%
1.1% HES 1.4%
0.7% HES 1.0%
0.5% HES 0.8%
0.6% HES 1.2%
2.3% HES 5.0%
2.2 HES 2.7
3.0 HES 3.6
4.0 HES 4.8
5.8 HES 7.9
10.6 HES 15.8
3.5 HES 5.3
3.4 HES 3.4
4.6 HES 6.1
5.2 HES 8.7
13.5 HES 17.4
0.0006% ONS 0.0017%
0.0004% ONS 0.0006%
0.0063% ONS 0.0167%
0.0733% ONS 0.1011%
0.3880% ONS 0.8536%
0.0000% ONS 0.0000%
0.0000% ONS 0.0068%
0.0000% ONS 0.0086%
0.0012% ONS 0.0035%
0.0403% ONS 0.0831%
0.0% Edmunds et al, 2001 0.0%
0.0% Edmunds et al, 2001 1.7%
2.6% Edmunds et al, 2001 4.9%
10.0% Edmunds et al, 2001 11.9%
28.7% Edmunds et al, 2001 33.4%
339 Edmunds et al, 2001 781
RCGP
RCGP
RCGP
RCGP
RCGP
HES
HES
HES
HES
HES
HES
HES
HES
HES
HES
HES
HES
HES
HES
HES
HES
HES
HES
HES
HES
ONS
ONS
ONS
ONS
ONS
ONS
ONS
ONS
ONS
ONS
Edmunds et al, Z001 
Edmunds et al, 2001 
Edmunds et al, 2001 
Edmunds et al, 2001 
Edmunds et al, 2001 
Edmunds et al, 2001
Vaccination*
Varicella: 0-14 
15+
Zoster
PHN
QALY Lost per case 
Varicella: 0-14 
1 5+
Zoster
Cost Estimates
Reported History of Chickenpox 
Sensitivity 
Specificity
52 Chapter 4D 69
45 Chapter 4E 60
52 Chapter 4F 176
76 Appendix 13° 176
523 Appendix 13h 847
0.01% Chapter 4' 0.64%
0.32% Chapter 4J 1.02%
0.85% Chapter 4* 1.67%
-25%Base +25% Base
90% Scuffham etal., 2000 99%
50% Ronan and Wallace, 2001 80%
Chapter 4° 
Chapter 4E 
Appendix 13F 
Appendix 13° 
Appendix 13H
Chapter 4' 
Chapter 4L 
Chapter 4L
Beutels et al., 1996 
Scuffham et al., 2000
A) Minimum is minimum number of varicella consultations observed in the RCGP data in a year between ^  
2000. Maximum is maximum number of varicella consultations in a year between 1991-2000 r i l  /  
varicella or zoster in the first diagnostic field (Hospital Episode S t a t i s t i c s ( H K ) i Z im u m X f i i f f  
in any of the diagnostic fields. C) Minimum is minimum case-fatality in a year between 1991-2000 iObsem»H in 
ONS mortality statistics). Maximum is maximum case-fatality in a year between 199U2000 m w r i r J w r l V  
vaccination, Chapter 4, Table 4 10 E) 95%Cl of WTP for treatment, Chapter 4? Tab e 4.10 F Average W ?  Z  
chickenpox and severe zoster. G) Average WTP for mild and severe zoster. H) 95%CI of w t p l a n  
Distribution of QALY values obtained from 42 parents of children with prior history of chfctenMx 1
QALY value obtained from 10 specialist registrars working at C0SC using the HUI2 generic healthsta^m w u?* ?! 
QALY value for Mild zoster. L) QALY value for severe zoster. 8 nc health status index- X)
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5.1.2 BURDEN OF VARICELLA AND ZOSTER
The overall burden of VZV related disease is substantial (Table 5.5). The 
predicted 651,000 cases of varicella per year in England and Wales result in an 
estimated 384,000 physician visits, 2,200 hospitalisations and 20 deaths. 
Comparatively, there are annually an estimated 189,000 cases of zoster and,
277,000 physician visits, 2,100 hospitalisations and 37 deaths. The estimated 
overall QALYs lost due to varicella and zoster is 18,000 (90% Crl 14,000-29,000), 
80% of which are due to zoster.
The overall societal cost of VZV related disease in England and Wales is estimated 
to be £223m annually (90%Crl, £181m-£288m - Table 5.5), 76% (£169m) of which 
are attributable to zoster. Most of societal costs (£175m, 78%) are due to work 
loss, £12m are due to household expenditures and £35m are due to direct medical 
costs. Of the annual £35m VZV is estimated to cost the NHS, £13m is due to 
varicella (£20 per case) and £22m is due to zoster (£116 per case).
Due to the simplified age-specific mortality of the model, predictions of the 
overall burden (morbidity and costs) of zoster are slightly underestimated 
compared to those of Edmunds et al. (2001). Nonetheless, results indicate that 
although there are more cases of varicella, the overall burden of disease is 
significantly higher for zoster.
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Table 5.5. Modelled Current Burden
Vari cella
Base (90%Crl) Base (90%CI)
Health Outcomes
Cases 651,000 189,000
PHN cases 26,000 (25,000 : 27,000)
GP Visits 384,000 (308,000 : *) 277,000
Hospitalisations 2,200 (* : 2,700) 2,100 C : 3,500)
Deaths 20 (19 : 26) 37 (30 :48)
Life Years Lost 900 (800: 1,200) 400 (400 : 600)
QALTs Lost 3,500 (1,900 : 4,700) 14,000 (12,100 : 24.000)
Welfare Lost (£m) 35 (33 : 44) 38 (34:49)
Costs (£m)
GP visits and VZig 10 (7:10) 16 (14 :18)
Hospitalisation 3 (3:4) 6 n  • -ni
Work Loss and
Household
Expenditures 41 (31 :60) 146 (119:183)
Total 54 (41 :74) 169 (140 : 214)
* Base Case is the minimum or maximum value of the parameter’s distribution.
5.1.3 EFFECTIVENESS OF VARICELLA VACCINATION
The predicted dynamics of varicella and zoster cases following mass vaccination in 
England and Wales under base assumptions are shown in Chapter 3 and 4. The 
projected discounted (3%) health benefits over 80 years derived from vaccination 
are shown in Table 5.6.
Infant vaccination (infant strategy) with 90% coverage is predicted to reduce the 
number of varicella cases, physician consultations, hospitalisations and deaths by 
15m (83%), 8m (79%), 47,000 (73%) and 22 (3%) respectively. If the catch-up 
strategy is introduced an additional 1.1m (6%), 0.7m (8%), 5,000 (9%) and 177 
(23%) of these outcomes respectively are expected to be prevented. In 
comparison, routine vaccination of 11 year olds (adolescent strategy) with 80% 
coverage reduces cases, hospitalisations and deaths by 2m (12%), 11,000 (16%) and 
128 (24%). Hence, although adolescent vaccination prevents a smaller proportion
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of varicella cases it saves more deaths than the infant strategy because it prevents 
most mortality in adults and does not lead to an upward shift in the average age 
at infection.
Table 5.6. 80-year discounted (3%) varicella and zoster outcomes and costs
Infant Catch-up Adolescent
Base (90%Crl) “ Base (90%Crl) Base
Health Outcomes Avoided 
Varicella
Cases (millions) 14.6
GP consultations (millions) 8.0
Hospitalisations (thousands) 46.9
Deaths 22
Life-years saved (thousands) 14.2
QALYs saved (thousands) 80.2
£m gained 1286
Zoster
(90%Crl)
(6.6 : *) 
(* : 58.6) 
(-23 : 126)
15.7
8.7
51.9
199
17.4
88.5 
1421
(7.1 : *) 
(* : 65.3) 
(109:296)
1.9
1.5
10.5 
128 
7.4
18.6 
NAa
(1.0:*) 
(* : 12.6) 
(111 : 210)
NAa
Cases (millions) -0.6 -0.7 -0.1
GP consultations (millions) -1.1 -1.3 -0.1
Hospitalisations (thousands) -15.5 (-31.1:*) *18.4 (-37.5:*) -1.5 (-2.9:*) 
-41 (-51:-31) 
-0 4
Deaths -444 (-550:-336) -526 (-650:-393)
Life-years saved (thousands) -4.1 •4.9
QALYs saved (thousands) -134.6 -145.7 -11.0
£m gained -251 -295 NAa NAaOverall VZV disease
Life-years saved (thousands) 10.0 (7.7: 16.0) 12.5 (11.2:21.5) 7.0 (6.0: 11.3) 
7.6 (-1.0 : 13.2) 
NAA na
QALYs saved (thousands) -54.4 (-155.6 : -44.1) -67.2 (-186.9: -40.6)
£m gained 1035 (907: 1168) 1126 (934:1202)
Costs (£mi!lion)
Vaccine Costs 524 (405 : 644) 698 (557: 863) 183 (138:240)
Direct medical costs
prevented
GP consultations 134 (88 : 146) 141 (90: 152) 30 (17:31)
Hospitalisations -5 (-72 : -1) -10 (-84 : -4) 10 (5:13)
Vzig 18 23 11
Total NHS costs prevented 147 154 52
Work Loss and Household 111 (-83 : 673) 271 (11:849) 293 (201 : 355)Expenditures prevented
Total societal costs 258 425 344prevented
Total Net Costs (NHS) 377 544 -110
Total Net Costs (Society) 266 273 -161* Base case is tne minimum or maximum value of the parameter’s distribution 
pay for varicella vaccination was not measured for the adolescent programme. The willingness to
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Cases of zoster are likely to significantly increase in the 80 years following 
vaccination (see Chapter 3 and 4). Under base case assumptions, the model 
predicts that, with infant vaccination at 90% coverage the discounted number of 
cases, hospitalisations and deaths due to zoster will increase by 0.6m (10%)
16,000 (13%) and 444 (37%) respectively over 80 years (Table 5.6). Hence, if the 
increase in zoster is taken into account, infant vaccination would result in an 
extra 422 VZV related deaths (varicella and zoster) over 80 years. The increase in 
zoster morbidity is greater for the catch-up stratesv (Table 5.6). On the other 
hand, the adolescent strategy has little impact on the burden of zoster. For the 
adolescent strategy, the model predicts that, with 80% coverage of susceptibles, 
the discounted number of cases, hospitalisations and deaths due to zoster 
increases by 0.1m (1%), 1,500 (3%) and 41 (5%) respectively over 80 years (Table 
5.6).
Life-years gained. The model predicts that 10,000, 13,000 and 7,000 discounted 
life-years will be gained by infant, catch-up and adolescent vaccination over 80 
years (Table 5.6). Although infant and catch-up strategies result in more 
discounted varicella and zoster deaths over 80 years they produce an increase in 
life years (Table 5.6). This is because the increase in zoster deaths following 
varicella vaccination are in the elderly while varicella deaths are mainly 
prevented in children.
QALYs gained. Under base case assumptions, infant and catch-up vaccination are 
expected to result in losses of QALYs over 80 years (-54,000 and -67,000 
discounted (3%) QALYs gained respectively). Only adolescent vaccination results in 
overall health (QALY) gains when taking into account zoster (7,000 discounted 
QALYs gained over 80 years).
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Monetary value of benefit (£). The predicted benefit of infant and catch-up 
vaccination in monetary terms over 80 discounted (3%) years is $1035m and 
$1126m respectively. Hence, as discussed in Chapter 4, our analysis predicts that, 
although routine childhood vaccination may produce losses in QALYs it may be 
deemed beneficial using Willingness to pay as a method of preference elicitation. 
This is because, WTP can capture non-health effects and it is less sensitive to 
increases in severity than QALYs (i.e. with WTP the increase in zoster has less of 
an impact on overall vaccination effectiveness).
It should be mentioned that we did not measure the willingness to pay for 
adolescent vaccination and hence could not assess the overall aggregated benefit 
of this strategy in monetary values.
5.1.4 COST ANALYSIS
The projected discounted costs of the infant and catch-up programs are £524m 
(90%Crl, £405m-£644m) and £698m (90%Crl, £557m-£863m) respectively, which is 
estimated to avoid £147m and £154m in direct medical costs (Table 5.6). Thus, 
under base case assumptions, infant vaccination (with or without catch-up) is 
estimated to result in a net cost from the NHS perspective. On the other hand, 
routine vaccination of 11 year olds (adolescent strategy) with 80% coverage is 
estimated to result in savings of £52m in direct medical costs over 80 years, but at 
a cost of £183m (90%Crl, £138m-£240m) (Table 5.6).
Of the strategies investigated only the adolescent strategy is cost saving from the 
societal perspective (present value of 161m over 80 years - Table 5.6). The infant 
and catch-up strategies are estimated to cost £266m and £273m over 80
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discounted years respectively (Table 5.6). The 90% Crl of these values are wide 
(Table 5.6) since little is known of the indirect costs of zoster.
5.1.5 COST-EFFECTIVENESS, COST-UTILITY AND COST-BENEFIT OF VARICELLA 
VACCINATION
Cost-Effectiveness. Under base case assumptions, the model predicts that from 
the health care payer’s perspective, the infant, catch-up and adolescent 
strategies cost £38,000, £44,000 and £19,000 per life-year gained respectively 
(Table 5.7). Although the catch-up strategy is the most effective vaccination 
strategy in terms of varicella reduction, it is estimated to be the least cost- 
effective strategy (Table 5.7).
Cost-Utility. Using QALYs as a measure of morbidity, the model predicts that 
infant and catch-up vaccination will produce more harm than good when taking 
into account the impact on zoster (i.e. negative QALYs gained - Table 5.6). 
Therefore, the cost-utility ratio is negative for these vaccination strategies (Table 
5.8). The cost-utility ratio for the adolescent vaccination is positive (£18,000 per 
QALY gained).
Thus, only adolescent vaccination would be deemed cost-effective using £20,000 
per QALY gained as the upper limit for an intervention to be considered as cost- 
effective.
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Table 5.7. Cost-Effectiveness, sensitivity analysis - NHS perspective
In fan t C a tch -u p A d o le sc e n t
B a se  C a se £38 ,3 8 1 £ 4 4 ,2 5 1 £ 1 9 ,1 0 9
V a c c in e  a n d  e p id e m io lo g ic a l p a ram ete rs  
V a c c in e  E ff ica cy
Best case £35,892 £35,471 £19,599
W orst case £21,012 £24,417 £17,913
V a c c in e  C o ve ra g e
50%  in fants, 50%  ch ild ren £243 ,114 £281,112 £22,694
95%  in fants, 90%  ch ild ren £30,356 £34,244 £18,374
P h y s ic ia n  v is it s  p e r  c a se  o f  va r ice lla
Low er bound  90% C rl £44,361 £49,705 £21,709
U pper bound  90% C rlB £37,819 £43,789 £19,069
R a te  o f  h o sp ita lisa t io n  a n d  Le n g th  o f  s ta y
A n y  ICD  Fie ld £47,104 £52,767 £19,601
S u m m a ry  O u tc o m e s  
C a se  F a ta lity  R a t io  o f  V a r ice lla
Low er bound  90% C rl £104,077 £100,228 £28,177
U p p e r bound  90% C rlB £21,325 £24,120 £10,443
C a se  F a ta lity  R a t io  o f  Z o s te r
Low er bound  90% C rl £34,518 £39,992 £18,768
U pper bound  90% C rlB £37,522 £43,500 £19,368
C o s ts
C o s t  p e r  v a c c in e  c o u rse
-25%  Base  C ase £25,109 £30,105 £12,488
+25%  Base  Case £51,653 £58,397 £25,731
C o s t  p e r  co n su lta t io n
-25%  Base  C ase £35,035 £41,428 £18,022
+25%  Base  Case £41,728 £47,073 £20,197
C o s t  p e r  in p a t ie n t  d ay
-25%  Base  C ase £38,254 £44,049 £19,467
+25%  Base  C ase £38,509 £44,453 £18,752
P r io r  H is to ry  o f  V a r ice lla
Sensitiv ity : 90% X £44,445 £20,626
99% X £44,170 £12,085
Spec ific ity : 50% X £50,253 £30,380
80% X £42,419 £15,670
M o d e l a n d  M e th o d o lo g ic a l A s su m p t io n  
D u ra t io n  o f  im m u n ity  to  z o s te r  a fte r  
e x p o s u re  to  V Z V
7 ye a rs  (low er bound  95%  C l) £21,927 £26,042 £16,553
11 y e a rs  (low er bound  75%  Cl) £28,575 £33,147 £17,857
41 ye a rs  (upper bound  95%  Cl) £47,380 £54,359 £19,896
E x c lu d in g  in d ire c t  e ffe c ts
No H e rd -im m un ity  and Exc lud ing  Zoste r 
W ith  H e rd -im m un ity  and  Exc lud ing Zoste r
£22,856
£18,158 £23,171 £16,423
D is c o u n t  ra te
B ene fits  6%, C osts 6% £33,890 £44,586 £27,465
B ene fits  3%, C o sts  6% £23,482 £32,174 £11,969
B ene fits  0%, C osts  6% £12,118 £18,290 £3,558
Be n e fits  0% , C o sts  3% £19,807 £25,155 £5,681
B ene fits  0% , C o sts  0% £37,477 £39,563 £11,764
T im e  Sca le
30 ve a rs £32,579 £34,407 £25,380
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infant
Base Case
Table 5.8. Cost-Utility, sensitivity analysis - NHS perspective
Catch-up Adolescent
QALY Loss* QALV Loss £17,673
Vaccine and epidemiological parameters 
Vaccine Efficacy
Best case 
Worst case 
Vaccine Coverage 
50% infants, 50% children 
95% infants, 90% children 
Physician visits per case of varicella 
Lower bound 90%CrlB 
Upper bound 90%CrlB
Rate of hospitalisation and Length of stay 
Any ICD Field 
Summary Outcomes 
Case Fatality Ratio of Varicella
Lower bound 90%CrlB 
Upper bound 90%CrlB 
Case Fatality Ratio of Zoster 
Lower bound 90%CrlB 
Upper bound 90%Crl8 
QALY of Varicella 
Lower bound 90%Crl8 
Upper bound 90%CrlB 
QALY of Zoster 
Lower bound 90%Crl8 
Upper bound 90%Crl8 
Costs
Cost per vaccine course
-25% Base Case 
+25% Base Case 
Cost per consultation 
-25% Base Case 
+25% Base Case 
Cost per inpatient day 
-25% Base Case 
+25% Base Case 
Prior History of Varicella 
Sensitivity: 90%
99%
Specificity: 50%
80%
Model and Methodological Assumption 
Duration of immunity to zoster after 
exposure to VZV
7 years (lower bound 95% Cl)
11 years (lower bound 75% Cl)
41 years (upper bound 95% Cl)
Excluding indirect effects 
No Herd-immunity and Excluding Zoster 
With Herd-Immunity and Excluding Zoster 
Discount rate 
Benefits 6%, Costs 6%
Benefits 3%, Costs 6%
Benefits 0%, Costs 6%
Benefits 0%, Costs 3%
Benefits 0%, Costs 0%
Time Scale
QALY LOSS 
£11,327
QALY LOSS 
£10,181
£24,755
£8,172
QALY LOSS 
QALY LOSS
QALY LOSS 
QALY LOSS
£22,841
£16,837
QALY LOSS 
QALY LOSS
QALY LOSS 
QALY LOSS
£19,566
£17,717
QALY LOSS QALY LOSS £18,021
QALY LOSS 
QALY LOSS
QALY LOSS 
QALY LOSS
£21,126
£11,129
QALY LOSS 
QALY LOSS
QALY LOSS 
QALY LOSS
£17,454
£17,801
QALY LOSS 
QALY LOSS
QALY LOSS 
QALY LOSS
£46,323
£9,582
QALY LOSS 
QALY LOSS
QALY LOSS 
QALY LOSS
£12,630 
QALY LOSS
QALY LOSS 
QALY LOSS
QALY LOSS 
QALY LOSS
£13,081
£22,266
QALY LOSS 
QALY LOSS
QALY LOSS 
QALY LOSS
£18,680
£16,667
QALY LOSS 
QALY LOSS
QALY LOSS 
QALY LOSS
£18,004
£17,306
X
X
X
X
QALY LOSS 
QALY LOSS 
QALY LOSS 
QALY LOSS
£19,047
£11,048
£28,058
£14,463
£9,396 
QALY LOSS 
QALY LOSS
£10,449
QALY LOSS 
QALY LOSS
£7,679
£11,421
£31,258
£4,199
£3,256
X
£4,665
X
£6,667
QALY LOSS 
QALY LOSS 
£6,249 
£10,214 
£19,327
QALY LOSS 
QALY LOSS 
£16,933 
£23,289 
£16,511
£74,511
£11,049
£1,579
£2,521
£5,228
vears __________________ QALY LOSS QALY LOSS £29,988
X ”~QALY Loss: Negative benefit of vaccination. B. 90% Crl of distribution in Table 5.3.
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Cost-Benefit. The base case Cost-Benefit ratios for the infant and catch-up 
strategies are 0.39 and 0.40 respectively. Hence, in contrast to Cost-Effectiveness 
and Cost-Utility analysis, Cost-Benefit analysis is deemed to be highly desirable 
from the NHS perspective.
5.1.6 SENSITIVITY ANALYSIS
5.1.6.1 Univariate Sensitivity Analysis.
The sensitivity of results to changes in the key parameters is shown in Tables 7-9
Cost-Effectiveness. The cost-effectiveness of infant and catch-up vaccination is 
most sensitive to vaccine efficacy, vaccine coverage, the cost per vaccine course, 
the case-fatality ratios, and the duration of immunity to zoster after exposure to 
VZV (Table 5.7). However, using £20,000 per life-year gained as the criteria for an 
intervention to be considered cost-effective, infant vaccination (with or without 
catch-up) remains cost-ineffective when varying these key parameters within their 
plausible ranges. Only when discount rates are set to 0% for benefits or the 
indirect effect of zoster is excluded from the analysis does the cost per life-years 
gained of infant varicella vaccination become lower than the £20,000 threshold
The results of the adolescent programme are relatively insensitive to changes in 
parameter values and oscillate around £20,000 per life-year gained. Parameters 
with the greatest impact on results are the case-fatality ratio of varicella and 
accuracy of reported history of varicella.
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Table 5.9. Cost-Benefit Analysis, sensitivity analysis - NHS perspective
= = = = = = = = = = = = = = = __=!_____________ In fan t
B a se  C a se
V a c c in e  a n d  e p id e m io lo g ic a l p a ra m e te rs  
V a c c in e  E ff ica cy
0 .3 9
C a tch -u p  
0 .4 0
Be st case  
W orst ca se  
V a c c in e  C o v e ra g e  
50%  in fants, 50%  ch ildren  
95%  in fants, 90%  ch ild ren  
P h y s ic ia n  v is it s  p e r  c a se  o f  va r ice lla  
Low e r b ound  90% C rlB 
U p p e r b ound  90% C rlB
R a te  o f  h o sp ita lisa t io n  a n d  Le n g th  o f  sta y  
A n y  ICD  Fie ld  
S u m m a ry  O u tc o m e s
W T P  f o r  V a r ic e lla  V acc in a t io n /T re a tm en t 
Low e r bound  90% C rlB 
U p p e r b ound  90% C rlB 
W T P  f o r  Z o ste r/ T re a tm e n t 
Low e r bound  90% C rlB 
U p p e r b ound  90% C rlB 
C o sts
C o s t  p e r  v a c c in e  c o u rse  
-2 5%  Ba se  Case  
+25%  Ba se  C ase  
C o s t  p e r  c o n su lta t io n  
-2 5 %  Ba se  C ase  
+25%  Base  C ase  
C o s t  p e r  in p a t ie n t  d a y  
-2 5%  Ba se  C ase  
+25%  B a se  C ase  
P r io r  H is to ry  o f  V a r ice lla  
Sensitiv ity : 90%
99%
Spec ific ity : 50%
80%
M o d e l a n d  M e th o d o lo g ic a l A s su m p t io n  
D u ra t io n  o f  im m u n ity  to  z o s te r  a f te r  e x p o su re  to  
V Z V
7  ye a rs  (low er bound  95%  C l)
11 ye a rs  (low er bound  75%  Cl)
41 y e a rs  (upper bound  95%  Cl)
E x c lu d in g  in d ire c t  e ffe c ts  
N o  H e rd -im m un ity  and  Exc lud ing  Zoste r 
W ith  H e rd -Im m un ity  and  Exc lud ing  Zoste r 
D is c o u n t  ra te  
Be n e fits  6%, C osts  6%
B e n e fits  3%, C osts  6%
Be n e fits  0%, C osts  6%
B ene fits  0%, C osts 3%
Be n e fits  0% , C o sts  0%
T im e  S ca le
30  ye a rs_________________________________________
0 .34 0.33
0.29 0 .27
0.56 0 .56
0.38 0 .39
0.45 0 .44
0.39 0 .38
0.45 0 .47
0.50 0.51
0.30 0.32
0 .37 0 .37
0.42 0.43
0.21 0 .24
0 .57 0.56
0.42 0.43
0.36 0 .37
0.39 0 .39
0.39 0.41
X 0 .40
X 0 .40
X 0 .40
X 0 .40
0 .24 0 .20
0 .30 0 .28
0.47 0.51
0.23
0.22 0 .18
0 .44 0 .42
0 .24 0 .24
0.08 0 .08
0.13 0 .14
0 .25 0 .25
0.51 0 .53
Cost-Utility. The cost-utility of infant and catch-up vaccination is most sensitive 
to vaccine efficacy and the duration of immunity to zoster after exposure to VZV.
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If vaccine efficacy is poor (worst case scenario), duration of immunity to zoster 
after exposure to VZV is 7 years (lower bound of the 95% Cl see Chapter 2) or the 
impact of zoster is excluded from the analysis, then infant and catch-up 
vaccination are estimated to be highly cost-effective (i.e. cost per QALY gained is 
lower than £10,000). The cost-effectiveness of infant varicella vaccination is also 
sensitive to the choice of discount rate and time frame of the analysis. Because 
zoster morbidity will eventually decline after 60 years (once all cohorts are 
vaccinated (see Chapter 3)), lower discount rates for benefits and longer time 
frames of analysis will cause varicella vaccination to be more cost-effective (Table 
5.8). Infant varicella vaccination remains highly cost-ineffective for changes in all 
other key parameters (Table 5.8).
The results of the adolescent programme are sensitive to changes in parameter 
values. However, most scenarios cost less than £25,000 per QALY saved. 
Parameters with the greatest impact on results are the case-fatality ratio of 
varicella, QALY lost due to varicella and zoster and the discount rate.
Cost-Benefit. The cost-benefit of varicella vaccination is most sensitive to vaccine 
coverage, WTP for varicella vaccination, the cost of the vaccine and the impact of 
vaccination on zoster. However, varicella vaccination remains highly cost- 
beneficial for changes in all parameters. It should be stressed that this is the case 
despite reducing by 50% the WTP values elicited in Chapter 4. In fact, the WTP 
values elicited in Chapter 4 must be reduced by more than 80% for the CBR ratio 
to be greater than one.
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The results of the multivariate analysis are shown in Figures 1*3. Unless stated 
otherwise, results are from the NHS perspective, and vaccine efficacy, vaccine 
coverage, duration of immunity to zoster WAIFW matrix, time frame of analysis 
and discount rates are held at base-case values. All other parameters are varied 
simultaneously according to their assigned probability distributions.
Cost-Effectiveness. For a given value along the x-axis, Figure 5.1 a and b show 
the proportion of simulations which result in a cost per life-year gained equal or 
less than that value. More loosely, for different programmes and epidemiological 
assumptions, these figures can be interpreted as showing the probability that 
varicella vaccination would be deemed cost-effective for alternative values of 
society’s maximum willingness to pay for a life-year gained. The results suggest 
that infant vaccination (with and without catch-up) is unlikely to be cost-effective 
(Figure 5.1a, b). Using £20,000 per life-year gained as the CEA threshold, the 
probability that infant vaccination is cost-effective is 0% (95%CI 7-41 yrs immunity, 
0-18%). The CEA threshold must be doubled for infant vaccination to have more 
than a 50% chance of being cost-effective. On the other hand, if the impact of 
zoster is ignored then varicella vaccination is cost-effective under many 
acceptable criteria. Consistent with the univariate sensitivity analysis, adolescent 
vaccination is the strategy, which is most likely to be cost- (Figure 5.1a).
Figure 5.1c presents the results of the probabilistic sensitivity analysis of infant 
vaccination on the cost-effectiveness (CE) plane. The continuous black line 
represents the CEA threshold (assumed at £20,000 per life-year gained) and each 
point on the CE plane represents the results of one realisation of the probability 
sensitivity analysis. Under the NHS perspective, more than half of simulations are
5.1.6.2 Multivariate Sensitivity Analysis
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deemed cost-effective (left of the continuous line) when the impact of zoster is 
excluded. However, if zoster is included, very few simulations produce results 
that are cost-effective. On the other hand, most simulations are cost-saving under 
the societal perspective (with or without the zoster externality). It should be 
stressed that including indirect costs due to zoster increases greatly the variability 
of results, which represents the high level of uncertainty concerning the cost of 
productivity loss due to shingles.
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Figure 5.1. Multivariate sensitivity analysis - Cost-effectiveness.
Cost-effectiveness acceptability curves for a) different vaccination 
strategies and b) different assumptions concerning the duration of 
immunity to zoster after exposure to VZV and excluding zoster 
outcomes from the economic analysis, c) Results of the multivariate 
probabilistic sensitivity analysis including and excluding zoster from 
the analysis and using the Societal and NHS perspectives presented 
on the Cost-effectiveness plane.
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Figure 5.2. Multivariate sensitivity analysis - Cost-Utility. Cost- 
effectiveness acceptability curves for a) different vaccination 
strategies and b) different assumptions concerning the duration of 
immunity to zoster after exposure to VZV and excluding zoster 
outcomes from the economic analysis, c) Results of the multivariate 
probabilistic sensitivity analysis including and excluding zoster from 
the analysis and using the Societal and NHS perspectives presented 
on the Cost-Utility plane.
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Figure 5.3. Multivariate sensitivity analysis - Cost-Benefit, a) 5% 50% and 95%
percentile of the Cost-Benefit ratio for different vaccination strategies andVarious 
assumptions concerning the duration of immunity to zoster after exposure to VZV 
and excluding zoster outcomes from the economic analysis, b) Results of thl  
multivariate probabilistic sensitivity analysis including and excluding zoster from 
the analysis and using the Societal and NHS perspectives presented on the C o T  
Benefit plane. u:a'
Cost-U tility. Figure 5.2 summarises the results of the multivariate probabilistic 
sensitivity analyses using Cost-Utility as the analytic technique. The results
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suggest that, infant vaccination (with or without a catch-up programme) would be 
highly unlikely to be cost-effective using cost per QALY gained. However, if the 
impact of zoster is excluded from the analysis, then the probability that infant 
vaccination will be cost-effective is 100% under many acceptable CEA thresholds.
Vaccination of susceptible 11 year olds is likely to be cost-effective (close to half 
of the simulations result in a cost per QALY gained of less than £20,000).
Figure 5.2c presents the results of the probabilistic sensitivity analysis of infant 
vaccination on the cost-utility (CU) plane. Interestingly, dependant on 
methodological assumptions varicella vaccination can produce results in all 4 
quadrants of the CU plane. If the impact of zoster is included, QALYs gained are 
negative. Furthermore, if the societal perspective is taken, the bulk of simulations 
produce results that are cost saving. This clearly shows that methodological 
assumptions can have a far greater impact on results than health outcome or cost 
parameters.
Cost-Benefit. All simulations/scenarios in the multivariate sensitivity analysis 
show infant varicella vaccination to be highly cost-beneficial (Figure 5.3).
5.1.7 DISCUSSION
Conclusions regarding the economic desirability of infant varicella vaccination 
(with and without catch-up) is largely dependant on the choice of analytical 
technique.
Cost-Effectiveness and Cost-Utility analysis. The Cost-Effectiveness and Cost- 
Utility analyses produce similar conclusions. First, the ’’cost-effectiveness” of
246
infant varicella vaccination rests heavily on the impact it will have on the 
incidence of zoster (Table 5.10). In Chapter 3, we show that the increase in zoster 
following vaccination is dependant on vaccine effectiveness at preventing 
varicella and the length of time exposure to VZV protects against zoster. If 
duration of immunity to zoster after exposure to VZV is more than 10 years (lower 
bound of the 85% Cl) and vaccination is effective (as it has been proven to be in 
the US (Seward et alM 2002, Vazquez et al., 2001) then universal infant strategies 
are unlikely to be cost-effective and, using QALYs as a measure of overall 
morbidity, are likely to produce more harm than good. This conclusion is robust to 
changes in all other health outcome and cost estimates investigated here. 
Secondly, if the discount rate for benefits is very low (i.e. if time preference is 
such that short and long term benefits are valued equally), then infant varicella 
vaccination would be worthwhile since after 60 years a reduction in zoster cases 
will occur provided vaccine recipients are less likely to develop zoster than 
individuals who have acquire natural infection (Garnett et al., 1992a,b)
Under all scenarios investigated, adolescent vaccination is the most cost-effective 
option from the health provider’s perspective because, per vaccinee, there is a 
larger reduction of serious disease than for the infant programs. Furthermore, it is 
the safest option since it has little effect on the age at infection and incidence of 
zoster. However, the cost-effectiveness of this strategy depends on the accuracy 
of the QALY measures for varicella and zoster.
Cost-Benefit analysis. Cost-benefits analysis results predict that infant varicella 
vaccination is highly desirable. This conclusion is robust to methodological (e.g. 
discount rate, time horizon of analysis) and modelling assumptions (i.e. 
including/excluding herd-immunity and zoster) as well as changes in all
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parameters investigated here (Table 5.10). In fact, the WTP for varicella 
vaccination or avoidance of varicella must be reduced by an additional 20% (the 
elicited values have already been halved) or the WTP for zoster must be increased 
by 300% (or elicited WTP be increased by 150%) for the cost-benefit ratio to 
exceed unity.
Strengths and limitations of the analysis. The analysis presented here expands on 
previous analyses in four major areas. Most importantly we include the possible 
effect of zoster on the economic desirability of varicella vaccination using a 
dynamic mathematical model parameterised from recent data. Secondly, we use 
other outcome measures than life-years gained. Using QALY or £, instead of life- 
years gained as previous studies have done (see Table 5.1), is arguably more 
appropriate since the main aim of varicella vaccination is to reduce VZV morbidity 
(because VZV causes little mortality). Thirdly, like Lieu et aL and Brisson et al. we 
take into account herd-immunity effects when assessing cost-effectiveness. 
Finally, we performed extensive univariate and multivariate sensitivity analysis, 
not only on the parameters used, but also on methodology.
The two main limitations of the economic analysis presented here are the lack of 
data on the indirect costs due to zoster and uncertainty surrounding the WTP to 
prevent zoster and PHN since values were taken from a convenient sample not 
representative of the UK population. Furthermore, the mathematical model has 
two main limitations. First, it has a simplified age structure in the elderly, which 
results in an underestimate of the overall burden of zoster in this age group 
(Edmunds et al., 2001). Hence, results may overestimate the cost-effectiveness of 
varicella vaccination. Finally, a better understanding of the mechanisms that lead
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to the development of shingles is needed to improve accuracy of model 
predictions.
Impact of model and methodological assumptions on results. In this section we 
show that model and methodological assumptions can have greater impact on 
results than parameter estimates. More particularly, we illustrate that the 
economic analysis can produce opposite conclusions depending on the choice of 1) 
outcome measure, 2) model (including or not herd-immunity and zoster) and 3) 
discount rate. Our analysis predicts that, while varicella vaccination is expected 
to increase morbidity using QALYs, it is deemed highly beneficial using WTP. As 
discussed in Chapter 4, this is because the average WTP per QALYs gained is higher 
for interventions that prevent acute mild disease (e.g. varicella) than severe long­
term disease (e.g. zoster). Hence, basing policy decisions on Cost-benefit (Cost 
per WTP) or Cost-Effectiveness (Cost-Utility) analysis will lead to very different 
resource allocation decisions.
Vaccination is a preventive intervention hence benefits can occur in the short to 
long term. Hence, the choice of discount rate can greatly influence results (has a 
greater impact on results than curative interventions). This is illustrated in our 
results: varicella vaccination is cost-effective when discounting is very low 
because the long-term benefits on zoster become significant.
These results reinforce the importance of not only clearly stating methodological 
and model assumptions, but also justifying the choices made and discussing their 
impact. Complexity of methodology or modelling technique should not be an 
acceptable justification for simplicity if the technique used has been proven to be 
inadequate (e.g. excluding herd-immunity when it can produce negative effects -
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see Discussion, Section 2, Chapter 3). Further research is needed to better 
understand the impact of the different methodological assumptions on results and 
resource allocation decisions, more particularly on the effects of the choice of 
outcome measure and elicitation technique. In the meantime, although this may 
be resource intensive, sensitivity analysis should be performed on key model and 
methodological assumptions.
5.2 SU M M ARY
In this section we assessed the cost-effectiveness, cost-utility and cost-benefit of 
varicella vaccination taking into account its impact on zoster. Furthermore, 
results from the different economic evaluation techniques, were compared to 
illustrate the importance of model and methodological assumptions on results and 
thus potentially on resource allocation. To do so, the age-structured transmission 
dynamic model, described in Chapter 3, was used to predict the future incidence 
of varicella and zoster. Data from national and sentinel surveillance systems were 
used to estimate age-specific physician consultation, hospitalisation and mortality 
rates. Unit costs, taken from standard sources, were applied to the predicted 
health outcomes.
The WTP and QALY outcome measures elicited in Chapter 4 where used. Using 
cost-utility and cost-effectiveness analysis, we predict that routine infant 
varicella vaccination is unlikely to be "cost-effective” . Furthermore, that 
adolescent vaccination is the safest and most "cost-effective” strategy but has 
the least overall impact on varicella. On the other hand, varicella is highly cost- 
beneficial when using £ as the outcome measure.
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In this Chapter we show that results are less sensitive to parameter estimates than 
model and methodological assumptions. Results were most sensitive to the 
inclusion/exclusion of externalities (impact on zoster and herd-immunity), the 
outcome measure, analytical perspective and discount rate.
The research in this chapter has been published in part in the following peer 
reviewed journals:
• Brisson M, Edmunds WJ. Varicella Vaccination in England and Wales: Cost- 
utility analysis. Arch Dis Child 2003; 88:862-9.
• Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in 
Canada. Vaccine 2002; 20: 1113-1125.
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Chapter 6
Summary findings and guidelines for 
the economic evaluation of 
vaccination programmes
6.0 G EN ERAL INTRODUCTION
This thesis has two broad aims, which are to: 1) assess the effectiveness and 
“cost-effectiveness” of introducing routine childhood varicella vaccination in the 
UK, and 2) investigate the methodological challenges related to the economic 
evaluation of vaccination programmes. In this chapter we give a brief overview of 
the findings which relate to these objectives and highlight where future work 
should be focussed. Further discussion is presented within each of the previous 
Chapters.
6.1 SU M M ARY  OF EM PIR ICAL FINDINGS
Two main concerns have limited the widespread acceptance of varicella 
vaccination: 1) it could increase the number of varicella cases in adults, where 
severity is greater, and 2) increase cases of zoster. To study these concerns, a 
deterministic realistic age-structured (RAS) model of varicella and zoster was 
built. The main findings from the modelling study were as follows:
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• The overall varicella incidence and morbidity is likely to decrease following 
mass infant vaccination. The model, presented in Chapter 3, predicts that 
mass vaccination of children in England and Wale will reduce both varicella 
incidence and morbidity. That is, it is unlikely that infant vaccination will shift 
the average age at infection to such an extent that morbidity due to varicella 
is worse than the pre-vaccination state. However, the overall level of 
effectiveness of routine immunisation depends highly on the level of coverage 
and the efficacy of the vaccine. Lower efficacy vaccines produce more cases in 
both vaccinated and unvaccinated individuals than better vaccines but 
paradoxically, may reduce morbidity more than better vaccines. Finally, while 
not increasing overall morbidity, there are many scenarios in which 
vaccination at intermediate levels of coverage results in only marginal long­
term benefits.
■ Cases of zoster are likely to significantly increase in the first 30 to 50 years 
following infant vaccination, but will decrease rapidly thereafter. In
Chapter 3 we predict that, if vaccination is highly effective against varicella 
(Chapter 3 section 1) and exposure to varicella is protective against zoster 
(Chapter 2 section 2), then an increase in zoster will occur following mass 
infant vaccination. These predictions depend on one main assumption. That 
exposure to varicella boosts against zoster. However, we estimate that the 
duration of immunity is likely to be long enough to produce a significant 
increase in zoster after vaccination. It should be noted that, in the long-term a 
reduction of zoster cases will occur provided vaccine recipients are less likely 
to develop zoster than individuals who acquire natural infection.
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In Chapter 4, we estimated, using electronic questionnaires, parents willingness to 
pay for varicella vaccination and the QALYs lost due to chickenpox using various 
elicitation techniques and aggregated these results to the population level using 
the model developed in Chapter 3. The key findings of Chapter 4 are:
■ The estimated WTP for varicella vaccination and QALY lost due to 
chickenpox (see Table 4.10, 4.16 and 4.23 for values).
■ Vaccination possesses measurable non-health attributes: insurance type 
benefits and prevention of work loss. Using the CV method we demonstrate, 
for the first time, that vaccination possesses different non-health attributes 
such as insurance type benefits (i.e. WTP for vaccination was greater than for 
treatment). Furthermore, we show that prevention of work loss is an 
important intervention attribute for parents. Altruism was not found to be a 
significant attribute of parents’ willingness to pay. However, this may have 
been due to insufficient sample size. QALYs did not capture non-health 
benefits.
■ WTP and QALY analysis produced conflicting results when all benefits were 
aggregated to the population level taking into account externalities. In
Chapter 4, we illustrate formally, for the first time, how individual 
preferences can be aggregated to estimate the overall benefit of vaccination 
at the population level taking into account externalities and non-health 
benefits. Results suggest that WTP and QALYs are not interchangeable and that 
this can produce conflicting results when all benefits are aggregated to the 
population level.
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In Chapter 5, we used the dynamic mathematical model of VZV transmission 
developed and presented in Chapter 3 to explore the possible economic 
desirability of mass varicella vaccination taking into account the external effects 
of herd-immunity and increase in zoster. To do so, we performed the three major 
types of economic evaluation techniques (cost-effectiveness, cost-utility and cost- 
benefit analyses) using the outcomes valued in Chapter 4. Data from national and 
sentinel surveillance systems were used to estimate age specific consultation, 
hospitalisation and mortality rates. Average unit costs, taken from standard 
sources, were applied to the predicted health outcomes. Univariate and 
multivariate sensitivity analyses were used to assess robustness of
results/conclusions. The main results of the analysis are:
■ Adolescent vaccination is the only programme estimated to  be cost saving 
from  the societal perspective.
■ Cost-Effectiveness and Cost-Utility of infant varicella vaccination rests 
heavily on the impact it  w ill have on the incidence of zoster. If, as
expected, zoster increases after mass infant varicella vaccination (see Chapter 
3), then it is unlikely to be cost-effective and may produce an increase in 
overall morbidity (i.e. QALYs lost). These results are robust to changes in all 
other health outcome and cost estimates investigated in the thesis. If zoster 
does not increase, varicella vaccination is likely to be cost-effective from the 
NHS perspective (£18,158 and £3,256 per Life-year saved and QALY saved 
respectively).
> Cost-benefit analysis results predict that infant varicella vaccination is 
highly desirable. This conclusion is robust to methodological and modelling
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assumptions as well as changes in all parameters investigated here.
Many economic evaluations of routine childhood varicella vaccination have been 
published (see Chapter 5, Table 1). However, we are the first to include the 
impact of varicella vaccination on zoster. Furthermore, all previous economic 
evaluations of varicella vaccination have used either direct cost, cost- 
consequence and/or cost-effectiveness analysis (Chapter 5, Table 1). That is, no 
cost-benefit or cost-utility analysis has been performed for varicella vaccination. 
As shown in Chapter 5, these are important omissions since the economic 
desirability of varicella vaccination is dependent on the impact it will have on 
zoster and the choice of analytic technique.
6.2 G U IDELINES FO R  TH E ECO NO M IC  EVALUATION OF  
VA CC IN A T IO N  PROGRAM M ES
Recently, Beutels et al. (2002) proposed specific guidelines for the economic 
evaluation of vaccination programmes, due to inconsistencies in the methods used 
to estimate the future benefit of immunisation programmes. In this section we 
discuss the challenges related to the economic evaluation of vaccination 
programmes and propose additions to the guidelines proposed by Beutels et al. 
(2002).
The important methodological components that must be considered when 
performing or judging the quality of an economic evaluation of a vaccination 
programme can be separated into 4 categories: 1) Model Structure, 2) Outcome 
measure and valuation technique, 3) Study design, and 4) Sensitivity analysis. 
Here, varicella vaccination is used as an example to illustrate and support 
recommendations.
256
1. Model Structure
As discussed in Chapter 1, there are two general types of models that are used to 
estimate the effectiveness of vaccination programmes: static and dynamic. 
Presently, the majority of economic analyses use static models due to their 
relative simplicity compared to dynamic models. Here, we propose guidelines 
(similar to those of Beutels et al. (2002)) for judging which type of model should 
be used (Table 6.1) and what should be included in the model. The guidelines are 
as follows:
■ Static model can be used 1) if vaccination is unlikely to change the force of 
infection or, 2) to estimate the worst-case scenario when herd-immunity 
cannot produce negative effects. The difference between static and dynamic 
models is that static models cannot take into account herd-immunity effects. 
Hence, when the force of infection is unlikely to change following vaccination 
(i.e. herd-immunity effects are unlikely to occur) then static models can 
adequately predict effectiveness. In Chapter 3, we show that if coverage is 
low or vaccination is targeted at groups that do not have an impact on overall 
transmission then static and dynamic models produce similar results. Although 
not shown in the thesis, results are also similar for vaccines that do not 
prevent the circulation of the pathogen (e.g. rotavirus vaccine) since herd- 
immunity effects are negligible.
■ Dynamic models should be used if vaccination is likely to change the force 
of infection. In Chapter 3, we illustrate the importance of incorporating herd- 
immunity externalities when assessing the effectiveness of vaccination 
programmes. To do this, we compare a dynamical model, in which the force of 
infection is an endogenous time-dependant variable, with a static model in
257
which the force of infection is treated as a time-independent exogenous 
variable. We show that, by taking into account the changes in the rate of 
infection following vaccination, dynamic models can 1) produce non-linear 
dynamics, 2) predict a higher number of cases prevented and 3) predict either 
increases or decreases in morbidity and mortality due to shifts in the age at 
infection. We further show that, contrary to what is generally assumed in the 
literature, using static models does not always produce conservative results. In 
fact the use of static models may grossly overestimate the effectiveness of 
mass vaccination at preventing serious disease since they cannot capture 
possible increases in morbidity due to shifts in the age at infection.
■ Externalities related to vaccination should be included in the model. If spill 
over effects are not included, their likely impact should be discussed. The 
possible equity implications should also be discussed In Chapters 3 to 5 we 
show that the conclusions regarding the effectiveness and cost-effectiveness of 
varicella immunisation rest heavily on the indirect effect it will have on 
zoster. Due to it’s importance, omitting zoster from the economic analysis of 
varicella vaccination because “no long term data exist on this question (Lieu et 
al., 1994)” or because “the relationship between varicella and zoster 
incidence is not completely investigated (Banz et al., 2002)” is unjustified and 
can mislead public health decision makers. There are many other types of 
positive and negative spill over effects that can be produced by vaccination 
(e.g. serotype replacement, vaccine cross protection), which can have an 
impact on economic evaluation. It is important that externalities be identified 
and if not incorporated into the model, their likely impact should be 
discussed. Furthermore, the distributional impact of externalities on the
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health of the population should be discussed (i.e. discuss the possible equity 
considerations related to vaccination).
2. Intervention outcome and valuation technique
There are different methods of assigning values to intervention outcomes 
(monetary, natural units and Quality of life). We propose guidelines for the choice 
of valuation technique, outcome measure and type of economic analysis. Here, we 
do not use theoretical foundation but rather empirical evidence and the possible 
implications the choice of outcome measure can have on resource allocation 
decisions as our primary basis for evaluation.
■ QALYs estimated from Multi-Attribute Utility Scale (MAUS) should be 
considered the preferred type of analysis. CV (WTP) should be considered 
as an additional type of measure to understand the value and relative 
importance of the different non-health attributes of vaccination.
■ Practicality: Concurrent with the literature (Table 1.2 and Table 1.5) we 
found CV and HUI2 to be practical, interviews were conducted rapidly and 
completion rates were 100%. On the other hand, we encountered a number 
of difficulties with the SG. First, we had difficulty getting ethical approval. 
Ethics committees were reluctant to approve the SG questionnaire, as they 
were worried that presenting to parents of very young children scenarios in 
which their child could die from vaccination could adversely affect vaccine 
coverage rates. Second, the SG demanded more explanation and parents 
were uncomfortable/reluctant to accept risk of death for their children for 
treatment.
■ Content Validity: It has been argued that, contrary to HR-QoL techniques, 
CV can capture non-health benefits as it imposes no restrictions on which
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dimensions of a programme people are allowed to express a value for 
(Olsen et al., 2001; Bala et al., 1998; O’Brien and Viramontes, 1994; 
O’Brien and Gafni, 1996). This was tested in Chapter 4. We found that CV 
can measure insurance type benefits (WTP was greater for varicella 
vaccination than varicella treatment) and the added benefit of preventing 
parental work loss (controlling for other factors WTP was greater for 
parents who must take time off work when their child is sick). However, 
their was no evidence that caring was an attribute of vaccination, perhaps 
due to lack of power to measure very small differences in WTP. These non­
health attributes represented 20% of the overall WTP for vaccination (i.e. 
80% of the overall value were direct health benefits). On the other hand, 
consistent with general belief, SG and HUI2 did not capture non-health 
attributes.
■ Empirical Validity: In the literature, hypothetical WTP (using CV) has 
been demonstrated to be greater than observed WTP (NOAA, 1993). 
Furthermore, there is, little empirical evidence concerning the criterion 
validity of SG and HUI2 (or other MAUS). On the other hand all three 
valuation techniques have demonstrated construct validity and convergent 
validity (see Table 1.2 and 1.5;. In Chapter 4, we demonstrate construct 
validity and convergent validity for HUI2 and CV. However, we found 
discrepancy between the QALY-weight elicited from HUI2-CV (HUI2 within 
the CV questionnaire in which the chickenpox lasted 1 week) and the SG 
questionnaire (in which the health state was described as lasting 15 years). 
SG produced a QALY weight of 56%, which seems unrealistic for varicella 
and is significantly lower than the HUI2 estimate (76%). We believe this 
highlights the difficulty of using SG for acute diseases as the risk of death 
individuals must trade-off in such circumstances are too small for them to
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comprehend. Furthermore, this raises issues regarding the theoretical basis 
of QALYs. That is, whether the proportional trade-off assumption holds. It 
should be pointed out that chained methods were not used in Chapter 4 
although they have previously been used to address the problem of 
assessing QALYs for temporary health states within the SG framework 
(Jansen et al., 1998). To our knowledge none have been used for health 
states that are as short and as mild as chickenpox. Furthermore, for 
durations as short as varicella, chaining will be difficult (e.g. use of many 
anchor levels) and the opportunity of including bias will be large. 
Nevertheless, in future work chained procedures should be considered as 
an alternative to the method chosen here and may prove to produce 
greater empirical validity.
■ Sensitivity: As mentioned above, SG could not capture small changes in 
Quality of Life (i.e. low morbidity or very acute disease) because risks of 
death that would rationally be taken are too small for individuals to 
comprehend. Some evidence suggests that CV can be oversensitive to small 
changes in well being (Clarke, 2002; Seip and Strand, 1992; Duffield and 
Patterson, 1991) or that it is limited by ability to pay. In Chapter 4, we 
show that, WTP is less sensitive to large increases in severity of disease 
than QALYs (based on HUI2). The fact that WTP is capped by ability to pay 
seems to explain results showing that WTP increases as QALYs increase but 
at a decreasing rate. This has been previously observed by Bala et al. 
(1998) and has produced concern about using the welfarist framework as a 
basis for the allocation of health care resources (Weinstein and Manning, 
1997). If we assume QALYs adequately measure disease severity, our 
results suggest that using WTP as the outcome measure may bias resource 
allocation towards less severe diseases, which may, as illustrated in
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Chapters 4 and 5, lead to reduction in overall quality of life thus justifying 
extra-welfarists’ concerns.
■ Conclusion: Of the valuation techniques investigated, the CV and HUI2 are 
best suited for the economic evaluation of vaccination programmes. The 
advantage of MAUS, compared to SG and TTO, is its practicality and its 
capacity to measure small changes in well being (see Chapter 1 and Chapter
4). More work is however required to assess whether SG and TTO are indeed 
incapable of valuing short and mild health states such as varicella. Although, 
CV possesses the same advantages as HUI2 (or other MAUS) our results raise 
concerns about its capacity to produce resource allocation decisions that will 
improve the overall health of a population. On the other hand, CV can be 
useful to better understand the non-health attributes related to vaccination 
and their relative importance compared to health gains. Hence, we prefer 
MAUS as valuation technique and thus QALY as outcome measure and Cost- 
Utility as type of analysis. We however believe CV (WTP) could be considered 
as an additional type of measure to understand the value and relative 
importance of the different non-health attributes of vaccination.
3. Study Design
■ The time span must be long enough to capture all relevant positive and 
negative effects. The introduction of routine infant mass vaccination typically 
produces dynamical effect, which are composed of three phases (see Chapter 
3 for description): 1) Honeymoon period, 2) Post-honeymoon epidemic, and 3) 
Post-vaccination endemic equilibrium. Furthermore, vaccination may produce 
external effects. In Chapter 3, we show that varicella vaccination can produce 
a short to medium term increase in zoster. Analyses should capture all of these
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effects. To assure this, as Beutels et al. (2002) suggest, the appropriate time 
span of analysis should be determined during the analysis and not prior.
■ Both discounted and non-discounted values should be presented.
Vaccination is a preventive intervention thus costs of the programme are 
incurred at the moment of vaccination while benefits can occur in the short to 
long term. Hence, the choice of discount rate can greatly influence results 
(has a greater impact on results than curative interventions). This is illustrated 
in Chapter 5 where varicella vaccination is cost-effective when discounting is 
very low because the long-term benefits on zoster become significant. Another 
example where discounting will have an impact is with the Human 
Papillomavirus (HPV) vaccine. The vaccine will most probably be given to pre­
adolescents to prevent cervical cancer 20 to 30 years later. In cases like these, 
where benefits occur in the medium to long term, higher discount rates bias 
against preventive measures. It should however be noted that a zero discount 
rate for health effects could lead to undesirable implications, such as infinite 
benefits arising from successful eradication programs (Edmunds et al., 1999; 
Beutels et al., 2002). As recommended by the US panel on cost-effectiveness 
we believe that that costs and benefits should be discounted at the same rate 
(Weinsten et al., 1996) and that discounting should be subject to thorough 
sensitivity analysis (Beutels et al., 2002).
4. Sensitivity Analysis
■ M ultivariate and univariate sensitivity analysis should be perform ed in  
addition to  an exploration of the impact of model/methodological choices. 
Because of the complex nature of infectious disease control, economic analysis 
of vaccination programmes is based on numerous uncertain parameter values
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and model and methodological assumptions. Because of this, ideally a 
probabilistic multivariate sensitivity analysis (uncertainty analysis) should be 
performed. However, this should be extended to account for methodological 
uncertainties as well as parameter uncertainties. In Chapter 5 we show that 
model and methodological assumptions can have greater impact on results 
than parameter estimates. More particularly, we illustrate that the economic 
analysis can produce opposite conclusions depending on the choice of 1) 
analytic technique, 2) model (including or not herd-immunity and zoster) and 
3) discount rate. Hence, it is essential that sensitivity analysis of model and 
methodological assumptions be performed in addition to parameter values.
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Table 6.1. Guidelines for the Economic Evaluation of Vaccination programmes
(adapted from Beutels et al., 2002) &______________
1. Model Structure
□  T h e  m athem atica l m ode l shou ld  be:
• Static, if  vacc ina tion  is  un like ly  to change  the  rate of in fection  in su scep tib le s (force  
o f  in fection ) o r  a s an e stim ate  o f  the  w orst-case  scenario  w hen  he rd-im m un ity  
ex te rna lit ie s can n o t p roduce  negative  effects.
• Dynam ic, if  vacc ina tion  is  like ly  to change  the  rate of in fection  in su scep tib le s (force  
o f  in fection )
□  Exte rna lit ie s re lated to vacc ina tion  shou ld  be  inc luded  in the  m odel.
« If  ex te rna lit ie s are  not inc luded, the ir like ly  im pact shou ld  be d iscussed .
■  T h e  possib le  equ ity  im p lications shou ld  a lso  be  d iscussed.
2. Outcome and Valuation technique
□  Q A LY s e stim ated  from  M u lti-A ttribu te  U tility  S ca le s (M AUS) shou ld  be con side red  the  
p re fe rred  ou tcom e  m easure.
• W T P  (m easured  from  CV) shou ld  be  con side red  as an add it iona l type  o f  m easure  to 
unde rstand  the  va lue  and  re la tive  im portance  o f  the  d iffe ren t non -hea lth  a ttribu tes o f 
vacc ina tion .
■  If life -years ga ined  is used, the  like ly  im pact o f  do ing  so  shou ld  be d iscussed.
3. Study Design
□  Time Span: T he  tim e  span  m ust be long enough  to cap tu re  a ll re levant posit ive  and 
negative  e ffects.
□  Discounting: Both d iscounted  and  non-d iscounted  va lu e s  shou ld  be p resented.
4. Sensitivity analysis
□  M u ltiva ria te  and  U n ivaria te  sensitiv ity  ana lysis shou ld  be  perfo rm ed  in add it ion  to  an 
exp lo ration  o f  the  im pact o f  m ode l/m ethodo log ica l cho ice .
a  Here, we discuss the methodological components of economic evaluation that have been covered 
in the thesis.
The guidelines presented above are meant to add to the previous 
recommendations made by Beutels ec at. (2002, and to highlight important 
methodological components that must be considered when performing or Judging 
the merit of economic analysis of vaccination programmes. Analysts, who ignore 
these methodological issues because of complexity, risk producing erroneous 
conclusions, which can have important detrimental public health consequences 
and thus adversely affect the credibility of economic analysis and modelling as 
decision making tools.
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6.3 FUTURE D IRECTIONS
Any thesis is necessarily limited in scope. In this final section highlight themes 
that the thesis has touched upon that may warrant further research.
6.3. t EFFECTIVENESS AND COST-EFFECTIVENESS OF VARICELLA VACCINATION
As shown in the thesis the effectiveness and cost-effectiveness of varicella 
vaccination is dependent on the impact of vaccination on zoster. Hence, more 
work is needed to understand the relationship between varicella and zoster. More 
precisely, studies are needed to confirm whether exposure to varicella does 
protect against zoster. Currently, a large clinical trial is underway to determine 
whether varicella vaccination can protect against zoster through boosting cell- 
mediated immunity to VZV (Oxman, 1995). If vaccination prevents zoster, then it 
is likely that exposure to the wild virus would perform a similar function. 
Furthermore, active surveillance is underway in the US (Seward ef at., 2002b), 
which should demonstrate within the next few years whether varicella vaccination 
produces an increase in zoster cases. Studies should also be aimed at determining 
the duration of protection following exposure to varicella to better predict the 
magnitude and duration of the increase in zoster cases.
6.3.2 METHODOLOGICAL ISSUES RELATED TO THE ECONOMIC EVALUATION OF 
VACCINATION
There are three main topics that have not been explored, which are important 
issues in the evaluation of the benefit of vaccination programmes. The first is the 
impact of vaccine side-effects and risk of disease on the demand and uptake of 
vaccines. It has been shown that the decision to vaccinate (or the WTP for a 
vaccine) is influenced by the probability of side effects, the severity of disease 
and perceived risk of disease (Hall et at., 2002; Sansom, 2001; Geoffard &
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Philipson, 1996; Geoffard & Philipson, 1997; Philipson, 2000). In the thesis, we 
could not, because of ethical considerations, measure the impact of the risk of 
side-effects on vaccine uptake and WTP for vaccination. Furthermore, it was 
beyond the scope of the thesis to evaluate whether perceived risk of disease could 
influence the demand for vaccine. However, we show historical vaccine coverage 
data from the UK, which clearly shows that vaccine coverage is relatively 
insensitive to prevalence of disease (see Figure 4.5). Clearly, further research is 
needed in this area to understand what really influences drops and increases in 
vaccine coverage and how we can incorporate this into the social welfare 
function. The second issue that was not investigated is the methodological 
challenges related to eliciting the Health State of children. This is an Important 
topic for vaccination as many vaccine programmes involve children. In his recent 
paper, Petrou (2003) identifies and discusses a number of methodological issues, 
which should be further investigated. These are, 1) who should be the respondent 
of questionnaires (the child, parent, physician or sample of the population), 2) 
what health dimensions should be valued, 3) what is the psychometric integrity of 
alternative measurement approaches, 4) what are the potential biases in the 
description and valuation process. To ensure the appropriate distribution of health 
care resources more research is clearly needed in this area. The third issue that 
has not been explored is the impact of externalities resulting from mass 
vaccination on the distribution of health in the population. As shown in Chapter 3, 
vaccinating a proportion of the population against an infectious disease affects the 
risk of disease in those in the population that are not immunised. Future research 
should explore these equity issues.
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The research produced in the thesis has raised many questions on which future 
work can be performed. First, we show that CV can capture different non-health 
attributes of vaccination. Future work can be directed towards estimating the 
relative importance of non-health attributes for various vaccines (e.g. 
pneumoccocal and meningococcal vaccines). This to better understand the 
relationship between the severity of the disease being prevented and non-health 
benefits such as altruism and insurance type benefits. In the thesis we also show 
evidence that the relationship between WTP and QALYs is non-linear and that this 
may be due to the fact that WTP is limited by ability to pay. Future research 
should be aimed at eliciting WTP and QALYs for diseases with varying severity and 
duration to test this relationship and to investigate the potential impact of this on 
resource allocation. Finally, we show that for varicella vaccination, the economic 
desirability is most sensitive to model and methodological assumptions. More 
research is needed to understand the impact of model and methodological 
assumptions (e.g. choice of elicitation technique, discounting and time frame of 
analysis) on results of economic analyses of vaccination, and other health care, 
programmes.
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6.4 GENERAL CONCLUSION
The thesis has two objectives. The first aim is to evaluate the effectiveness and 
“cost-effectiveness” of routine childhood varicella vaccination in the UK. The 
findings presented here have major public health implications. We show, using a 
dynamic model parameterised from population data, that varicella vaccination is 
likely to provoke an increase in zoster cases, which would produce an overall 
increase in morbidity. These results strongly support that, before introducing 
varicella vaccination public health take careful consideration of the potential 
detrimental external effect of vaccination on zoster and support the need of 
sensitive zoster surveillance where immunisation is underway. These results were 
requested and discussed at various meetings meant to establish recommendations 
for the routine administration of varicella vaccination: the Canadian National 
Varicella Consensus Conference (Canada, 1999), the Joint Committee on 
Vaccination and Immunisation (England and Wales, 2002) and, the Advisory 
Committee on Immunization Practice (United-States, 2003). This demonstrates the 
willingness of public health officials to use dynamic mathematical modelling 
(which take into account externalities such as herd-immunity) and cost- 
effectiveness studies as an aid in policy decision making.
The second aim of the thesis is to address the major methodological issues related 
to the economic evaluation of vaccination programs. We compared results from a 
dynamic model with those of a static model to illustrate the impact of including 
herd-immunity and to help provide guidance on which model should be used when 
assessing the impact of vaccination. Secondly, we assessed the average willingness 
to pay for varicella vaccination and the QALY lost due to chickenpox using various 
elicitation techniques. We then identified important attributes of vaccination and 
what elicitation techniques can capture these components. Results were
269
compared to investigate what valuation techniques should be used in the 
economic evaluation of vaccine programmes. Thirdly, we assessed the sensitivity 
of economic analysis to the choice of model, methodological assumptions and 
parameter estimates. In order to improve/maintain the credibility and usefulness 
of economic evaluation for decision-makers, it is important that further research 
investigates the impact of methods on results of economic analysis and that 
specific guidelines such as those presented here be followed.
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APPENDIX
A PPEN D IX  1 - VACC IN E  EFF ICACY M O DEL  
MATHEMATICAL STRUCTURE
The model represents natural history of varicella in a cohort of vaccine responders 
stratified according to time since vaccination. The population is divided into 3 
mutually excusive vaccinated groups (see Chapter 3, Figure 3.1 for flow diagram): 
the proportion completely protected, denoted VP(t); the proportion vaccinated 
but susceptible to varicella, VS(t); and immune to varicella VR(t). The rates at 
which individuals flow between the vaccine states are described by the following 
set of differential equations:
dVP(t)/dt = T(t) • (W + KX) VP(t) (1)
dVS(t)/dt = [1 -T(t)] +VV VP(t) - bXVS(t) (2) 
dVR(t)/dt = bX VS(t) + K XVP(t) (3)
Where, X is the force of varicella infection (X = 0.2 per year). The flow between 
vaccinee states are: T(a), the percent of vaccine responders who become 
temporarily protected after vaccination; W, waning rate; bX, rate of infection 
among vaccine susceptible vaccinees; kX, rate of boosting.
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APPENDIX 2 - MODEL 1
MATHEMATICAL STRUCTURE
Model 1 represents the transmission dynamics of varicella. The model possesses 66 
age cohorts (0, 1, 2,..., 64 and 65+). Children enter continuously throughout the 
year into the first age cohort (at 6 months of age). Thereafter, individuals change 
age cohorts at the beginning of each school year thus taking into account the 
importance of school transmission on the dynamics of varicella (Schenzle, 1984). 
Vaccination is performed at the end of the year as individuals move up an age 
class. Within each cohort, the differential equations for this deterministic RAS
model are as follows:
dS(a,t)/dt = B(a) - [X(a,t) + (c(a) (1 -P) + p(a)] S(a,t) (1)
dE(a,t)/dt = X(a,t) S(a,t) - (cr + p(a)) E(a,t) (2)
dl(a,t)/dt = g E(a,t) - (a + p(a)) l(a,t) (3)
dR(a,t)/dt = a  l(a,t) - p(a) R(a,t) (4)
dVP(a,t)/dt = c(a) T S(a,t) - (W + K X(a,t)+ ^(a)) VP(a,t) (5)
dVS(a,t)/dt = c(a) [1 -T-P] S(a,t) +W VP(a,t) - (b X(a,t) + p(a))VS(a,t) (6)
dVE(a,t)/dt = b X(a,t) VS(a,t) - (a + p(a)) VE(a,t) (7)
dVI(a,t)/dt = a VE(a,t) - (a + p(a)) Vl(a,t) (8)
dVR(a,t)/dt = K X(a,t) VP(a,t) + a Vl(a,t) - p(a) VR(a,t) (9)
The number of individuals of age a at time t who are varicella susceptible, 
naturally infected but not infectious, infectious, immune, temporary protected, 
modified susceptible, vaccinated infected but not infectious, vaccinated 
infectious, vaccinated immune are defined by the state variables S(a,t), E(a,t), 
l(a,t), R(a,t), VP(a,t), VS(a,t), VE(a,t), VI (a,t) and VR(a,t) respectively. The 
different parameters determining the rates of flow between disease states for 
natural varicella are: B(a), rate of entry into the first age cohort; p(a) mortality
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rate; c(a), vaccine coverage; X(a,t), force of varicella infection by age group; o 
and a, rates of flow from latent to infectious and infectious to immune.
The flow between vaccinee disease states are: c(a) T, the percent of vaccinées 
who become temporarily protected after vaccination; c(a)P, the percent of 
vaccinées for which vaccine fails completely after vaccination; W, waning rate; b 
X.(a,t), rate of infection among vaccine susceptible vaccinées; kX(a,t), rate of 
boosting.
FORCE OF VARICELLA INFECTION
The pre-vaccination force of varicella infection was estimated using the 
methodology described in section 2.3.
In Model 1, the age and time dependant force of varicella infection is defined as: 
X(a,t) = Xv(a,t) + Xz
= ZaMD P(a’,a)(l(a’,t) + m Vl(a’,t)) + X* (10)
Where, Xv(a,t) is the force of infection due to varicella, XJs the force of infection 
due to zoster, p(a’,a) is the rate at which an infective of age a’ will infect a 
susceptible of age a, L is life expectancy and m is the rate of varicella 
infectiousness of vaccines compared to non-vaccinees.
A PPEN D IX  3 - M O DEL 2
MATHEMATICAL STRUCTURE
Model 2 represents the transmission dynamics of both varicella and zoster. 
Differential equations 1, 2, 3, 6, 7, 8 and 9 are identical for Model 1 and 2. The 
remaining differential equations for Model 2 are as follows:
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dR(a,t)/d t = a  1(a) + z  X,(a,t) ZS(a,t) - (8 + p(a)) R(a,t) (11)
dZS(a,t)/dt = 5 R(a) - (p(a) + zX(a,t) + p(a)) ZS(a,t) ( 12)
dZI(a,t)/dt = p(a) ZS(a) - (az + p(a)) Zl(a,t) (13)
dZR(a,t)/dt = az Zl(a,t) - p(a) ZR(a,t) (14)
The zoster disease states are: lifelong immunity to varicella and temporary 
immunity to zoster (R(a,t)), susceptible to zoster (ZS(a,t)), reactivation episode 
(Zl(a,t)) and permanently immune to zoster. The rates are determined by: 8, rate 
of loss of immunity to zoster; zX(a,t), rate of boosting against zoster; and p(a), 
the age-dependent rate of reactivation of VZV in those who are susceptible to 
zoster.
FORCE OF VARICELLA INFECTION
The age- and time-specific force of varicella infection is defined as:
X(a,t) =M a,t) + M t)
= I a.L0p(a’,a) (l(a’,t)+ m Vl(a\t)) + co I a..0ZI1(a,,t) (15)
Where, ra = 5.4*'7.
RATE OF REACTIVATION
The age-specific rate of reactivation, p(a), and duration of boosting (1/8) were 
estimated in section 2.4.
COMPUTER DETAILS
Numerical results were generated by a Model Maker version 3.0 program. The 
system was solved using Runge-Kutta (Burden and Faires (1993)) integration of 
ordinary differential equations with adaptable time steps. Simulations were 
performed on a PC.
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APPENDIX A  - WAIFW MATRIX ESTIMATION AND STRUCTURE
The standard technique developed by Anderson and May was used to describe the 
age-dependant mixing patterns of the population (Who-Acquired-Infection-From- 
Whom (WAIFW) matrix) (Anderson and May, 1991). The elements of the WAIFW 
matrix, P(a’,a), were estimated from the pre-vaccination force of infection, 
>„(a,0), using equation 10. Here, we present the estimation the base matrix values 
as an example.
The base case matrix structure is:
0-1 2-4 5-11 12-18 19-24 25-44 45-64 65+
0-1 P i P i P i P i Ps P ô p7 Pa
2-4 P i P2 Ps Ps P ô P ô P7 Pa
5-11 P i Ps P i Ps P ô P ô p7 Pa
12-18 P i Ps Ps P4 P ô P ô P7 Pa
19-24 Pô Pô Pô Pô 1.5*p4 P7 p7 Ps
25-44 P ô Pô Pô Pô P7 P7 P7 Pa
45-64 P7 P / P7 P7 P7 P7 P7 Pa
65+ Pa Pa Ps Pa Pa Pa Pa Pa
The value of the WAIFW matrix (Pi’s) are estimated by solving the following set of 
linear equations (based on equation 10):
M1,0)* Pi(l(1,0)+ l(2,0)+ 1(3,0)+ 1(4,0))+ p6( 1(5,0). 1(6,0))+ p71(7,0)+ p81(8,0) 
M2,0)=p,l(1,0)+ p2l(2,0)+ps(l(3,0)+l(4,0))+p6(l(5,0). I(6,0))+ p7l(7,0)+ pgl(8,0) 
M3,0)=p,l(1,0)+ p3l(3,0)+p5(l(2,0)+l(4,0))+p6(l(5,0). I(6,0))+ p7l(7,0)+ psl(8,0) (16)
M4,0)=p, 1(1,0)+ps(l(2,0)+l(3,0))+p4l(3,0)+p6(l(5,0). I(6,0))+ p7l(7,0)+ p8l(8,0) 
M5,0)=p6(l(1,0)+I(2,0)+I(3,0)+I(4,0))+ 1.5*p4l(5,0) + p7( l(6,0)+l(7,0))+ p8l(8,0) 
M6,0)= p6( l(1,0)+l(2,0)+ l(3,0)+ l(4,0))+p7( l(5,0)+l(6,0)+l(7,0)) + p8l(8,0)
M6,0)= p7( 1(1,0)+l(2,0)+ l(3,0)+ l(4,0)+l(5,0)+l(6,0)+l(7,0))+ p8l(8,0)
M8,0)= p8( l(1,0)+l(2,0)+ l(3,0)+ l(4,0)+l(5,0)+l(6,0)+l(7,0)+l(8,0))
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where, pt=p(a,i), Xv(a,0) is the force of infection of varicella calculated in section
2.3 and l(i,0) is the annual number of infectives in age group i calculated by 
applying the pre-vaccination force of infection (calculated in section 2.3) to an 
imaginary cohort of susceptibles. The WAIFW matrix does not change during the 
simulation, only the number of infectives.
Five different Matrix structures were used, yielding the following values for the 
V/AIFW matrices:
Base Matrix (p units are effective contact per 100 day):
0-1 2-4 5-11 12-18 19-24 25-44 45-64 65+
0-1 1.6 1.6 1.6 1.6 1.2 1.2 1.0 1.0
2-4 1.6 5.2 1.1 1.1 1.2 1.2 1.0 1.0
5-11 1.6 1.1 3.4 1.1 1.2 1.2 1.0 1.0
12-18 1.6 1.1 1.1 3.2 1.2 1.2 1.0 1.0
19-24 1.2 1.2 1.2 1.2 4.8 1.0 1.0 1.0
25-44 1.2 1.2 1.2 1.2 1.0 1.0 1.0 1.0
45-64 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
65+ 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Matrix 1:
0-1 2-4 5-11 12-18 19-24 25-44 45-64 65+
0-1 1.60 1.60 1.60 1.60 1.19 1.17 1.02 1.02
2-4 1.60 5.19 1.07 1.07 1.19 1.17 1.02 1.02
5-11 1.60 1.07 3.45 1.07 1.19 1.17 1.02 1.02
12-18 1.60 1.07 1.07 3.45 1.19 1.17 1.02 1.02
19-24 1.19 1.19 1.19 1.19 5.17 0.82 0.82 0.82
25-44 1.17 1.17 1.17 1.17 0.82 0.82 0.82 0.82
45-64 1.02 1.02 1.02 1.02 0.82 0.82 0.82 0.82
65+ 1.02 1.02 1.02 1.02 0.82 0.82 0.82 0.82
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Matrix 2:
0-1 2-4 5-11 12-18 19-24 25-44 45-64 65+
0-1 1.60 1.60 1.60 1.60 1.25 1.15 1.00 1.00
2-4 1.60 5.10 1.14 1.14 1.25 1.15 1.00 1.00
5-11 1.60 1.14 3.38 1.14 1.25 1.15 1.00 1.00
12-18 1.60 1.14 1.14 2.74 1.25 1.15 1.00 1.00
19-24 1.25 1.25 1.25 1.25 2.74 1.15 1.00 1.00
25-44 1.15 1.15 1.15 1.15 1.15 1.15 1.00 1.00
45-64 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
65+ 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Assortative:
0-1 2-4 5-11 12-18 19-24 25-44 45-64 65+
0-1 8.91 1.00 1.00 1.00 1.00 1.00 1.00 1.00
2-4 1.00 5.45 1.00 1.00 1.00 1.00 1.00 1.00
5-11 1.00 1.00 3.64 1.00 1.00 1.00 1.00 1.00
12-18 1.00 1.00 1.00 5.01 1.00 1.00 1.00 1.00
19-24 1.00 1.00 1.00 1.00 10.74 1.00 1.00 1.00
25-44 1.00 1.00 1.00 1.00 1.00 5.37 1.00 1.00
45-64 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
65+ 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Proportional:
0-1 2-4 5-11 12-18 19-24 25-44 45-64 65+
0-1 0.43 1.88 1.85 0.62 0.49 0.45 0.30 0.28
2-4 1.88 3.13 2.63 1.48 1.38 1.24 1.04 1.04
5-11 1.85 2.63 2.04 1.40 1.53 1.34 1.26 1.28
12-18 0.62 1.48 1.40 0.87 0.80 0.71 0.51 0.49
19-24 0.49 1.38 1.53 0.80 0.73 0.65 0.43 0.32
25-44 0.45 1.24 1.34 0.71 0.65 0.58 0.39 0.33
45-64 0.30 1.04 1.26 0.51 0.43 0.39 0.23 0.19
65+ 0.28 1.04 1.28 0.49 0.32 0.33 0.19 0.14
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APPENDIX 5 - SIMPLIFIED DYNAMIC MODEL USED FOR COMPARISON
W ITH  STAT IC  M O DELS
The model possesses 66 age cohorts (0, 1, ..65+). Following Schenzle (1984) 
children enter continuously throughout the year into the first age cohort at 6 
months of age. Thereafter, individuals change age cohorts at the beginning of 
each school year (boundary conditions). Vaccination is performed at the end of 
the year as individuals move up an age class. Within each age cohort i, the 
differential equations for this deterministic model are as follows:
dSi(t)/dt = B, - [Mt) + vt + nG Sj(t) (17)
dE,(t)/dt = M t) Sj(t) - (ct + (¿¡) Ei(t) (18)
dlj(t)/dt = a Ej(t) - (a + nO ls(t) (19)
dRj(t)/dt = a  l,(t) - n, Rj(t) + v&it) (20)
where the number of individuals in age cohort / at time t who are varicella 
susceptible, naturally infected but not infectious, infectious, and immune are 
given by the state variables S((t), Ej(t), lj(t) and Rj(t) respectively, Bj is the birth 
rate, ^  the mortality rate, Vj vaccine coverage (by age), a and a, rates of flow 
from latent to infectious and infectious to immune groups, and X,(t) the force of 
infection by age group (see Section 2.3 for values). The initial conditions for the 
set of equations are taken to be the pre-vaccination equilibrium number of 
individuals in each epidemiological class by age, which are determined by treating 
>.¡(0) as a fixed parameter (i.e. by using the static cohort model). The equations 
are solved numerically using a Fourth -Order Runge-Kutta algorithm (Burden and 
Faires (1993)).
Note that the model (above) differs from that used in section 3.2 only in that 
vaccination is assumed to result in lifelong immunity, hence it is no longer
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necessary to include vaccinated classes (with varying degrees of immunity and 
infectiousness), as all those who are vaccinated pass directly into the immune 
class (Rj(t)).
A P P E N D IX  6 - IN FO RM A T IO N  LE A F L E T
City University
London
I n f o r m a t i o n  L e a f l e t
T h e  S u r v e y : Valuing the benefit o f treatm ent and vaccination
W e are currently recruiting parents and care givers fo r a survey, which is being carried out 
by the Public Health Laboratory Service (PHLS) and City University. The recruitment will 
take place in Health Centers a t the  moment of the 9 and 18-month check-up of your child. 
This leaflet tells you more about the survey and why it is being done.
W hat is i t  about?
I  am a member of a research team, which is trying to find out what parents value in the  
treatm ent and prevention of disease in their children. The aim is to help health policy 
decision-making taking into account parents' preferences.
W hat will you be required to do?
I f  you agree to participate in the study we will ask you to  fill in a short face-to-face  
questionnaire, which will last about 10 minutes.
Remember, this questionnaire is not a test. There are no right or wrong answers. I f  at any 
time you feel uncomfortable about a specific question simply do not answer it.
Is  the survey confidential?
Yes. Your answers will remain confidential and your name will not be w ritten on the  form.
Is  the survey compulsory?
No. Our survey relies on voluntary co-operation. The success of the survey depends on the  
goodwill and co-operation of those who take part. Future care will not be a ffected  if the  
questionnaire is not completed.
Parents should fee l free to discuss the questionnaire with health visitors, medical 
professionals and/or GPs.
We hope tha t this leaflet answers some of the questions you might have. Your co-operation 
is very much appreciated.
I f  you have any queries please contact Marc Brisson at the following address.
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APPENDIX 7 - SOCIO-ECONOMIC QUESTIONNAIRE
Form Vew
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APPEN D IX  8 - CO NT INGEN T VALU AT IO N  Q U EST IO N NA IRE
PART 1 - DISEASE DESCRIPTION CARDS
Description o f Chickenpox
• Typically, chickenpox lasts fo r  7  days
• During th is  time, your child:
1. I s  covered (face, body and arm s) with up to 5 0 0  red  spo ts tha t 
itch intensely, which is highly fru stra t in g
2. H as mild feve r with cold-like sym ptom s
3. H as problems sleeping
4. H as no problems walking about
5. Cannot go to school or day care until all the  spots have d ried  or 
crusted.
6. H as problems with perform ing h is/her usual activ ities (e.g. 
hobbies, sport, playing)
• W ork ing  parents take an average 2 days o f f  work per case o f 
chickenpox
Description o f Mild Chickenpox
• Typically, mild chickenpox lasts f o r  5  days
• During th is  time, your child:
1. H as only a few  red  spots
2. H as no feve r or problems walking about
3. H as some problems with perform ing h is/her usual activities 
(e.g. hobbies, sport, playing)
4. M is se s  1 day from  school o r childcare.
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PART 2 - 85% VACCINE EFFICACY AND ALTRU ISM
W T P  F O R  T R E A T M E N T  
ki'ji-iKi'j.'iiifl.Lffi.m, mum
H jE 'ta  E0 * In»-« Format a b o r ts  Ipoh  flmdow gelp
JDJÜ
Section 2: Willingness to pay for chickenpox treatment
Imagine that:
•  Your child has chickenpox (see attached sheet card for description of the disease)
-  A new drug exists which can immediately cure your child 
■ The drug has no side effects
You have the choice whether or not your child takes the drug. Th e  decision can have the 
following consequences: _________
Without the Drug
■Your child continues to have chickenpox, which will 
last 7 days
With the Drug
■Your child has an 85% chance of being immediately 
cured, and a 15% chance of getting mild chickenpox 
■You prevent your child from giving chickenpox to other 
children
Full blown Chickenpox
o o o o o o o o o o
o o o o o o o o o o
o o o o o o o o o o
o o o o o o o o o o
o o o o o o o o o o
o o o o o o o o o o
o o o o o o o o o o
o o o o o o o o o o
o o o o o o o o o o
i Mild Chickenpox
For the purpose of the questionnaire we would like you to imagine that you live in a country where people do have to pay 
for drugs. Because of the way the health service is run in the UK, there is no question of you being asked to actually pay 
any money. We are only interested in the value you place on a drug that could cure your child once he/she gets 
chickenpox.
W T P  F O R  V A C C IN A T IO N
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PART 3 - 85% VACCINE EFFICACY
W T P  F O R  T R E A T M E N T
W T P  F O R  V A C C IN A T IO N
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PART 4 - 100% VACCINE EFFICACY AND ALTRU ISM
W TP FOR TREATM ENT
W T P  F O R  V A C C IN A T IO N
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PART 5 - 100% VACCINE EFFICACY
W TP FOR TREATM ENT
W T P  F O R  V A C C IN A T IO N
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PART 6 - W ILLINGNESS-TO -PAY QUESTION
W TP FOR TREATM ENT
W T P  F O R  V A C C IN A T IO N
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APPENDIX 9 - STANDARD GAMBLE QUESTIONNAIRE
PART 1 - DISEASE DESCRIPTION CARD
Description of the Imaginary Disease
• T h e  d isea se  la sts f o r  15 ye a rs
• D uring  th is  time, you r child:
1. I s  covered (face, body and a rm s) w ith up to  5 0 0  red  sp o ts  tha t 
itch  intensely, w hich  is h igh ly  f ru s t ra t in g
2. H a s  mild fe ve r  w ith  cold-like  sym ptom s
3. H a s  prob lem s sleeping
4. H a s  no prob lem s walking about ,
5. Cannot go  to  school o r  day  care
6. H a s  prob lem s w ith perfo rm ing  h is/h e r usual a ct iv it ie s (e.g. 
hobb ies, spo rt, playing)
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PART 2- STANDARD GAMBLE QUESTION - NO ALTRU ISM
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PART 3- STANDARD GAMBLE QUESTION - ALTRU ISM
Form Vaw
i m  Eie Ed« v e »  ÿv e rt  Format Bscords lo o t  Ï ÏM o w  Hep
r M »i
Imagine that taking the drug carries the following risks:
0 9 9 %  chance of returning to normal health 
•  1% chance of instant painless death
This risk can be visualised thus
• • oo ooo oo o
• • O O O O O O O O
• • O O O O O O O O
• • oo ooo oo o••oooooooo
oooo ooo oo o
oooo ooo oo o
oooo ooo oo o
oooo ooo oo o
oooo ooo oo o
oooo ooo oo o
oooo ooo oo o
oooo ooo oo o
oo oooooooo
oo oooooooo
oo oooooooo
oooo ooo oo o
oo oooooooo
oo oooooooo
oooo ooo oo o
oo oo ooo oo o
oo oo ooo oo o
oo oo ooo oo o
oo oo ooo oo ooooooooooo
oo oo ooo oo o
oo oo ooo oo o
oo oo ooo oo o
oo oo ooo oo o
oo oo ooo oo o
oo oo ooo oo o
oo oo ooo oo o
oo oo ooo oo o
oo oo ooo oo o
oo oo ooo oo o
oo oo ooo oo o
oo oo ooo oo o
oo oo ooo oo o
oo oo ooo oo o
oo oo ooo oo o
oooooooooooooooooooo
oooooooooo
oooooooooooooooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oo ooo oo o
oo oo ooo oo o
oo oo ooo oo oooooo ooooo
oo oo ooo oo o
oo oo ooo oo o
oo oo ooo oo o
oo oo ooo oo o
oo oo ooo oo o
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oo oooooooo
oooo ooo oo o
oooo ooo oo o
oooo ooo oo o
oooo ooo oo o
o o o o o o o o o o
oooo ooo oo o
oooo ooo oo o
oooo ooo oo o
oooo ooo oo o
oooo ooo oo o
oooo ooo oo o
o o o o o o o o o o
oooo ooo oo o
o o o o o o o o o o
oooo ooo oo o
oooo ooo oo o
oooo ooo oo o
oooo ooo oo o
oooo ooo oo o
oooo ooo oo o
Instant Death
Taking into account the risks, would you want your child to take the drug to remove him/her 
from the disease state and prevent him/her from giving the disease to other children?
*  Yes 
r  No
r Indifferent/Dont Know 
r n.a.
j J
Farmv«w t rTt:~ f-rr;
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A P P E N D IX  10 - H E A L T H  U T IL IT IE S  IN D E X  M A R K  2 (H U I2 )  
Q U E S T IO N N A IR E  (AS USED IN t h e  sg  q u e s t io n n a ir e )
Q  Mtrrosofl A c c e s s  - |common p i 2  1 ormj
[rFl 01b  Edit yew  Insert Format Records loots Window yelp
Section 3: Describing your ch ild ’s health w ith  the imaginary disease
Please tick ONE box in each section which best describes your child’s health 
if he/she is in the health state described on the attached sheet
Mobility
r  Able to walk, bend, lift, jump, and run normally for age 
Walks. bends, lifts, jumps, or runs with some limitations but does not require help
r  Requires mechanical equipment (such as canes, crutches, braces, or wheelchair) to walk or get around independantly 
r  Requires the help of another person to walk or get around and requires mechanical equipment as well
Self-care
r  Eats bathes, dresses, and uses the toilet normally for age 
a  Eats, bathes, dresses, or uses the toilet independantly with difficulty 
r  Requires mechanical equipment to eat, bathe, dress, or use the toilet 
r  Requires the help of another person to eat, bathe, dress, or use the toilet
Pain
r  Free of pain and discomfort
r  Occasional pain. Discomfort relieved by non-prescription drugs or self control activity without disruption of normal activities 
Frequent pain. Discomfort relieved by oral medicines with occasional disruption of normal activities 
r  Frequent pain, frequent disruption of normal activities. Discomfort requires prescription narcotics for relief
_ il
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APPEND IX  11 - RESIDUAL D ISTRIBUTION
a)
Residual (£)
b)
1 6 %  -T
14% 4
12%  -
-175 -125 -75 -25 25 75 125 175
Residual (£)
Figure A. 1. WTP interval regression model, distribution of residuals, a) WTP
for treatment - Residuals are normally distributed (e ~ N(0,892)), b) WTP for 
treatment - Residuals are normally distributed (e~ N(0,1092)).
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PART 1 - DISEASE DESCRIPTION.
See Chickenpox description in Appendix 8 - Part 1.
APPENDIX 12 - CONTINGENT VALUATION QUESTIONNAIRE TO
ASSESS RELATIONSHIP BETWEEN RISK OF DISEASE AND WTP
PART 2 - CV QUESTIONNAIRE
Three different lifetime risks of chickenpox were presented.
25% RISK
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50% RISK
Section 2: W illingness to pay for chickenpox treatment
Elle Edit yew  Insert Fe-mat Sacord* loo» jgJ»J
Imagine that:
■ You have a 1-year old child
_ A vaccine exists which can prevent chickenpox (see attached card for description of the disease) 
.  The vaccine has no side-effects
You have the choice whether or not to vaccinate your child. The decision can have the 
following consequences for your child:
W ithout the Vaccine With the Vaccine 1
1  -  Because others have vaccinated their children your -Your child will never get chickenpox
jfl child has a 50% lifetime chance of getting chickenpox 1
1 -Average age children get chickenpox is 6 years
o o o o o o o o o o  E| 
o o o o o o o o o o  M
o o o o o o o o o o  |y|
o o o o o o o o o o
o o o o o o o o o o  111
o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o  h:;
o o o o o o o o o o o o o o o o o o o o  |g|
o o o o o o o o o o O O O O O O O O O O
________ o o o o o o o o o o O O O O O O O O O O  [' •
•  Full Health Full blown Chickenpox •  Mild Chickenpox
For the purpose of the questionnaire we would like you to imagine that you live in a country where people do have to pay 
for vaccines. Because of the way the health service is run in the UK. there is no question of you being asked to actually 
pay any money. We are only interested in the value you place on a vaccine that can prevent your child from getting 
chickenpox.
Trrr-rfrr
zl
100% RISK
EE
npiB  f r«  yew  Insert Format accords loots yyndow ye« ..-M S)
Section 3: W illingness to pay for chickenpox vaccination
Imagine that:
■ You have a 1-year old child
■ A new vaccine exists which can prevent chickenpox (see attached card for description of the disease)
■ The vaccine has no side-effects
You have the choice whether or not to vaccinate your child. The decision can have the 
following consequences for your child:
Without the Vaccine
-Your child has a 100% lifetime chance of getting 
chickenpox
-Average age children get chickenpox is 6 years
With the Vaccine 
-Your child will never get chickenpox
For the purpose of the questionnaire we would like you to imagine that you live in a country where people do have 
to pay for vaccines. Because of the way the health service is run in the UK. there is no question of you being asked 
to actually pay any money. We are only interested in the value you place on a vaccine that can prevent your child 
from getting chickenpox.
3  j J
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PART 3 - WILLINGNESS-TO-PAY QUESTION
The bidding scale used is identical to the one presented in Chapter 4 - Table 4.4.
Form View
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APPENDIX 13 - CONTINGENT VALUATION QUESTIONNAIRE FOR
ZOSTER AND PHN
Form Vew
PART 1 - SOCIO-ECONOMIC QUESTIONNAIRE.
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Description o f mild Shingles
• Typically, shingles lasts fo r 2 weeks
• During th is  time you have:
• Clusters o f  blister-like lesions in a strip-like pattern on your body 
(either on the back, chest, head or face)
• A  tingling, burning, pin-prick sensation in the affected area. Any 
contact with the affected area is uncomfortable.
• Some patients who have had mild shingles pain said:
• " I t  feels like surges o f pain from inside"
• " I t  itches terribly, it drives me up the wall”
• ' I t  feels like someone has stuck a pin in me"
Description o f Post-H erpetic Neuralgia (PHN)
• PH N  occurs in individuals who’s  shingles rash has healed.
• On average, PHN  lasts fo r  1.5 year.
• PHN  causes pain where shingles initially appeared.
• PH N  pain can:
1. be continuous or intermittent
2. be sharp, burning, throbbing or stabbing.
3. interfere with daily routines and quality o f life.
• The skin may be unusually sensitive to even the lightest touch (as 
from clothing or bed sheets), to  the smallest breeze, and to changes 
in temperature (either hot or cold).
Description o f severe Shingles
• Typically, shingles lasts fo r  2 weeks
• During this time you have:
• Clusters of blister-like lesions in a  strip-like pattern on your body 
(either on the back, chest, head or face)
• A  constant, excruciating pain, like electrical shock.
• Shingles patients often cannot:
• sleep
• concentrate
• perform common household tasks.
• Some patients who have had severe shingles pain said:
• T v e  never had so much pain in my life"
• “I t  hurts so much I  can’t  keep still, all I  can do is pace."
• T v e  passed kidney stones and this is comparable."
• " I  don’t  enjoy life as much anymore -  it interferes with my life 
style."
PART 2A,B,C - DISEASE DESCRIPTION CARDS FOR A) MILD 
ZOSTER, B) SEVERE ZOSTER AND C) PHN
Form v«w
Form V w
PART 2D -CV QUESTIONNAIRE FOR MILD AND SEVERE ZOSTER.
322
PART 3 - CV QUESTIONNAIRE FOR PHN.
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